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A b s t r a c t
The two-stage procedure had been used  as a  standard  method to 
analyse cross-over trials for many years before its major deficiency 
was found. The inflated type I error rate of the two-stage procedure 
indicates tha t there have been more trials which have produced 
false positive results than  originally believed.
Because of the 24 years gap between the introduction of the 
method and the publishing of its deficiency, it is conceivable th a t 
the im pact of the change in the perception about the validity of the 
two-stage procedure might not have taken effect overnight. The 
objective of this thesis is to examine the im pact of the change in the 
perception about the validity of the two-stage procedure on four 
different aspects of medical statistics. The areas of medical 
statistics include both applications of, and references to, the 
analysis of cross-over trials to give a  full picture of the use of the 
two-stage procedure. Methods used are citation analysis for all 
scientific journals, systematic review for medical journals, 
comprehensive review for general medical statistics books and 
questionnaire survey for the pharm aceutical industry.
The resu lts  have been inconclusive in term s of the estimation of 
how prevalently the two-stage procedure has been used. However, 
the four studies dem onstrated th a t the analysis of cross-over trials 
is often associated with the two-stage procedure while the 
deficiency of the two-stage procedure has not been generally 
acknowledged. It can be concluded th a t further understanding of
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the two-stage procedure and better references in the analysis of 
cross-over trials are needed in all four areas of medical statistics.
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Chapter 1 - Literature Review________
1.1. Introduction
The ‘cross-over’ trial is a  particular design of clinical trial for which 
no consensus about statistical analysis has been reached. Since 
1965, a  debate has been going on as to w hat constitu tes a  valid 
method for statistical analysis of such trials. The m ethod th a t was 
introduced to target the major weakness of cross-over trials, the 
‘cany-over effect’, was proven to be “too potentially misleading to be 
of practical use” [8] 24 years after it was first introduced.
This thesis looks into the applications of analysis of cross-over 
triads in four realms of medical statistics (medical journals, 
statistical journals, medical statistics books and the 
pharm aceutical industry), using four different research m ethods 
(citation analysis, systematic review, comprehensive review and 
questionnaire survey).
1.2. The cross-over trial
The cross-over trial is one of the m ost frequently used  designs of 
clinical trials. The main difference between a  cross-over trial and a 
parallel trial (the m ost commonly used clinical triad design) is the 
num ber of treatm ents given to each patient. In a  parallel trial, each 
patien t is random ised to a  treatm ent group where only one 
treatm ent is given. Treatm ent effects can only be evaluated by 
betw een-patient differences (i.e., compairing results from different 
treatm ent groups). By contrast, in a  cross-over trial, each treatm ent
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group involves sequences of two or more treatm ents (depending on 
the design of the cross-over trial). Treatm ent effects of a  cross-over 
trial can then be compared using w ithin-patient difference. In other 
words, each patient acts as h is /h e r own control in comparing the 
treatm ents.
1.2.1. Definition
“A cross-over trial is one in which subjects are given sequences of 
treatm ents with the object of studying differences between 
individual treatm ents (or sub-sequences of treatm ents)” [1].
1.2.2. Advantages of the cross-over design
One of the most im portant advantages of the cross-over design is 
th a t the treatm ent effect can be evaluated using w ithin-patient 
comparisons. The design of cross-over trials allows each participant 
to receive more than  one treatm ent or, sometimes, all the 
treatm ents to be evaluated by the trial. It gives information on the 
effects of different treatm ents in each participant, therefore 
providing statistics for within-patient comparison. Such a  feature is 
especially valuable for diseases for which the between-patient 
variation is substantial.
Another related advantage of the cross-over design is th a t the 
sample size required to achieve the same statistical power is m uch 
smaller than  w hat would be required for a  parallel trial. As clinical 
trials are very costly and recruiting patients is very time
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consuming, saving on sample size is, w ithout a  doubt, a  very 
attractive feature for clinical researchers.
In addition to the advantages above th a t benefit the researchers, 
patients may also benefit from a cross-over trial. In contrast to a  
parallel trial where patients may have little or no benefit if they are 
random ised to the treatm ent group where only the placebo is given, 
patients of a  cross-over trial receive a t least one active treatm ent. 
Furtherm ore, because participants may have the chance to take 
different treatm ents they may be able to find their optim um  
treatm ent. Experimenting with different treatm ents may also help 
patients to gain a  better understanding of their disease.
1.2.3. Disadvantages of the cross-over design
The main disadvantage of cross-over trials is known as the ‘carry­
over’ effect (sometimes referred to as the ‘residual effect’). It is 
defined as “the persistence (whether physically or in term s of effect) 
of a  treatm ent applied in one period in a  subsequent period of 
treatm ent” [1]. The United States Food and Drug Administration 
(FDA) considers the carry-over effect “the chief difficulty” [31] of 
such  designs.
With the interference of the carry-over effect, a  difference in the 
effect of treatm ents is very difficult to evaluate. The practical 
solution is to introduce a ‘w ash-out period’, a  period of time in 
which no active treatm ent is given to the patients between any two 
treatm ent periods. However, a  w ash-out period is less appropriate
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for disease types for which patients require constant treatm ents 
(such as epilepsy, Alzheimer and other psychotic disorders).
Another disadvantage of the cross-over design is th a t it is not 
universally applicable: it is not appropriate for all therapeutic 
areas, especially for diseases which are curable, fatal or acute. The 
reason is tha t the baseline conditions of patients should be similar 
for all treatm ent periods. Therefore, therapeutic areas where 
patients might be cured or die before the second or further 
treatm ent period commences are not suitable for cross-over 
designs.
An additional disadvantage of cross-over designs affects both 
patients and clinical researchers. The fact th a t cross-over trials 
involve m ulti-treatm ent periods usually implies a  longer trial period 
than  for a  parallel design. Patient compliance is therefore likely to 
be lower and they are more likely to leave the trial before it is 
completed. With similar drop out rates (i.e., the percentage of 
patients who drop out before the trial is complete am ongst all 
patients who were enrolled into the trial), the problem is more 
serious within a cross-over trial than  a  parallel trial. The reason is 
that, in a  cross-over trial, each patient is given more than  one 
treatm ent and the analysis of the treatm ent effect is based on the 
m easurem ents of all treatm ents they were given. For a  parallel trial, 
each patient is given one treatm ent and therefore accounted for 
m easurem ents of one treatm ent only. Furtherm ore, a  longer
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duration of the trial for both investigators and participants may 
cause more inconvenience to patients [1].
1.2.4. Therapeutic areas of the cross-over design
The therapeutic areas where cross-over designs have been used 
extensively include asthm a, migraine, hypertension, insomnia, 
diabetes, angina and bioequivalence studies. O ther therapeutic 
areas where cross-over trials are sometimes used  b u t are more 
debatable (as endpoints of these treatm ents are not reversible) 
include the treatm ents of infertility [39] and dental care.
1.3. Analyses of cross-over trials
The main concern about analyses of cross-over trials is the issue 
with the carry-over effect. Although the carry-over effect is a  design 
problem which involves pharm acokinetics and pharm acodynam ics, 
statisticians have attem pted to find a  solution to ‘prove’ th a t the 
carry-over effect has not occurred in the trial. Analyses of cross­
over trials before this ‘solution’ was introduced were 
straightforward b u t with some uncertainly. A statistical solution to 
the carry-over effect was first introduced by Grizzle in 1965. The 
m ethod is known as the two-stage procedure and is also often 
called the Hills-Armitage analysis [8], especially in the UK. The 
context of the two-stage procedure and its developments are 
described below.
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1.3.1. The two-stage procedure of cross-over trials
The first stage of this method is to determ ine w hether there was an  
unequal carry-over effect between the two treatm ents. The 
evaluation of the treatm ent effect is determ ined by the significance 
level of the test for the unequal carry-over effect. If the differential 
carry-over effects is found to be significant a t the 10% level as 
suggested, the treatm ents effect would be evaluated using the first 
period data only. As a  result, the advantage of the w ithin-patient 
comparison cannot be utilised and the sam ple size which is 
calculated based on the cross-over design will not be sufficient to 
achieve the statistical power it was designed for. If the unequal 
cany-over effects were found to be non-significant a t the 10% level, 
data  from both periods would be used to evaluate the treatm ent 
effect, in the sam e way the treatm ent effect was analysed before the 
two-stage procedure was introduced.
1.3.2. History of the two-stage procedure
The two-stage procedure was first introduced by Grizzle (1965) [4]. 
He dem onstrated how unequal carry-over effects could be tested. It 
was suggested in this paper tha t only if the null hypothesis of the 
carry-over effects of both treatm ents being equal was not rejected a t 
the 10% level, was analysis of variance using data  from both 
periods appropriate. He sum m arised this: “the two-period
changeover design is preferable when the residual effects of the 
treatm ents are equal and the correlation between the responses to
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the two treatm ents is positive. Otherwise the design in which there 
is random  assignm ent to a  single treatm ent is preferable.”
However, prior to Grizzle’s paper, it had  not been suggested how 
treatm ent effects should be analysed if unequal carry-over effects 
were found to be significant. Grizzle’s approach was popularised by 
Hills and Armitage in 1979 [7], who suggested th a t “We should 
therefore place m uch more reliability on the com parison of 
treatm ents in period 1, and it seems sensible to study these alone 
when a treatm ent by period interaction is p resen t.” They further 
added that, “If the resu lts of the trial suggest a  definite interaction 
between treatm ents and periods then the chance has not come off 
and the treatm ent comparison should be based on the first period 
alone. This might seem to be a  great loss since this is ju s t  w hat 
would have happened in a  parallel group study b u t all too often the 
size of the trial, chosen with cross-over in mind, is too small for a  
proper comparison between groups.” Regarding the issue of sample 
size and achieving adequate power, Hills and  Armitage [7] 
suggested th a t a  cross-over tried should always be large enough for 
it to be analysed as a  parallel group study, and  also for any 
appreciable interaction to be detected on a  between-subject basis.
1.3.3. The deficiencies of the two-stage procedure
Hills and  Armitage [7] m entioned th a t the two-stage procedure was 
not w ithout flaws. They showed th a t the statistical power of the 
two-stage procedure was especially low when the ratio of true 
treatm ent difference to standard  error was low. However, it was not
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until 10 years later (in 1989) th a t the more serious deficiency of 
testing for the carry-over effect was dem onstrated in a  paper by 
Freem an in Statistics in Medicine [8]. The key finding of this paper 
was th a t the type I error rate (the probability of falsely declaring 
there to be a  difference between the treatm ents) of the two-stage 
procedure is much higher than  the nom inal 5% claimed for it. 
Freeman concluded th a t “the two-stage analysis is too potentially 
misleading to be of practical u se”.
The overall type I error rate of the two-stage procedure is the 
probability weighted sum  of the type I error rate of both arm s of the 
results of significance of the carry-over effect. The key to such a  
result was tha t the correlation between the te st for the carry-over 
effect and the test of evaluating first period d a ta  only is actually as 
high as 0.866. Senn [22] dem onstrated th a t instead of the 5% 
claimed, the actual type I error rate of the two-stage procedure is 
between 7% and 9.5%.
1.3.4. Change in validity of statistical methods for the 
analysis of cross-over trials
The development of the analysis of cross-over trials has been 
m ainly m arked by the development of the two-stage procedure 
which was m arked by two major events (the introduction of the 
two-stage procedure and the finding of its m ajor deficiency) and can 
therefore be classified into three periods: the pre-two-stage 
procedure period, the two-stage procedure period and the post-two- 
stage procedure period. The optimal method for analysing cross-
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over trials was different in those three periods. Such a  division 
provides the background to possible m ethods used  in the analysis 
of cross-over trials of research objects.
The pre-two-stage procedure period (before 1965): before the two- 
stage procedure was introduced by Grizzle [4] in the British Journal 
o f Pharmacology. References on analyses of cross-over trials 
published before then recommended using cross-over differences 
w ithout taking carry-over effect into consideration.
The two-stage procedure period (1965-1989): Although Hills and 
Armitage (1979) [7] had ascertained one of the m ain deficiencies of 
the two-stage procedure, its validity was only challenged by 
Freeman [8] in 1989. He concluded th a t the two-stage procedure 
was too potentially misleading for practiced use. One might then 
describe the analysis of cross-over trials as having entered a  post- 
two-stage procedure era. Although the finding of the deficiency of 
the two-stage procedure by Freeman (1989) [8] was an  im portant 
breakthrough, the two-stage procedure has not been completely 
eliminated from the analysis of cross-over trials. Evidence of its 
applications can often be found in general medical statistics 
textbooks and trial reports in medical journals. The two-stage 
procedure rem ains one of the m ost recommended methods of 
analyses of cross-over trials in general medical statistics books. 
Despite its lack of statistical validity, testing for carry-over effect 
can also be found in statistical analyses sections of cross-over trial 
reports in medical journals.
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1.4. Objective of the thesis
With the change in accepted validity of the statistical m ethods for 
analyses of cross-over trials, the objective of this thesis is to 
investigate methods used to analyse the two-period two treatm ent 
(AB/BA) designs, with the main focus on applications and 
recommendations of the two-stage procedure in four domains of 
medical statistics (medical journals, statistical journals, general 
medical statistics books and pharm aceutical companies) where 
analyses of cross-over trials are applied and  advised. The core 
question to be answered is whether the finding of the high type I 
error rate had any im pact on the use of the two-stage procedure in 
different realms of medical statistics. This question can be 
answered by looking at:
• how frequently the two-stage procedure has been used  and 
recommended in different realms of medical statistics a t 
different periods of its development;
• how up to date the information on m ethods of analyses of cross­
over trials is in different realms of medical statistics.
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Chapter 2 - Statistical Analyses for 
AB/BA Trials_______________________
2.1. Introduction
This chapter describes the statistical m ethods th a t have been used 
to analyse cross-over trials. Part A of th is chapter presents 
potential analyses which do not include the carry-over effect in the 
statistical model. For the purpose of referencing the results of the 
systematic review of the medical literature and  the comprehensive 
review on general medical statistics books, the m ethod of testing for 
the carry-over effect and the two-stage procedure will be illustrated 
in part B. Relevant literature on the performance of the two-stage 
procedure will be reviewed in part C.
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2.A The correct analysis of cross-over trials
This section illustrates how cross-over trials can be correctly 
analysed. The effects tha t are included in these analyses include 
the treatm ent effect, the period effect and  patien t effects. This does 
not include any test on the carry-over effect as the potential of the 
carry-over effect should have been dealt with by design.
2.A.1 Statistical model
For the patient j  of the treatm ent sequence i , the observation 
during the k  -th period can be denoted as y ijk.
A commonly used statistical model for an  AB/BA trial is as follows:
y.jk =  M+7rk+(Pi+£ijk (2.A.1)
where
y jJk =  th e  m e asu rem en t of j - t h  p a tien t in  th e  i-th  seq u en ce  a t  th e  k- th  period, 
jj. = general m ean
7Tk = th e  effect of th e  fc-th period [k  =1 or 2),
(pt = th e  d irect effect of th e  d rug  I [For p a tie n ts  ran d o m ised  to  th e  tre a tm e n t 
seq u en ce  1 (z = 1), /=  A w hen k  = 1, /  =B w hen k  =2. F or p a tie n ts  ran d o m ised  to  
th e  tre a tm e n t sequence 2 (z =2), /  =B w hen k  = 1, /  = A w hen  k  =2],
%tJ = th e  effect of p a tien t j  of th e  i -th  sequence. T his ca n  be tre a te d  a s  a  fixed or
ran d o m  effect. It is  a s su m e d  to be fixed a t th is  stage. P a tien t effect a s  a  ran d o m  
effect will be d isc u sse d  in  Section 2.A.7.
Sijk = th e  ran d o m  flu c tu a tio n  w hich is  no rm ally  d is tr ib u te d  w ith  m ean  0 an d  
variance ( j\ , a n d  is  in d ep en d en t of the  p a tie n t effect £  .
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For an AB/BA trial, patients (N=m) random ised to sequence 1 
receive treatm ent A during the first period and treatm ent B during 
the second period. The order of the treatm ents is reversed for 
patients (N=ri2) randomised to sequence 2.
The design and the param eters of the statistical model for each 
period in each sequence are as follows:
Table 2.A.2 __________________________________________________________________________
n = nx + n2 Period 1 Period 2
Sequence 1
(N=n,)
Receiving Treatment A
y  I j l  = M  + K i + < P a + £ W
Receiving Treatment B
y  1 j 2 =  M + * 2  + <Pb +*U2
Sequence 2
(N=n2)
Receiving Treatment B
y 2Jl + ^  + < P b + £ 2jx
Receiving Treatment A
y 2J2 = M  + X 2 + ( P a + £ 2j 2
2.A.2 Evaluate the treatment effect using simple cross-over 
differences
The most straightforward way to analyse a  cross-over trial is to use 
a  m atched-pairs t test on the treatm ent difference. To estim ate the 
difference q>b -  (pa between treatm ent A and trea tm ent B, differences 
y Xj2 - y XjX are calculated for patients random ised to sequence 1 and
yij\ ~yij2 for patients randomised to sequence 2.
The m ean of treatm ent differences —----------------- —---------------  and
«, + n2
their standard  deviation are then used to te st against the null 
hypothesis th a t there are no treatm ent differences using the 
m atched-pairs t test. The underlying assum ptions of this analysis 
are tha t the cross-over differences are distributed a t random  about 
the true treatm ent effect and th a t any differences in the
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observations between themselves are random . This was also the 
analysis commonly adopted before the m ethod to test for the carry­
over effect (the two-stage procedure) was introduced.
2.A.3 Testing for the period effect
It was dem onstrated by Hills and Armitage [7] th a t the period 
difference it2 -  nx can be estim ated by
an independent t-test is used to compare (ylj2 - y XjX) of patients 
randomised to sequence 1 and (y2jX - y 2j2) °f patients random ised to 
sequence 2.
2.A.4 Adjusting for the period effect
The period effect can also be adjusted for when testing for the 
treatm ent effect. This can be done by using an  independent t-test to 
compare the period difference, i.e., period 2 -  period 1 for both
. To test the hypothesis th a t = 71 \ ,2
sequence groups, with
n,
(«, + n2 -2 )  degrees of freedom[19].
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2.A.5 An example of analysis
An example of AB/BA trial da tase t from Hills and Armitage [7] is 
used  to illustrate the three types of analyses d iscussed in Sections 
2.A.2, 2.A.3 and 2.A.4. The triad was conducted on patients with 
enuresis (bed-wetting), the num bers shown in the colum ns of 
period 1 and period 2 aire the num bers of dry nights out of 14 days 
tha t they were given the treatm ent or placebo. The analysis will first 
be calculated step by step such as might be done using a  scientific 
calculator or spreadsheet, followed by the SAS® code and output.
Example: Twenty-nine patients are random ised to either group 1 or 
group 2. Patients (nj= 17) randomised to the sequence 1 receive the 
active treatm ent in the period 1 and placebo in the second period. 
The order of drug/placebo is in the reverse order for patien ts (n2=12) 
randomised to sequence 2. The observations of each patient from 
each treatm ent period are listed in Table 2.A.3. The sum s, m eans 
and standard deviations were calculated using Microsoft Excel®.
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Table 2.A.3
Sequence 1 (drug/placebo)
Patient Period 1 Period 2 Treatment Period
Number (drug) (placebo) Difference (drug- 
placebo)
Difference
17 Yi y2
r
CM
>-1> <
 
i 
|
-< M 
1
1 8 5 3 3
3 14 10 4 4
4 8 0 8 8
6 9 7 2 2
7 11 6 5 5
9 3 5 -2 -2
11 6 0 6 6
13 0 0 0 0
16 13 12 1 1
18 10 2 8 8
19 7 5 2 2
21 13 13 0 0
22 8 10 -2 -2
24 7 7 0 0
25 9 0 9 9
27 10 6 4 4
28 2 2 0 0
Sum 138 90 48 48
Mean 8.12 5.29 2.82 2.82
Standard
Deviation
3.84 4.25 3.47 3.47
Sequence 2 (Placebo/drug)
Patient Period 1 Period 2 Treatment Period
Number (placebo) (drug) Difference 
(drug -  placebo)
difference
02=12 Yi y2 Y z-Y , Yi -Y2
2 12 11 -1 1
5 6 8 2 -2
8 13 9 -4 4
10 8 8 0 0
12 8 9 1 -1
14 4 8 4 -4
15 8 14 6 -6
17 2 4 2 -2
20 8 13 5 -5
23 9 7 -2 2
26 7 10 3 -3
29 7 6 -1 1
Sum 92 107 15 -15
Mean 7.67 8.92 1.25 -1.25
Standard
Deviation
2.99 2.81 2.99 2.99
U s e  o f  t h e  t w o - s t a g e  p r o c e d u r e  f o r  a n a l y s i s  o f  c r o s s - o v e r  t r i a l s  in  f o u r  a s p e c t s  o f  m e d ic a l  s t a t i s t i c s
2.A.5.1 Testing the cross-over difference using paired t-test
If the period effect is ignored, the treatm ent effect is evaluated by 
the cross-over differences as described in Section 2.A.2. The t-
statistics for a  paired t-test is defined as: t = — — —  
where:
x  are the within-patient difference between treatm ents A and B,
H is the population m ean under the null hypothesis (usually =0 
and this is the value adopted here)
N -  m + ri2,
and SD denotes the standard  deviation of the m ean
Mean of cross-over difference= sum(cross-over difference) /  N  = 63 
/  29 = 2.17
Degrees of freedom= (ni-1) + (n2-l) = (17-1) + (12-1) = 27 
SD (Standard deviation) = 3.32
SE (Standard error of the mean) = SD /  VN = 3.32 /  V29 = 0.61 
t statistics = m ean/SE = 3.53 
p-value = 0.0015
The p value of the paired t-test shows th a t the difference between 
the placebo and the treatm ent is significant a t the 5% level.
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2.A.5.2 Calculation of the independent t-test
The independent t-test is used to examine the treatm ent effect with 
an  adjustm ent for the period effect (Sections 2.A.3 and 2.A.4). The 
t-statistics of an independent t-test is defined as:
t = (dx- d 2) - ( n x- m2)
nx- n 2- 2
where
dx are the w ithin-patient difference between periods for sequence 
/ (/ = 1,2), and
//, is the population m ean under the null hypothesis (both jux and 
/i2 are set a t 0)
The formulae used to calculate the t-sta tistics for the tables of 
results (2.A.5.3 and 2.A.5.4) are listed in Table 2.A.4.
Table 2.A.4
Independent t-test
N = nx+n2 Sequence 1
n2
Sequence 2
Mean (of the period 
difference) ~dx ~d 2
Standard Deviation SDX sd 2
Correlated sums square SSx=(nx- \ ) x S D 2 SS2 =(n2- \ ) x S D 2
Pooled estimate of 
variance
EV = (SSx+SS2) / (N -  2)
Difference in Mean D = J X-  ~d2
Standard error of 
difference in means s.E.=pvx(y i+yn2)}
t statistics = D// S.E.
Pr > t (p-value) If the experiment is conducted an infinity of times, the 
probability of obtaining this t-statistic or more extreme.
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2.A.5.3 Testing for the period effect
The period difference of each patien t and  its m ean and standard  
deviation in each sequence were already provided in Table 2.A.3. 
Using the formulae shown on Table 2.A.4, the t-statistics for the 
period effect is 1.28. The correspondent p value a t 27 degrees of 
freedom is 0.21. The period effect was therefore not significant a t 
the 5% level.
Table 2.A.5
Testing for the period difference using Independent t-test
Sequence 1 Sequence 2
(Drug/placebo) (Placebo/drug)
/i, =17 n2 = 12
Mean 2.82 1.25
Standard Deviation 3.47 2.99
Correlated sums square = 16x3.47"= 192.47 = 11 x 2.99" =98.25
Pooled estimate of variance = (192.47+98.25) / (29-2) = 10.77
Difference in Mean = 2 .82 -1 .25  = 1.57
Standard error of difference 
in means
= V{10.77x (1/17 + 1/12)}= 1.23
t statistics = 1.57/1.23 = 1.28
Pr > t 0.21
2.A.5.4 Adjusting for the period effect
The statistics for the test of the treatm ent effect with ad justm ent for 
the period effect are similar to those for the te st for the period effect 
except the mean difference. The t-statistics derived is 3.31 with a 
correspondent p-value of 0.0028. The trea tm ent effect rem ains 
significant a t the 5% level after ad justm ent for the period effect.
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Table 2.A.6
Examining the treatment effect with adjustment for the period effect using independent
t-test
Sequence 1 
(Drug/placebo)
n, = 1 7
Sequence 2 
(Placebo/drug)
n2 = 12
Mean (of the period 
difference)
2.82 -1.25
Standard Deviation 3.47 2.99
Correlated sums square = 16x3.47 '=  192.47 = 11 x 2.99'=98.25
Pooled estimate of variance = ( 192.47 + 98.25 ) / ( 29 - 2 ) = 10.77
Difference in Mean = 2 .8 2 - (-1.25) = 4.07
Standard error of difference 
in means
= V{10.77 x (1/17 + 1/12)} = 1.23
t statistics = 4.07/1.23 = 3.31
Pr > / 0.0028
2.A.5.5 SAS programming for the analysis of cross-over trials
The SAS codes for the three types of analyses are as following:
input id group drug placebo;
/* specifying variables*/
/*id = patient's id number*/
/*group = randomised sequence; 1 = drug/placebo, 2 = place/drug*/ 
/*drug = measurement of the patient of the drug period*/
/*placebo = measurement of the patient of the placebo period*/ 
Datalines; /*data entry*/
1 1 8  5 
2 2 11 12
3 1 14 10
4 1 8  0
5 2 8 6
6 1 9  7
7 1 11 6
8 2 9 13
9 1 3  5
10 2 8 8 
11 1 6 0
12 2 9 8
13 1 0 0
14 2 8 4
15 2 14 8
16 1 13 12
17 2 4 2
18 1 10 2
19 1 7 5
20 2 13 8
21 1 13 13
22 1 8 10
23 2 7 9
24 1 7 7
25 1 9 0
26 2 10 7
27 1 10 6
28 1 2 2 
29 2 6 7;
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run;
proc print data=save.example; 
run;
data exa;
set save.example;
If group =1 then pdiff= placebo - drug;
Else if group =2 then pdiff = drug- placebo; /*taking period
difference*/
run;
/*Testing for the CROSS-OVER DIFFERENCE using paired t-test*/
Proc ttest;
Paired drug*placebo;
Run;
/♦Testing for the PERIOD EFFECT using independent t-test*/
proc ttest;
class group;
var pdiff;
run;
/♦Adjusting for the PERIOD EFFECT*/ 
proc ttest;
Class group; 
var tdiff; 
run;
The code above produced the same results as the manual 
calculation dem onstrated in Section 2.A.5. The outputs of the three 
analyses are as following:
SAS Output:
The TTEST Procedure 
Statistics
Lower CL Upper CL Lower CL Upper CL
Difference N Mean Mean Mean Std Dev Std Dev Std Dev
Std Err
drug - placebo 29 0.9106 2.1724 3.4343 2.6326 3.3174 4.4866
0.616
T-Tests
Difference DF t Value Pr > |t|
drug - placebo 28 3.53 0.0015
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CL
Variable 
Dev Std
pdiff
5.2786
pdiff
5.0743
pdiff
4.4664
CL
Variable 
Std Err
tdiff
0.8412
tdiff
0.8627
tdiff 
1.2372
The TTEST Procedure 
Statistics
Lower CL Upper CL Lower CL Upper
GROUP N Mean Mean Mean Std Dev Std Dev Std
Err
17 -4.607 -2.824 -1.04 2.5831 3.4683
0.8412
1
12 -0.649 1.25 3.1489 2.1171 2.9886
0.8627
2
Diff (1-2) -6.612 -4.074 -1.535 2.5943 3.2814
1.2372
T-Tests
Variable Method Variances DF t Value Pr > |t|
pdiff Pooled Equal 27 -3.29 0.0028
pdiff Satterthwaite Unequal 25.8 -3.38 0.0023
Equality of Variances 
Variable Method Num DF Den DF F Value Pr > F
pdiff Folded F 16 11 1.35 0.6260
Statistics
Lower CL Upper CL Lower CL Upper
GROUP N Mean Mean Mean Std Dev Std Dev Std Dev
17 1.0403 2.8235 4.6068 2.5831 3.4683 5.2786
1
12 -0.649 1.25 3.1489 2.1171 2.9886 5.0743
2
Diff (1-2) -0.965 1.5735 4.1121 2.5943 3.2814 4.4664
T-Tests
Variable Method Variances DF t Value Pr > |t|
tdiff Pooled Equal 27 1.27 0.2143
Equality of Variances 
Variable Method Num DF Den DF F Value Pr > F
tdiff Folded F 16 11 1.35 0.6260
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2.A.6 Analyse of cross-over trials using general linear models
As the t-test is a special case of the Analysis of Variance (ANOVA) 
which is a  type of general linear model, identical resu lts can also be 
derived using the general linear model shown in 2.A. 1. When 
patients are fitted as fixed effect in the general linear models, the 
results derived from the general linear models are identical to the t- 
test. In order to fit general linear models for cross-over trials, the 
d a tase t was re-structured  in a  way th a t each m easurem ent was 
treated as an  observation, the treatm ent received for the 
m easurem ent and the treatm ent period (first or second) were 
specified for each observation.
The SAS code for the general linear models w ithout and  w ithout 
ad justm ent to the period effect are as following:
data exa;
/* Re-arrange the data structure*/
/*group =randomized sequence; l=drug/placebo, 2=placebo/drug*/ 
/*treatment=the treatment the patient received during that 
period*/
/*obs=measurement of the patient of that period*/ 
/*period=treatment period*/ 
input group id treat$ obs period; 
cards;
1 1 drug 8 1 
1 1 placebo 5 2 
1 3 drug 14 1 
1 3 placebo 10 2 
1 4 drug 8 1 
1 4 placebo 0 2 
1 6 drug 9 1 
1 6 placebo 7 2 
1 7 drug 11 1 
1 7 placebo 6 2 
1 9 drug 3 1 
1 9 placebo 5 2 
1 11 drug 6 1 
1 11 placebo 0 2 
1 13 drug 0 1 
1 13 placebo 0 2 
1 16 drug 13 1 
1 16 placebo 12 2 
1 18 drug 10 1 
1 18 placebo 2 2
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1 19 drug 7 1 
1 19 placebo 5 2 
1 21 drug 13 1 
1 21 placebo 13 2 
1 22 drug 8 1 
1 22 placebo 10 2 
1 2 4 drug 7 1 
1 24 placebo 7 2 
1 25 drug 9 1 
1 25 placebo 0 2 
1 27 drug 10 1 
1 27 placebo 6 2 
1 28 drug 2 1
1 28 placebo 2 2
2 2 placebo 12 1 
2 2 drug 11 2
2 5 placebo 6 1 
2 5 drug 8 2 
2 8 placebo 13 1 
2 8 drug 9 2 
2 10 placebo 8 1 
2 10 drug 8 2 
2 12 placebo 8 1 
2 12 drug 9 2 
2 14 placebo 4 1 
2 14 drug 8 2 
2 15 placebo 8 1 
2 15 drug 14 2 
2 17 placebo 2 1 
2 17 drug 4 2 
2 20 placebo 8 1 
2 20 drug 13 2 
2 23 placebo 9 1 
2 23 drug 7 2 
2 2 6 placebo 7 1 
2 26 drug 10 2 
2 29 placebo 7 1 
2 2 9 drug 6 2
run;
/*Evaluating the treatment effect using general linear model*/
proc glm;
class treat id;
model obs= treat id;
run;
/*Test and adjust for the period effect using a general linear
model*/
proc glm;
class treat period id; 
model obs=treat id period; 
run;
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SAS output:
The GLM Procedure
Dependent Variable: obs
Source DF Squares
Model 29 669.3275862
Error 28 154.0689655
Corrected Total 57 823.3965517
Sum of
Mean Square F Value 
23.0802616 4.19
5.5024631
R-Square Coeff Var Root MSE obs Mean
0.812886 31.86241 2.345733 7.362069
Source
treat
id
DF Type I SS Mean Square F Value
1 68.4310345
28 600.8965517
68.4310345 
21.4605911
12.44
3.90
Dependent Variable: obs
Source
Model
Error
Corrected Total 
R-Square 
0.823463
Source
treat
id
period
The GLM Procedure 
Class Level Information
Sum of 
Squares Mean Square F Value 
4.20678.0362576 22.6012086
145.3602941 5.3837146
823.3965517 
Coeff Var Root MSE obs Mean
31.51673 2.320283 7.362069
DF Type I SS Mean Square F Value
1
28
1
68.4310345
600.8965517
8.7086714
68.4310345 
21.4605911 
8.7086714
12.71 
3.99 
1 .62
Source
treat
id
period
DF
1
28
1
Type III SS Mean Square F Value
58.3638438
600.8965517
8.7086714
58.3638438 
21.4605911 
8.7086714
10.84 
3.99 
1 .62
Pr > F 
0 .0001
Pr > F
0.0015
0.0003
Pr > F 
0 .0 0 0 2
Pr > F
0.0014
0.0003
0.2143
Pr > F
0.0028
0.0003
0.2143
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2.A.7 Patient Effect and missing data using mixed models
The m ethods shown in Sections 2.A.2 to 2.A.6 can only be applied 
to datasets  which are balanced. Therefore patien ts who did not 
complete both treatm ent periods would be excluded from the 
analysis. As the trial period is often longer for a  cross-over trial 
than  a  parallel trial, patients are more likely to drop out and 
consequently the da tase t may contain som e/m ore m issing values.
A mixed model th a t contains both fixed and random  effects (also 
called multi-level analysis in some areas of research such  as 
sociology and epidemiology) can be used to deal with the missing 
values in cross-over design.
Fitting patient effect as a  random  effect utilises the information on 
patients who have no t completed the trial. The information of 
patients who have not participated in the second period can be 
used to pool betw een-patients differences. The resu lts of fixed or 
random  effects analyses are identical when there are no missing 
values.
A statistical model th a t incorporates the patient effect as random  
can be denoted as:
y,jk =M + &j +*k+(Pi+ £,jk 
where
gg = the effect of patien t j  of the i -th sequence and ^  ~ N(0,ar^) 
Definitions of all o ther term s are the sam e as the equation (2.A.1)
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2.A.8 Statistical programming for the analysis of cross-over trials 
using mixed model
When there is no period effect, the SAS® code below shows the 
statistical model th a t contains the trea tm ent effect and patient 
effect as random.
proc mixed;
class treat patient; 
model y = treat; 
random patient; 
run;
The period effect can also be tested and adjusted for using  a  similar 
procedure, the SAS® code below shows the statistical model th a t 
contains the treatm ent effect, the period effect and patien t effect as 
random.
proc mixed;
class treat patient; 
model y = treat period; 
random patient; 
run;
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2.B Testing for the carry-over differences and the two-stage 
procedure
This section describes Grizzle’s [4] and Hills and  Armitages’ [7] 
m ethods to examine the carry-over effect, followed by two examples 
of applications of the two-stage procedure to cover both cases 
(carry-over effect significant and insignificant). With the actual type 
I error rate of 7-9.5%, the two-stage procedure is the recommended 
m ethod for analysis of cross-over trials. The examples only serve 
the purpose of referencing the results found in the system atic 
review on published cross-over tried reports and the comprehensive 
review of general medical statistics book.
2.B.1 Grizzle’s model
Testing for the carry-over effect was first introduced by Grizzle 
(1965). In addition to the direct drug effect (treatment) effect, the 
residual (carry-over) effect, the period effect, and the patien t effect 
were also included in the model. The statistical model he suggested 
was as follow:
yijk=M + £ij + Xk+Vi + *i+ £ijk (2.B. 1) 
where
y jjk = the  m easurem ent of j-th  patient in the i-th sequence a t the /c th  period.
[A = general m ean
= the effect of j- th  patient, within the i-th sequence 
7Tk = the  effect of the fc-th period
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<pt = the  direct effect of the drug  I [For p a tien ts  random ised to the  trea tm ent 
sequence 1 (/ =1), / =A when k= 1, I =B w hen k =2. For pa tien ts  random ised to 
the treatm en t sequence 2 (/ =2), / =B w hen k = 1, /  = A w hen k =2]
A, = the residual effect of the  Z-th drug and
eijk = the random  fluctuation which is normally distributed with 
m ean 0 and variance cr], and is independent of ^
For a  AB/BA trial, the param eters for each trea tm ent period would 
be as follow:
Table 2.B.2 ___________________________________________________________________________
Period 1 Period 2
Sequence 1
(N = nx) yijl=M + £ l j + X l + < P a + S l j \
y\j2 =  A + Z\j + n 2 + 9 b  + K  +  e\j2
Sequence 2
(N = n2)
y 2j 1 =M + Z 2j + X i + < P b + £ 2 j i y2J2 -  P  + %2j + n2 +  <Pa +  A  +  S2J2
The m ain objective of this paper was to present the unbiased 
estim ates of contrasts of treatm ent effects and the carry-over 
effects. Based on the assum ption tha t patient effects are the sam e 
(in expectation) for both sequences
£fc}= £ ^ 2 }, the unbiased estimates of contrasts of the carry-over 
effect are y u + y x2~ y 2,i ~ y 2,2 default estim ates of con trast for 
trea tm ent effects were set to be based on the period 1 data  only 
(yM -  y 2,)• The method used to test the hypothesis of equal carry­
over effect was the one-way Analysis of Variance (ANOVA).
Grizzle [4] suggested th a t I f  the residual effects of the two drugs are 
equal we can delete residual effects from the model.’ This would
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then perm it one to estim ate the treatm ent effect using within 
patien t differences. The decision of w hether to delete the residual 
effect should be based on a  preliminary test of high significance 
level. He then set a  = .10 as ‘Larson and Bancroft (1963) 
dem onstrated th a t few serious errors would be m ade if the 
preliminary test were m ade a t this level’.
The significance level of the residual effect also determ ined how the 
trial would be analysed. If the hypothesis th a t \  using a  = .10 
was accepted, then the analysis of the treatm ent would be based on 
the analysis of variance with residual effect omitted. If such  a  
hypothesis was rejected a t the 10% level, the analysis of treatm ent 
effects would inevitably fall back to the default estim ates of contrast 
which would base on the  da ta  from period 1 only.
2.B.2 Hills and Armitages’ (1979) approach to the carry-over 
effect
A very similar approach with different presentation was adopted by 
Hills and  Armitage [7]. To test the hypothesis \  , they used  the
independent t-test to compare the m eans of (yi7l+yu2) from 
patien ts random ised to sequence 1 with the m eans of (y2j\+ylj2)
from patien ts random ised to sequence 2. The m athem atics of the 
independent t-test are however, equivalent to the one-way ANOVA 
suggested by Grizzle [4].
Testing for the carry-over effect and testing for the treatm ent effect 
using either period 1 only or the differences between the two
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periods are the three tests th a t form the two-stage procedure (or 
Hills and Armitage method). Three labels, CARRY, CROS and PAR 
are commonly used to denote these three tests.
CARRY indicates the test for the carry-over difference.
CROS indicates the test for the treatm ent effect using cross-over 
differences.
PAR indicates the te st for treatm ent effect using first period only. 
2.B.3 Previous Example
The datase t used  in p a rt A is used here to dem onstrate Hill and 
Armitage’s approach to the carry-over effect. An independent t-test 
is used to examine the difference between sum s of the 2 periods of 
both sequences. The p value for the t-statistics of -1.30 a t 27 
degrees of freedom is 0.20. Therefore the carry-over effect is not 
significant a t the 10% level. According to the two-stage procedure 
proposed by Hills and  Armitage [7], the treatm ent would be 
analysed using the cross-over difference as illustrated in Section 
2.A.5.I.
Table 2.B J
Testing for the carry-over effect using independent t-test
Sequence 1 Sequence 2
(Drug/placebo) (Placebo/drug)
ni~ 17 n2 = 12
Mean (of period total) 13.41 16.58
Standard Deviation 7.32 4.98
Correlated sums square = 16 x 7.32* = 857.32 = 11 x 4.98^ = 272.80
Pooled estimate of variance = ( 857.32 + 272.80) / (29-2) = 41.86
Difference in Mean = 13.41-16.58= -3.17
Standard error of difference 
in means
= V{41.98x (1/17+ 1/12)} =2.44
t statistics = -3.17/2.44 = -1.30
Pr > 0.20
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2.B.4 Modified dataset
In order to illustrate the method used  to analyse the treatm ent 
effect when the carry-over effect is found to be significant, the data  
were m anipulated with the purpose of showing significance in the 
carry-over effect a t the 10% level.
The m easurem ents of patients were modified so th a t the carry-over 
effect would be tested to be significant while the num ber of patients 
in each group and the sequence each patient was random ised to 
rem ain the same.
The modified datase t is as following:
Table 2.B.4
S eq u en ce  1 (drug/placebo)
Patient Period 1 Period 2 Sum
Number (drug) (placebo)
n!=17 Yi y 2 Y i + Y2
1 8 15 23
3 14 16 30
4 10 17 27
6 9 12 21
7 11 16 27
9 13 5 18
11 16 8 24
13 0 2 2
16 13 16 29
18 10 12 22
19 7 15 22
21 13 14 27
22 8 10 18
24 7 8 15
25 9 12 21
27 10 12 22
28 2 3 5
Sum 160 193 353
Mean 9.41 11.35 20.76
Standard
Deviation
4.07 4.70 7.66
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Sequence 2 Placebo/drug)
Patient Period 1 Period 2 Sum
Number (placebo) (drug)
n2 = 12 Yi y2 Yi + Y2
2 6 5 11
5 6 8 14
8 3 9 12
10 8 8 16
12 8 9 17
14 4 8 12
15 8 14 22
17 2 4 6
20 5 13 18
23 6 7 13
26 7 10 17
29 7 8 15
Sum 70 103 173
Mean 5.83 8.58 14.41
Standard
Deviation
1.99 2.84 4.08
2.B.4.1 Testing for the carry-over effect
An independent t-test is used on the sum  of the two treatm ent 
periods from each sequence. The t statistics derived from the  two 
sequences is 2.43 and  it gives a  p value of 0.01 a t 27 degrees of 
freedom. The carry-over effect is significant a t the 10% level. 
Therefore the treatm ent effect will be evaluated using the first 
period only.
Table 2.B.5
Testing for the carry-over effect using independent t-test
Sequence 1 Sequence 2
(Drug/placebo) (Placebo/drug)
nx = 17 n2 = 12
Mean (sum of 2 periods) = 20.76 = 14.41
Standard Deviation = 7.66 = 4.08
Correlated sums square =16 x 7.66* = 938.81 = 11 x 4.08* = 183.11
Difference in Mean = 20.76-14.41 =6.35
Pooled estimate of variance =(938.81+183.11)/(29-2) = 41.55
Standard error of difference 
in means
= V{41.55 x (1/17 + 1/12)} = 2.43
t statistics = 6.35/2.43 = 2.61
Pr > / 0.01
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2.B.4.2 Examining the treatment effect using first period data only
To examine the treatm ent effect, an independent t-test is used on 
the first period data. Patients in sequence 1 received drug during 
period one while patients in sequence 2 received the placebo. The t- 
statistics of 2.82 a t 27 is significant a t 1% level.
Table 2.B.6
Examining the treatment effect using first period data only by independent t-test
Sequence 1 Sequence 2
(Drug/placebo) (Placebo/drug)
w, = 17 n2 = 1 2
Mean (of period 1) = 9.41 = 5.83
Standard Deviation = 4.07 = 1.99
Correlated sums square = 16 x 4.07^ = 265.04 = 11 x 1.99* =43.56
Difference in Mean = 9 .4 1 -5 .8 3  = 3.58
Pooled estimate of variance = ( 265.04 + 43.56 ) / ( 29 - 2 ) = 11.43
Standard error of difference 
in means
= V{11.43 x (1/17+ 1/12)} =1.27
t statistics = 3 .58 /1 .27= 2.82
Pr > t 0.0093
2.B.4.3 SAS code
The following are the SAS code and outputs for the analyses in 
Sections 2.B.4.1 and 2.B.4.2.
libname save 'c:\';
data save.example;
input id group drug placebo;
Datalines;
1 1 8 15
2 2 5 6
3 1 14 16
4 1 10 17
5 2 8 6
6 1 9 12
7 1 11 16
8 2 9 3
9 1 13 5
10 2 8 8 
11 1 16 8
12 2 9 8
13 1 0 2
14 2 8 4
15 2 14 8
16 1 13 16
17 2 4 2
18 1 10 12
U s e  o f  t h e  t w o - s t a g e  p r o c e d u r e  f o r  a n a l y s i s  o f  c r o s s -o v e r  t r i a l s  in  f o u r  a s p e c t s  o f  m e d i c a l  s t a t i s t i c s
19 1 7 15
20 2 13 5
21 1 13 14
22 1 8 10
23 2 7 6
24 1 7 8
25 1 9 12
26 2 10 7
27 1 10 12
28 1 2 3
29 2 8 7
run;
data exa;
set save.example;
If group =1 then pdiff= placebo - drug;
Else if group =2 then pdiff = drug- placebo; /*taking period 
difference*/
tdiff=drug-placebo; /*taking treatment difference*/ 
carry=drug+placebo; /*taking the sum of the 2 periods*/
If group =1 then periodl = drug; /*specify the period 1 data*/
Else if group =2 then periodl = placebo;
run;
proc ttest; /*testing for the carry-over difference*/
class group;
run;
proc ttest; /*testing for the treatment difference using period
data only*/
class group;
var periodl;
run;
SAS output
The TTEST Procedure 
Statistics
Lower CL
Variable GROUP N Mean Mean
Upper CL Lower CL Upper CL
carry
carry
17 16.826 20.765
carry Diff (1-2) 
8.7743 2.4305
Mean Std Dev Std Dev Std Dev Std Err
24.704 5.7057 7.661 11.66 1.8581
12 11.826 14.417 17.008 2.8887 4.0778 6.9237 1.1772
1.3611 6.348 11.335 5.0966 6.4463
Variable
carry
Variable
Method
Pooled
T-Tests
Variances
Equal
DF t Value Pr > |t| 
27 2.61 0.0145
Equality of Variances 
Method Num DF Den DF F Value Pr > F
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carry Folded F 16 11 3.53 0.0393
The TTEST Procedure 
Statistics
wer CL Upper CL Lower CL Upper CL
Variable GROUP N Mean Mean Mean Std Dev Std Dev Std Dev Std Err
periodl 17 7.3149 9.4118 11.509 3.0374 4.0783 6.2068
0.9891
1
periodl 12 4.5674 5.8333 7.0993 1.4114 1.9924 3.3829
0.5752
2
periodl Diff (1-2) 0.958 3.5784 6.1989 2.678 3.3873
4.6105 1.2771
T-Tests
Variable Method Variances DF t Value Pr > |t|
periodl Pooled Equal 27 2.80 0.0093
Equality of Variances 
Variable Method Num DF Den DF F Value Pr > F
periodl Folded F 16 11 4.19 0.0204
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2.C Performance of the two-stage procedure
This section presents a  literature review on the perform ance of the 
two-stage procedure, which has been discussed in term s of its 
power and the type I error rate.
The first paper tha t discussed the type I error rate  of the two-stage 
procedure was Freeman [8]. It was presented by the coverage 
probability which is 1-type I error rate. One assum ption  m ade in 
this paper was to eliminate the between patient variations. The d a ta  
were reduced to the w ithin-patient variation only by subtracting the 
baseline value a t the beginning of the experiment. With the sam e 
notations as the statistical model described in equation 2.A.1, the 
param eters and methods used  by Freeman [8] are as follow:
^ij ~ yyi yiji 2y(j01 f j  — yy\ y ijq i d ^  — y^ y
S — i
and F = — S + D 
2
The sam pling distributions of S , F and D are:
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The correlation coefficient between two distributions with variances 
1S, and S2 is=
1 +
y
The correlation between 
1
and S is therefore
Act2 
1+ n
L = r  =  —  =s 0 . 8 6 6  
1 2
1 +
\ 2 g 1
n
Coverage probability (=l-type I error rate) of the two-stage 
procedure:
CPa = prob 
(2.C.1)
S_ n_ 
a  V 12
< Z„ and (D-(j>)4n <Z„ + prob 5 \n_ 
(TV 12
> Z„ and
2(7
Since CARRY was set a t 10%, and CROS and PAR were both set a t 
5% a, = 0.10, a = 0.05 => Zai = 1.645, Za = 1.96
Since F and 5 are normally distributed and correlated, the second 
term  can be expressed as a  Bivariate norm al distribution. The 
probability under the Bivariate normal distribution can be
evaluated using a  double integration:
P(U < u,V < v,p) =
2n-yJ\ -
v u
S /exp (U2 -  2pUV +V2)2(1 ~ v ) dUdV
where p  is the correlation between the two distributions
Therefore
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prob > Z„ and
= prob
prob
- E- V 12 
cr V12 “>
V
s_ IV
a  V12
2a
<Z„
— >Z„ -Z  <
— < -Z„ -  Z„ <
(F -</>)4n 
2a
(F -  fajn  
2 a
<Z„
<Z„
2W T O’ z„ -z,
J Jexp
-2 x 0 .8 6 6  x - J ^ - x  I cr V 12 , o-V12
S \~n (F -  <p)4n ( {F -  <f>)4n^
2 a 2 a
2 x ( l -0.866 )
~Z<n z«
+W T^iJexp
1—  ^n -2x0.866 x—J-n ^(F-0)y/n ( f  ( F - 0 ) ^
V1 2 J a  VI12 2a [  2 a  J
2x(l -0.8662)
Freeman [8] showed th a t the coverage probability was only 0.917 
when there is no carryover (A = 0) and the coverage probability
drops to the lowest point (0.56) when a(Vw)/<7 is around 5. The 
calculations of these two examples are as following:
Case 1: A = 0
prob S_ \n_ 
a  V12
>Z„ and (D -  <f>)4n
2 a
<Z„ + prob S_ \n_ 
a  V 12
> Z„ and
2 a
<Z.
= 0.90x0.95 + prob —J —  >1.645 and 
a \  12
prob —J —  <-1.645 and 
a  V12
1 9 6 < ( F - ^ < 1 9 6
2< t
\
2cr
96
/
= 0.8550+ 0.031 +0.031A 
= 0.917
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The double integral used  to evaluate the probability under the 
Bivariate distribution was evaluated using a  Maple program  as 
shown in Figure A.
Maple Code: Bivariate Normal Distribution Function
>f :=(x,y,rho) ->(1/ (2*Pi*sqrt(l-rhoA2) ) ) *exp ( (-1/ (2* (1- 
rhoA2)))*(xA2+yA2-2*rho*x*y));
f  1 7x  + y  ~ 2 p x y
f  '= (x,y, rho) —> —
2 ^ 1  - P 2
>int(int(f <x,y,0.866) ,x=-infinity..-1.645) ,y=-l. 96..1.96) ;
0.03147187089
> int (int (f(x,y,0.866) , x=l. 645. . infinity) ,y=:-l. 96. . 1. 96) ;
0.03147187089
The coverage probability of the two-stage procedure while there is 
no carryover is therefore 0.8550+0.062=0.917
_ _ Xyfn _Case 2:  = 5
The first part of the equation 2C is evaluated as the follows. 
prob
= prob Z„ <—J — <Z„ x prob 
<r V 12
f
<Z„ and (D -fyJn
\
<za
V(T V12
a\ cr
S \n \ 'z A D z » C n '
o
o
-Z . -  A
cr V12
V r r
X o
) _ .  V
1 Xyfn Z„ + --------
2 cr
-O i-z„ +—-
“  2 <7
1.645— ~  1-0  
yf\2
-1.645-
Vl2
O 1.96 + —x5J-Ol-1.96 +—x5
= (0.5798 -  0.001) x (1 -  0.7054) 
= 0.5788x0.2946 
= 0.1705
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For the second part of the equation 2C, the value of the double 
integral was calculated using a  Maple program  as shown in Figure 
B.
Let S’ be a  normal distribution.
Let U  be a  normal distribution.
Let F  be a  normal distribution.
v
>Z„ and
> Z„ and - Z  <
/
= prob (S ' > 1.645 +1.443 and -1.96 -  2.5 < Z)' < 1.96 -  2.5) + 
prob (S '< - 1.645 +1.443 and -1.96 < F ' < 1.96)
= prob ( S ' > 3.088 and -4.46 < D' < -0.54) + 
prob(S'< -0.202 and -1.96 < F ' <  1.96)
= 1.480 xl0~14 +0.3951 
*0.3951
Maple Code: Bivariate Normal Distribution Function
> f : = (x,y,rho) ->(1/ (2*Pi*sqrt (l-rhoA2))) *exp< (—1/(2* (1 — 
rhoA2)))*(xA2+yA2-2*rho*x*y));
> int(int(f(x,y,0.866),x=3.08837567297406. . infinity) ,y=-4.46..-0.54) ;
1.480240143 1 0 '14
> int(int(f(x,y,0.866),x=-infinity..-0.20162432702594),y=-l.96..1.96);
0.3951169099
is therefore 0.1705 +0.3951=0.56
The conclusion of Freeman [8] was th a t the two-stage procedure
f  :- (x ,y , rho) —>e
2 7T 1/1 - p 2
The coverage probability of the two-stage procedure while
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is slightly misleading even when there is no carryover whatsoever, 
and potentially very misleading when there is even a  small 
differential carryover effect.
The deficiencies of the two-stage procedure in com parison with 
CROS and PAR were also discussed by Jones and Lewis [45] and 
Grieve and Senn [46].
Jones and Lewis [45] used a  simulation to dem onstrate th a t the 
power and bias of the two-stage procedure were only slightly 
misleading under a  m oderate level of carry-over effect.
The assum ptions they used  for the simulation were:
Treatm ent effect <f> = 0
W ithin-patient variance cr\ = 48
Between-patient variance g\ = 96
Number of patients in both groups w, = n2 = 22
Although Jones and Lewis [45] considered th a t using the CROS 
procedure under the assum ption tha t no carry-over effect is the 
best strategy, they showed that the power of the two-stage 
procedure is only 10% below the target level when A (the carry-over 
effect) is less than  1.5. They also showed th a t the CROS procedure 
has a  higher bias level than  the two-stage procedure.
Grieve and Senn [46] considered the false-positive rate is the more 
serious deficiency of the two-stage procedure by calculating the p- 
values of PAR and CROS conditional on the value of CARRY. They
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explained the reason th a t the two-stage procedure appeared to be 
less problematic in Jones and  Lewis [45] was th a t CROS was used 
m ost of the time. They showed th a t the PAR procedure is also 
vulnerable to the CARRY as
PAR = CROS + carry/ 2
E[PAR | CARRY] = E[CROS] =
and E[PAR \ CARRY] -(j> = {CARRY -A ) 12
which lead to E[PAR | CARRY] = + CAR^ L
If the two-stage procedure is used, large absolute values of CARRY 
would lead one to use the PAR procedure. When absolute values of 
CARRY are low, the two-stage procedure would be very sim ilar to 
CROS. However when PAR is used, it is subject to high level of bias. 
Grieve and Senn [46] suggested tha t the two-stage procedure 
should be examined especially when it differs from the CROS. They 
showed th a t the p-value of the treatm ent effect is only reduced to 
the claimed 5% level or lower when the p-value of the CARRY test is 
around 15% or above. However, the PAR procedure would not have 
been used when the p-value is 10% or higher. In other words, when 
the PAR procedure is used, it is usually very misleading. Therefore 
the two-stage procedure would perform extremely badly when p- 
value of the CARRY test is low (when PAR is used). They therefore 
concluded th a t power comparisons are misleading.
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One way of correcting the size of the two-stage procedure to the 
level th a t was originally claimed, was suggested by Senn [22]. He 
showed th a t by setting PAR a t 0.5%, the size of the two-stage 
procedure would be between 4.75% and 5%. However, such  an 
adjustm ent is not recommended as the two-stage procedure loses 
its advantage in power.
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Chapter 3- Methodology____________
3.1. Introduction
Applications of and references to the two-stage procedure can easily 
be found in various domains of medical statistics where cross-over 
trials are introduced or analysed. The four m ain areas of medical 
statistics th a t involve analyses of cross-over trials are medical 
journals, statistical journals, medical statistics books and  the 
pharm aceutical industry. These four dom ains can be categorised 
into two: applications of, and references to, statistics. Applications 
of analyses of cross-over trials are found in medical jou rnals and 
the pharm aceutical industry. Trials reported in medical journals 
and analysed in the pharm aceutical industry are usually  m utually 
exclusive and present different phases of clinical triads. References 
to atnadyses of cross-over trials can be found in generad medicad 
statistics books and statisticad journals. Medical statistics books 
provide references to basic anadyses for clinicians or health  
practitioners while statisticad joumads publish statisticad m ethods 
a t a  more adveinced level.
Although the methods used in each area of medicad statistics may 
have an im pact on other areas, the contexts are m utually exclusive. 
Therefore, research on references and actual anadyses of cross-over 
trials will be conducted in adl four areas using  appropriate reseairch 
methods for each area of medical statistics.
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3.2. Research methods
3.2.1. Periodicals: All subjects
All three major articles (Grizzle 1965 [4], Hills and Armitage 1979 
[7] and  Freeman 1989 [8]) about the two-stage procedure were 
published in periodicals (statistical and m edical journals). Although 
the m ain issue with the method is its validity in  theory ra th e r than  
difficulties in applications, the development of the two-stage 
procedure has sparked some discussion in both  types of journals. 
Applications of the two-stage procedure are usually found in 
medical journals and discussions of such  a  statistical procedure 
are usually found in statistical journals. This p a rt of the thesis uses 
the num ber of citations given to the 3 publications of the two-stage 
procedure to quantify the influence of the  two-stage procedure and 
the finding of its deficiencies in journals covering both  applications 
and  methodologies of the different subjects.
Objective: The m ain objective of this study is to highlight the 
seriousness of the issue by quantifying the overall im pact of the 
two-stage procedure and  its deficiencies on both theories and 
applications of analyses of cross-over trials.
Research method: Citation analysis.
Citation analysis is a  bibliometric method th a t uses reference 
citations found in scientific papers as the  prim ary analytical tool 
[28].
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Strengths: The main strength  of the citation analysis is th a t all 
papers th a t contained any reference to the two-stage procedure 
(regardless of the subject of journals) are included in the study. The 
im pact of the two-stage procedure and its m ajor deficiency in 
different fields can be discussed in term s of their fields of research.
Weaknesses: Citation analysis is based on the assum ption tha t 
citations indicate use which is in fact not confirmed. Furtherm ore, 
it cannot be established whether the absence of citations of the 
two-stage procedure implies th a t it is not in use. Therefore, the 
study may not be able to give a  precise estim ate of w hat percentage 
of cross-over trials have been analysed with the two-stage 
procedure. In order to overcome this w eakness, a  system atic review 
is made of a  num ber of randomly selected cross-over trial reports 
published in medical journals.
3.2.2. Cross-over trials published in medical journals
The term  ’’medical jou rnals’ is used here to m ean all periodicals 
tha t publish medical advances. These are published a t regular 
intervals which may be weekly, fortnightly, monthly, bi-m onthly or 
quarterly. Their target readers are medical professionals. Clinical 
trials are one of the most common topics in medical journals. The 
typical cross-over trial published in medical journals is conducted 
in a  hospital (often a  teaching hospital) with the objective of 
comparing an existing popular treatm ent with a  new one. Results of 
such cross-over trials can often affect clinicians’ choices of 
treatm ents.
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In addition to the recruitm ent of patients and assigning of 
treatm ents, the physician who is in charge of the trial is often also 
responsible for designing and analysing it. There m ight be some 
occasional consultation with statisticians if resources permit. 
Otherwise the most common references used  for statistical analyses 
are medical statistics books and journals. Some description of the 
statisticad method used to ainalyse the triad is usually  pa rt of the 
report, as it is required by most medicad journals. This system atic 
review uses the descriptions of statistics in cross-over trial reports 
to study methods used for analysing cross-over trials in medical 
journals.
Objective: The objective of this study is to investigate actual 
analyses of cross-over trials published in medical journals, 
including im pact for the validity of the two-stage procedure and  the 
change in methods used to analyse cross-over trials across time.
Research method: Systematic review.
Systematic review is a review of a  clearly formulated question th a t 
uses systematic and explicit methods to identify, select and 
critically appraise relevant research, and to collect and  analyse data  
from studies th a t are included in the review. Statistical methods 
(meta-analysis) may or may not be used to analyse and sum m arise 
the resu lts of the included studies [35].
Relation to other realms o f m edical statistics: Results of the 
systematic review on analyses of cross-over trials in the medical 
literature will be compared with m ethods used  in the
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pharm aceutical industry to illustrate differences (or similarities) in 
analyses by researchers of different professions.
Results of the systematic review of cross-over trials published in 
medical journals will also be com pared with recom m endations for 
analyses of cross-over trials given in medical statistics books. 
Results of such comparisons will give an  indication of the im pact of 
general medical statistics books on actual analyses published in 
medical journals.
Strengths: The system atic review allows a close exam ination of 
statistical methods used for cross-over trials published in medical 
journals. By comparing the description of the statistics used  in the 
trial report with references cited, this method also com plem ents the 
shortage of the citation analysis by establishing the relationship 
between citations and actual applications.
W eaknesses: There are two main w eaknesses of th is m ethod. The 
first is th a t the num ber of reports reviewed in the system atic review 
is limited. Due to time limitation, it is not feasible to review every 
cross-over trial report. The second weakness is th a t information 
given in medical journals regarding to statistical m ethods used  can 
be inadequate [32].
3.2.3. General medical statistics books
General medical statistics books are one of the m ost commonly 
used references of statistics for non-statisticians. Such books 
usually include basic statistical concepts and tests for simple
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analysis. Methods for the analysis of cross-over trials are 
sometimes covered. Their target readers are usually clinicians with 
limited statistics backgrounds and  medical students. Because 
cross-over trials are often reported by the former population in 
medical journals, it is hypothesised th a t statistical m ethods used to 
analyse cross-over trials are to some extent influenced by 
recommendations given in general medical statistics books.
Methods of analyses of cross-over trials commonly used  before the 
two-stage procedure was introduced were simple and 
straightforward, often in the form of m atched paired t-tests. 
Although the two-stage procedure involves an  additional 
preliminary t-test, the statistics involved are similar. The difference 
between the statistical methods used to analyse a  cross-over trial 
with and without testing the carry-over effect (the two-stage 
procedure) is the type of t-test being used. For a  simple cross-over 
difference, the t-test used  is one sample, while the two-sample t- 
test is used  to test the carry-over effect and to evaluate treatm ent 
effect using the first period only (when the hypothesis th a t there is 
no differential carry-over effects is rejected). As the statistical 
m ethods recommended in the general medical statistics books 
rarely involve complicated and specific topics, it is partly the 
objective of this thesis to discover how general medical statistics 
books have dealt with the more complicated side of the two-stage 
procedure: the low power and high type I error rate.
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As the statistics required to understand  the concept are beyond the 
scope of general medical statistics books, the absence of m entions 
of the deficiencies of the two-stage procedure is conceivable. On the 
other hand, it cannot be verified w hether the void is due to au th o rs’ 
concern for not confusing the reader or because au thors are not up  
to date with the change in validity of the two-stage procedure. 
Assuming th a t the au thor is aware and agrees with the deficiencies 
of the two-stage procedure, h e /sh e  still h as the options of 
dism issing the two-stage procedure altogether or m entioning the 
two-stage procedure and explaining why it should not be used 
anymore.
Objective: The objective of this study is to investigate statistical 
methods recommended for analysing cross-over trials in general 
medical statistics books and to examine how up  to date the general 
medical statistics books are in the analysis of cross-over trials.
Research method: Comprehensive review.
Strengths: The comprehensive review includes all general medical 
statistics books published in English. Therefore, all 
recom m endations of statistical methods to which clinical 
researchers may be exposed are captured.
W eaknesses: The relationship between actual analyses of cross­
over trials and the general medical statistics books is not 
confirmed. The extent of the influence of these books is unknown.
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3.2.4. Pharmaceutical industry
The pharm aceutical industry conducts hundreds of clinical trials 
each year and their results often have direct influence on w hether a  
new treatm ent will be licensed and brought out to the general 
public. In contrast to clinical trials published in medical journals, 
which are usually conducted and analysed by clinicians, trials 
conducted by pharm aceutical companies are designed, planned and 
analysed by statisticians. Results of such trials are rarely published 
in medical journals and the only way to gain information on such 
m ethods and statisticians’ views on analyses of cross-over trials is 
by contacting the companies directly. A questionnaire survey is 
considered the most appropriate method for this purpose as it can 
be designed to target the objective of the research which includes 
questions th a t cannot be answered by any other research method.
Due to the professional background of those who are responsible 
for the analyses of cross-over trials, it is assum ed th a t statistical 
methods used by the pharm aceutical industry provide higher levels 
of statistical analyses than  cross-over trials published in medical 
journals. Therefore, results drawn from the questionnaire survey 
am ongst the pharm aceutical statisticians should not be used  to 
generalise to other realms of medical statistics.
Objective: There are two main objectives of this study. First, to 
gain some insights about statistical m ethods used to analyse cross­
over trials by the pharm aceutical industry. Second, to understand  
pharm aceutical statisticians’ rationales behind the choice of
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statisticad methods used to anadyse cross-over triads as well as their 
views on the two deficiencies of the two-stage procedure.
Research method: Questionnaire survey.
Strengths: Gaining insights on m ethods and  a ttitudes towairds 
design and analyses of cross-over trials which can not be obtadned 
elsewhere.
W eaknesses: Results are not representative if the response rate  is 
low. To maximise the response rate, follow-up em ails/letters are 
sent a  few weeks after the first round of questionnaire is 
distributed.
3.3. Plan of this thesis
Chapters 4 to 7 summairise methodologies and the resu lts  of the 
four independent studies. Conclusions of results from all four 
studies will be presented in chapter 7 to give a  complete picture of 
anadyses of cross-over triads.
To give an overall indication of the influence and im pact of the two- 
stage procedure on amalyses of cross-over triads, the citation 
analysis (Chapter 4 - Citation amalysis on three major papers about 
the two-stage procedure) is the first study to be reported in this 
thesis. It also acts as a  confirmation of the necessity of 
investigating the use of the two-stage procedure for amalyses of 
cross-over trials and to determine the importamce of the three madn 
publications of the two-stage procedure.
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Following the citation analysis is the system atic review on 
published cross-over trials (Chapter 5 - Cross-over trials in medical 
journals -  a  systematic review) in medical journals. This includes 
cross-over trial reports which did or did not cite any of the two- 
stage procedure papers. The focus is on statistical m ethods used  to 
analyse cross-over trials.
To track references and sources of influences on analyses of cross­
over triads published in medical journals, the system atic review is 
followed by a  comprehensive review of general medical statistics 
books (Chapter 6 - Analyses of cross-over trials in general medicad 
statistics books -  a  comprehensive review).
Finally, a  questionnaire survey of the pharm aceutical industry  
(Chapter 7 - Analysis of cross-over triads in the pharm aceutical 
industry - A questionnaire survey) is reported in order to fill the gap 
between cross-over trials conducted and published by different 
reseairch populations.
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Chapter 4 - Citation analysis on three 
major papers about the two-stage 
procedure__________________________
4.1. Introduction
The first research method and domain of medical statistics used  to 
investigate the two-stage procedure of cross-over trials is the 
citation analysis on published periodicals. Despite the problems of 
low power and high type I error rate, the two-stage procedure can 
still be seen in recent medical literature and is recom m ended by 
general medical statistics books without m entioning the statistical 
implications of applying it. The objective of this chap ter is to 
establish the im pact of the two-stage procedure on published 
research papers in term s of quantities of citations they received. It 
also serves the purpose of illustrating the background of this 
thesis.
4.2. Objective
The objective of this study is to evaluate the im pact of the three 
major papers about the two-stage procedure (Grizzle 1965 [4], Hills 
and Armitage 1979 [7] and Freeman 1989 [8]) on both the 
theoretical and actual analysis of cross-over trials using citation 
analysis.
4.3. Methodology
Citation analysis is a  bibliometric m ethod th a t uses reference 
citations found in scientific papers as the prim ary analytical tool
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[28]. It has been used to quantify the influences of research articles 
on scientific development [23]. Citation analysis has also been used 
to search for fundam ental articles and identify key contributors in 
many research areas, including biomedicine, economics, 
information systems, computing and  chemistry.
This chapter is the first report of a  citation analysis which follows 
the development of a  statistical application. It contains a  detailed 
bibliometric study of the major publications of the two-stage 
procedure regarding citation rates, journal types and citation types.
4.3.1. The Web of Science
Data for the citation analysis of the two-stage procedure was 
generated on the Science Citation Index expanded on the Web of 
Science [40] provided by the Institute of Science (ISI) which is 
hosted and supported by the M anchester Information and 
Associated Services (MIMAS). The Science Citation Index expanded 
is a  source database of articles published in journals and  contains 
all the end-of-article citations in papers published by more than  
5,700 scientific journals across 164 scientific disciplines. The 
database includes journal titles of all research fields in which 
cross-over trials are applied. With an  average of 17,750 new records 
added every week, results of this chapter were based on a  search 
performed in February 2002.
It was learnt th a t an  introduction to MIMAS bibliographic services 
including ‘cited reference search’ was offered by MIMAS after the
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citation analysis was completed. Therefore instead of learning the 
m ethod of citation search, the purpose of attending the one day 
course was to confirm th a t the search on the Web of Science for the 
citation analysis had been conducted properly.
The course took place in the University of London Com puter Centre 
on the 19th of March 2002. Strategies used  for searching citing 
papers on the three key papers on the two-stage procedure were 
consulted with the Web of Science Support officers on the day of 
the course. Thereafter, several emails regarding further details and 
developments of the Web of Science were exchanged with the 
MIMAS helpdesk before the citation rates for the analysis were 
finalised.
4.3.2. The search strategy
The three m ost im portant publications which m arked the history of 
the two-stage procedure in analyses of two-period tw o-treatm ent 
cross-over trials are: Grizzle (1965) [4], Hills and Armitage (1979) [7] 
and Freeman (1989) [8] (as described in Sections 1.3.1. 1.3.2. ). The 
database was searched for papers citing any of these three papers. 
The results searched on the Web of Science gave details of the 
citing paper, including the title, author, publishing journals, year of 
publication, and abstract in most cases.
The analyses carried out on these bibliographic data  included (a) 
citation rates of each paper over time, (b) journal types in which 
citing papers are published (c) the citation type and (d) the
U s e  o f  t h e  t w o - s t a g e  p r o c e d u r e  f o r  a n a l y s i s  o f  c r o s s - o v e r  t r i a l s  in  f o u r  a s p e c t s  o f  m e d i c a l  s t a t i s t i c s
development of statistical models to compare the differences 
between the three cited papers.
4.4. Results
Results are first presented by citation rates of each individual 
paper, followed by the characteristics of citations including citation 
years, citation types and types of citing journals, in order to 
investigate areas of impact of each paper and  to seek explanations 
for these impacts.
4.4.1. Citation rates
The two papers describing the two-stage procedure were:
(i) Grizzle (1965)[4], The two-period change-over design and its  
use in clinical trials, Biometrics
(ii) Hills and Armitage (1979)[7], The Two-Period Cross-Over 
Clinical Trial, British Journal of Clinical Pharmacology
The two papers describing the two-stage procedure together 
received 1328 citations over the period of 22 years from 1981 to 
February 2002. Hills and Armitage (1979)[7] contributed 961 
citations while Grizzle (1965)[4] accounted for the other 367. On 
average for the past two decades, there have been around 60 
citations on the two-stage procedure every year, with about 44 
citations on Hills and Armitage (1979) [7] and 17 on Grizzle 
(1965)[4].
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The significance of these citation ra tes were weighed against 
Garfield’s conclusion in 1971 th a t only 1% of all published items 
were cited more than  15 times a  year [Garfied, C urrent Contents, 
#18, 1971]. The above figures indicate th a t both Grizzle (1965)[4] 
and Hills and Armitage (1979)[7] on the two-stage procedures were 
among the top 1 per cent of all cited publications.
High citation rates of the two-stage procedure also m ade these two 
papers citation ‘classics’. Garfield [43] suggested th a t ‘in general, a 
publication cited more than 400 times should be considered a classic; 
but in some fields with few er researchers, 100 citations might qualify 
a work’. Hills and Armitage (1979)[7] qualifies all for a  ‘citation 
classic’ by all standards while Grizzle (1965) [4] would be considered 
a citation classic if analysis of cross-over trials is considered to be a 
less researched discipline.
Changes in citation rates on Grizzle [4]( 1965) and  Hills and 
Armitage (7](1979) over the years have not been substantial. The 
publication year of each citing article was recorded so as to plot the 
frequency of citation over time (Figure 4.4-1). Although Grizzle 
[4](1965) was the original paper of the two-stage procedure, citation 
rates on Hills and Armitage [7](1979) soon superseded Grizzle 
[4]( 1965) two years after it was published. Hills and Armitage
[7] (1979) had received more citations th an  any other papers on 
analyses of cross-over trials ever since.
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Figure 4.4-1 Citation rate by year and author (1981-2002)
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Freeman (1989), The performance o f the two-stage analysis o f  
two-treatm ent, two-period crossover trials. S ta tistics  in 
Medicine
In contrast to the two papers of the two-stage procedure, Freem an
[8](1989), the latest development on the two-stage procedure which 
showed the major deficiency of the two-stage procedure, had 
noticeably lower citation rates. This paper was cited only 56 times 
for the 12 year period from 1990 to 2001. Although it could be 
qualified as a  ‘classic’ when total citations over the years are 
averaged, there were a few years when Freem an [8](1989) was cited 
less than  four times.
The results of the search showed th a t none of these publications 
have generated as m uch impact as Grizzle [4](1965) and Hills and 
Armitage [7](1979) in term s of the citation rates. It can therefore be 
concluded th a t these two papers dom inated the citations on the 
analysis of cross-over trials and were appropriate to be used to
U s e  o f  t h e  t w o - s t a g e  p r o c e d u r e  f o r  a n a l y s i s  o f  c r o s s -o v e r  t r i a l s  in  f o u r  a s p e c t s  o f  m e d ic a l  s t a t i s t i c s
indicate the use of the two-stage procedure in the medical 
literature.
4.5. Discussion
Despite the similarity in context, the differences in citation rates of 
Grizzle [4]( 1965) and Hills and Armitage [7](1979) have been 
substantial. Citation rates are often influenced by a  few factors. It 
has been suggested tha t “papers containing important ideas will not 
necessarily continue to be highly cited for all time. Eventually an 
idea or paper may become so widely known that citing its original 
version is unnecessary. Or a new paper will supersede the original 
one by reformulating the idea in more up-to-date terms so the newer 
paper then receives all the citations to the idea.” [Garfield, Citation 
data  as science indicator]
These statem ents are applicable to the Grizzle [4]( 1965) and  Hills 
and Armitage [7] (1979), since the later paper provided a  complete 
version of the two-stage procedure while Grizzle [4]( 1965) did not 
recommend methods of analysis if the carry-over effect was found 
to be significant.
The disparity between the citation rates for these two papers is 
partly explained by this. The fact tha t the two-stage procedure has 
been proven invalid may imply tha t application of the method may 
not be the only reason th a t these two papers were cited. Other 
possible causes will be investigated when other citation 
characteristics are discussed in following sections.
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The differences between Freem an [8] (1989) and  the two papers 
which promoted the two-stage procedure were more complicated. 
These differences will be further d iscussed in this chapter after 
characteristics of the cited and citing papers are analysed.
Table 4.5-1: Total number of citations on the three papers from 1981 to 2001
Grizzle Hills and Armitage Freeman
1965 1979 1989
Total Number of Years 22 22 12
Total Number of Citations 367 961 56
Table 4.5-2; Citation rate by year for the period 1981-2001
Year Grizzle
1965
Hills and Armitage 
1979
Freeman
1989
Total Number of 
Cross-over Trial 
Reports from 
Medline Search
1981 20 17 N/A 95
1982 15 28 N/A 126
1983 20 45 N/A 121
1984 21 32 N/A 129
1985 17 49 N/A 134
1986 19 58 N/A 168
1987 19 59 N/A 160
1988 12 65 N/A 156
1989 22 84 N/A 165
1990 24 61 1 148
1991 24 49 3 182
1992 24 57 2 181
1993 20 60 8 177
1994 13 49 5 166
1995 14 50 6 166
1996 29 41 8 167
1997 17 42 6 161
1998 6 31 5 126
1999 12 32 5 122
2000 10 21 4 124
2001 5 30 3 188
Total 367 961 56 3,162
4.5.1. Citation types
Citation type is a  classification of a  citation by its purpose. It is 
used in this section as an indicator to identify areas of im pact of 
the three papers. Although one assum ption made for citation 
analysis is similarity of content (Smith (1981 and Garfield, 1979)}, it 
does not apply to citations on the two-stage procedure due to its
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controversial history. Citation types cannot be assum ed to be 
similar in this citation analysis b u t are treated as an  indicator of 
areas of impact.
Papers citing Grizzle [4](1965), Hills and  Armitage [7](1979) and 
Freeman [8] (1989) can be categorised into two broad citation types 
according to the purpose of the citation. One is to use  the citation 
as a  reference of the statistical method applied in the paper. For 
example, the citation received from a  cross-over trial report was 
assum ed to be a reference to the statistical analysis. The other 
citation type was methodological discussion on designs or 
statistical methods of the two-stage procedure. This type of citation 
included Freeman [8](1989), which cited both Grizzle [4](1965) and 
Hills and Armitage (1979). Implications of these two citation types 
were not the same and sometimes contrasted.
The three papers to be investigated represented two very different 
viewpoints of analyses of cross-over trials. Depending on the paper 
being studied, implications of influences were sometimes different 
within the same citation type. Cross-over trial reports which cited 
any of these three papers usually used it as a  reference for their 
statistical anadyses. When Grizzle [4](1965) or Hills and  Armitage 
[7] (1979) received a citation from a  cross-over trial report, the 
implication is th a t the two-stage procedure had been used to 
analyse the trial. In contrast, a  citation given to Freem an [8] (1989) 
from cross-over trial would imply th a t the two-stage procedure was 
not used. In other words, Freeman [8] (1989) was more likely to
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provoke discussions on methodological publications than  Grizzle 
[4](1965) or Hills and Armitage [7](1979). There are also 
publications which cited two or all three papers. This is called co­
citation and will be discussed in Section 4.5.4.
4.5.2. The classification of citation type
To classify the citation types of papers giving citations to Grizzle 
(1965), Hills and Armitage [7](1979) and Freem an [8]( 19S9), titles of 
citing papers were first screened to identify w hether they were trial 
reports (abstracts were searched where the classification could not 
be made from the title alone). All papers citing any of the three 
publications were categorized into two citation types: cross-over 
trial reports and non-trial papers. The results are shown in Table 
4.5-3.
The distribution of citation types am ongst papers citing Grizzle 
[4](1965), Hills and Armitage [7](1979) and Freem an [8](1989) were 
notably different. Both papers describing the two-stage procedure, 
Grizzle [4] (1965) and Hills and Armitage [7](1979) were more often 
cited in cross-over trial reports than  in any other type of 
publication.
Among all 961 citations Hills and Armitage (1979) received between 
1981 and 2002, 89 per cent were given by trial reports. In 
comparison, Grizzle [4]( 1965) received a  lower percentage of 
citations from cross-over trial reports (62 per cent) and a higher 
percentage from non-trial reports.
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Based on the assum ption th a t citations given to Grizzle (1965)[4] 
and Hills and Armitage (1979) [7] by cross-over trial reports
indicated adopting the method, there had been a t least one
thousand cross-over trials analysed with the two-stage procedure. 
With the actual type I error rate of the two-stage procedure being 
between 7-9.5%, there may have been between 20 to 45 more 
cross-over trials with false positive results than  expected.
Although Grizzle (1965)[4j and Hills and Armitage (1979)[7]
described the same statistical method in their papers, the
distributions of their citations were different. There were two 
characteristics tha t differentiated these two papers: one was the 
type of journal they were published in; the o ther was the 
description of the method. Hills and Armitage (1979)[7] was easier 
to follow, giving a more carefully illustrated dem onstration of how 
to apply the two-stage procedure. This paper clearly indicated th a t 
the analysis should be based on period 1 data  solely if the carry­
over effects were statistically significant while Grizzle (1965)[4] only 
suggested th a t “the change-over design should be avoided unless 
residual effects are of interest in their own right and are not 
regarded as a  nuisance when residual effects are thought to be 
unequal”.
Citation types for Freeman (1989)
In contrast, Freeman (1989)[8], showing the deficiency of the 
methodology applied in the previous two papers, was cited in a  very 
different context. Ninety-five per cent of its citations were given by
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non-trial papers, such as discussions of statistical m ethods and 
design issues of cross-over trials. Freem an (1989)[8] was rarely 
cited in cross-over trial reports. Only 3 of the 56 citations given to 
Freeman (1989)[8] were from cross-over trial reports, including two 
papers published by the same group of authors.
The distribution of citation types of papers citing Freem an (1989)[8] 
implied this paper was more of theoretical value th an  practical use. 
It raised awareness of the deficiency of the two-stage procedure bu t 
did not succeed in putting an end to its use.
Table 4.5-3; Number o f citation rates by citation type
Citation Type Grizzle
1965
Hills and Armitage 
1979
Freeman
1989
Trial reports 229 62% 860 89% 3 5%
Non-trial
reports
138 38% 101 11% 53 95%
Total 367 100% 961 100% 56 100%
Possible w eaknesses o f the citation analysis on the two-stage 
procedure o f cross-over trials: First, the assum ption th a t citation 
indicates use was not verified for this analysis. The citation 
analysis can only give an approximation of the prevalence of u se  of 
the two-stage procedure. There might be occasions where the 
method was not applied even when Grizzle (1965)[4] or Hills and 
Armitage (1979) [7] was cited.
Secondly, the citation analysis did not cover cross-over trial reports 
th a t did not cite any of the 3 papers of the two-stage procedure. 
Therefore, m ethods of analysis for cross-over trials which did not 
cite any of these three papers rem ained unknow n. Both w eaknesses 
will be overcome in the next chapter by the system atic review which
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will give a  closer examination of statistical m ethods used  in cross­
over trial reports.
The high citation rates on Grizzle (1965)[4] and  Hills and Armitage 
(1979) [7] by cross-over trial reports and  the low citation rate of 
Freeman (1989)[8] among cross-over trials implied th a t the 
deficiency of the two-stage procedure was virtually unknow n to 
clinical researchers or the research com m unity who published 
cross-over trials. In order to investigate statistical m ethods 
recommended to researchers who analysed these papers, another 
common reference of medical statistics, general medical statistics 
books will be reviewed and discussed in C hapter 5.
4.5.3. Journal types
There has been some considerable differences in the distribution of 
citation types between Grizzle (1965)[5] and Hills and  Armitage 
(1979) [7] despite their similarity in content. One of the differences 
between these two papers was the area of research covered by the 
journals in which they were published. Grizzle (1965)[4] published 
the original paper of the two-stage procedure in Biometrics, a 
publication of the International Biometrics Society which focuses 
on the development of new methods in the biological sciences. Hills 
and Armitage (1979)[7], the most frequently cited paper of the two- 
stage procedure, was published in the British Journal o f Clinical 
Pharmacology, which contains reports on all aspects of drug action 
and is published on behalf of the British Pharmacology Society.
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These two journals have different target audiences, which is likely 
to affect the distribution of citation types.
The titles of journals in which these three papers are cited were 
checked manually according to their research areas. The resu lts of 
the analysis of journal types Eire shown in Table 4.5-4.
Differences in citation types were noticeable am ongst the three 
papers. There were however, some similarities between the two 
papers promoting the two-stage procedure, which were both most 
cited in medical journals. Hills and Armitage (1979)[7] received 
nearly 90 per cent of their citations from medical jou rnals while 
three quarters of Grizzle’s (1965)[4] were given by papers published 
in medical journals.
The difference in citation types seen previously between Grizzle 
(1965)[4] and Hills Eind Armitage (1979)[7] could probably be 
explsiined by the type of journal in which the cited papers were 
published. Grizzle (1965)[4] was published in a  statistical journal 
(Biometrics), while Hills and Armitage (1979)[7] was published in a  
medical journal (British Journal o f Clinical Pharmacology).
All three papers were more cited in medical journals th an  journals 
of other disciplines. Statistics in Medicine, where Freeman 
(1989)[8] was published, has a  similEir objective to the journal 
where Grizzle (1965)[4] was published. Although Freem an (1989)[8] 
was more cited in medical journals them statistical journals, the 
contents of the citation papers were mostly methodology issues 
ra ther than  practical applications (see Table 4.5-3).
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Table 4.5-4: Number of citations by citing journal type
Grizzle
1965
Hills and Armitage 
1979
Freeman
1989
Biometrics British Journal of 
Clinical Pharmacology
Statistics in Medicine
Medical Journals 267 73.5% 856 89.3% 22 39%
Statistical Journals 83 23% 51 5.3% 34 61%
Journals of Other 
Disciplines
13 3.5% 52 5.4% 0 0%
Total 363 100% 959 100% 56 100%
Table 4.5-5; Impact factors of the original papers
Author Journal Title Impact
Factor*
2000
Total
Cites
2000
Articles
Immediacy
Index**
Citation
Half-
Life***
Grizzle Biometrics 1.170 6,816 171 0.129 >10.0
1965
Hills and British Journal 2.151 5,725 167 0.623 7.8
Armitage of Clinical
1979 Pharmacology
Freeman Statistics in 1.717 4,088 231 0.190 6.7
1989 Medicine
*Impact Factor measures how often articles in a specific journal have been cited. The total number o f quotes during a year 
o f the two immediately preceding years' issues, for example quotations in 1994 of the journals published in 1992 and 1993, 
are weighed against the number o f articles published in 1992 and 1993 in that journal.
** Immediacy Index measures the average number o f times that an article, published in a specific year within a specific 
journal, is cited over the course of the same year.
***Cited Half-life measures the number o f years, going back from the current year, that account for half the total citations 
received by the cited journal in the current year.
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Table 4.5-6: Journal Distribution o f Citations to Freeman 1989
Statistical Journals N=34 Number of Citations
Statistics in Medicine 15
Biometrics 7
Journal of Statistical Planning and Inference 3
Journal of Royal Statistics Society D-Stat 3
Biometrical Journal 1
Biometrika 1
Journal of American Statistics Association 1
Journal of Applied Statistics 1
Statistical Methods in Medical Research 1
Communication in Statistics-Theory and Methods 1
Non-Statistical Journals N=22
Journal of Clinical Pharmacology 4
British Journal of Clinical Pharmacology 3
European Journal of Clinical Chemistry and Clinical Biochemistry 2
International Journal of Clinical Pharmacology and Therapeutics 2
Archives of General Psychiatry 1
Controlled Clinical Trials 1
BMJ 1
Pharmacology World and Science 1
European Journal of Clinical Pharmacology 1
Drug and Alcohol Dependence 1
Psychopharmacology 1
Nephrology Dialysis Transplantation 1
Angiology 1
Clinical Pharmacology Therapeutics 1
Postgraduate Medicine 1
4.5.4. Co-citation analysis
Due to the contrasting implications of citations given to Freem an 
(1989) [8] and the other two papers describing the two-stage 
procedure, the co-citation was investigated. Co-citation reflects the 
association between highly cited papers as perceived by the current 
population of specialists who have themselves published papers. 
[Garfield, Citation data  as science indicator]
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The focus of this section is on co-citation of Freem an (1989) [8] with 
Grizzle (1965)[4] or Hills and Armitage (1979)[7). All papers citing 
any of the three papers were checked to see w hether there was any 
co-citation with the other papers. Results are shown in Table 4.5-7.
Freeman (1989)[8] was often cited with Grizzle (1965)[4] or Hills and 
Armitage (1979)[7] in methodological publications. While there is 
usually only one statistical referenced cited in cross-over trial 
reports, co-citation between these three papers rarely occurred in 
cross-over trials reports.
Since Freeman (1989) [8] only received three citations from cross­
over trial reports and none of them  co-cited either Grizzle (1965)[4] 
or Hills and Armitage (1979)[7], it indicates th a t all co-citations 
among Freeman (1989)[8] with Grizzle (1965)[4] o r /a n d  Hills and 
Armitage (1979)[7] were by methodology papers.
Freeman (1989)[8] and Grizzle (1965)[4] had been co-cited 23 times 
in a  period of 12 years since Freeman (1989)[8] was published. 
Eighteen of these co-citations were published in statistical journals 
and five of them  in medical journals (one in the European Journal o f 
Clinical Chemistry and Clinical Biochemistry, two in the 
International Journal o f Clinical Pharmacology and Therapeutics, two 
in the British Journal o f Clinical Pharmacology).
There were 19 publications which co-cited Freem an 1989 with Hills 
and Armitage 1979. Among these 19 papers, 9 were published in 
non-statistical journals and were contributed by 4 individuals. One 
author contributed 6 co-citations in non-statistical journals.
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The titles and authors of the 9 papers are listed below:
1. Journal o f  Clinical Pharmacology -  statistical issue, binary data - Cleophas
2. International Journal o f clinical Pharmacology and Therapeutics -  a simple 
analysis o f  crossover studies with one-group interaction - Cleophas
3. Nephrology Dialysis Transplantation -  Statistical aspects o f  the design and 
analysis o f  studies to compare hemodialysis membranes -  Matthews JNS
4. Journal o f  Clinical Pharmacology -  Interaction in crossover studies - Cleophas
5. Journal o f  Clinical Pharmacology -  Carryover bias in clinical investigations - 
Cleophas
6. Clinical Pharmacology and Therapeutics -  Crossover studies -  a modified 
analysis with more power - Cleophas
7. Angiology -  Interaction in Cardiovascular crossover studies -  the standard and 
the clinical analysis -  Cleophas
8. British Journal o f Clinical Pharmacology -  Should w e cross o ff  the crossover -  
Armitage
9. British Journal o f Clinical Pharmacology -  Problems with the 2 stage analysis 
o f  crossover trials -  Senn
There were also eight papers which cited all three papers and  all
were on theoretical publications on the design and statistics of
cross-over trials.
The titles are as follows:
1. Cross-over trials in drug development: theory and practice -  Journal o f
Statistical Planning and Inference
2. Multivariate AB-BA crossover trial -  Journal o f  Applied Statistics
3. A comment on interim analysis in crossover trials - Biometrics
4. Design considerations in crossover trials with a single interim analysis and 
serial patient entry - Biometrics
5. Interim analysis in 2X2 crossover trials -  Biometrics
6. A simple analysis o f  crossover studies with one-group interaction -  
International Journal o f Clinical Pharmacology Theory
7. Should we cross o ff the crossover -  British Journal o f  Clinical Pharmacology
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8. Problems with the 2 stage analysis o f  crossover trials -  British Journal o f  
Clinical Pharmacology
Table 4.5-7: Co-citation rates_____________________________________________________
Number of co­
citations
Grizzle
1965
Hills and Armitage 
1979
Both Grizzle 1965 and 
Hills and Armitage 1979
Freeman 1989 23 19 8
Total number o f 367 961 56
citations
Co-citation Strength
Two formulas: Jaccard’s index and Salton’s cosine formula, have
been used to express the degree of similarity in citation analysis. 
Salton’s cosine formula is used here to quantify co-citation strength 
as “Salton’s  cosine formula deals more effectively w ith links between  
high- and low-cited papers than does Jaccard’s. ” [25]
Salton’s cosine formula for co-citation strength between docum ent 
i and j  is defined as:
COCn
SsQ,j) =
yjci t . xc i t j  
where
COCj j = num ber of citations between docum ents i and  j, 
citi -  num ber of citations for docum ent I, and 
citj = num ber of citations for docum ent j
23 + 8
Co-citation strength between Freeman and Grizzle was —— = = =  = 0.2162 .
V367x56
Co-citation strength between Freeman and Hills and Armitage was
/ 9 + 8 =0 .1164 .
V961x 56
The coefficients showed tha t co-citation was stronger between 
Freeman (1989)[8] with Grizzle (1965)[5] than  Freeman (1989)[8] 
with Hills and Armitage (1979) [7]. As 53 of the 56 citations on
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Freeman (1989) [8] were non-trial reports, m ost co-citations between 
Freeman (1989) [8] and  the other two papers were methodological or 
theoretical papers. It can be concluded th a t the original paper of a  
new method was more likely to be cited in theoretical papers than  
the follow-up paper. Furtherm ore, papers which were easier to 
follow were more likely to be cited in the papers of practical 
applications.
4.5.5. Citation age
Citation age is the am ount of time (in years) between the 
publication of the cited docum ent and the publication of the citing 
document. The citation rate often decreases with the citation age as 
new and more advanced references may be conducted in the field. 
Citation age is used instead of citation years in this section to 
compare citation rates. As the three papers were published in three 
different decades, there was no common citation age for all three 
papers.
Papers were only available in the Science Index Expanded if they 
were published after 1981. The database provided citation ages of 
the citing papers from 16 to 36 for Grizzle (1965)[4], 2 to 22 for 
Hills and Armitage (1979)[7], 1 to 13 for Freem an (1989)[8] (as 
shown in Table 4.5-8). The only common years th a t allowed direct 
comparisons were the seven years from 16 to 22 for both Grizzle 
(1965)[4] and Hills and Armitage (1979)[7], and 2 to 12 for Hills and 
Armitage (1979) [7] with Freeman (1989) [8].
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Table 4.5-8: Number of citations by citation age
Citation age 
(years)
Grizzle
1965
Hills and Armitage 
1979
Freeman
1989
1 1
2 17 3
3 28 2
4 45 8
5 32 5
6 49 6
7 58 8
8 59 6
9 65 5
10 84 5
11 61 4
12 49 2
13 57
14 60
15 49
16 20 50
17 15 41
18 20 42
19 21 31
20 17 32
21 19 20
22 19 16
23 12
24 22
25 24
26 24
27 24
28 20
29 13
30 14
31 29
32 17
33 6
34 12
35 10
36 3
There has not been an obvious decline in num bers of citations on 
all three papers as the age of cited docum ents increased. Citation 
rates did not seem to be affected by the length of time between cited 
and citing papers.
Citation rates on Hills and Armitage (1979) [7] superseded Grizzle 
(1965)[4] in all calendar years except 1981, the results were similar 
when the citation age was used for comparison instead of calendar 
years. Hills and Armitage (1979)[7] received more citations than
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Grizzle (1965)[4] for all citation ages they had  in common except 
year 22. The difference is twice as m uch for citation ages 16 to 18, 
the difference in their citation rates got sm aller as the cited paper 
got older. Eventually, a t citation age 22, there were more citations 
on Grizzle (1965)[4] than  on Hills and  Armitage (1979)[7]. It can be 
concluded th a t Hills and Armitage (1979) [7] had  a  bigger im pact 
than  Grizzle (1965) [4] in term s of the total num ber of citations.
Hills and Armitage (1979) [7] and Freem an (1989) [8] could be 
compared from citation age 2 to 12 years. For these 11 years, 
citations to Hills and Armitage (1979) [7] had  far exceeded citations 
to Freeman (1989) [8]. The difference in citing rate has been 
substantial and there was no indication of any change as times 
passes.
There was no common citation age to com pare citation rates 
between Grizzle (1965)[4] and Freeman (1989)[8). However, it can 
be predicted th a t Freeman (1989) [8] is unlikely to exceed Grizzle 
(1965)[4] in the near future unless aw areness of the deficiency of 
the two-stage procedure is raised among the researchers involved 
with cross-over trials.
4.5.6. The statistical model of the citation analysis 
Generalised Linear Model for Count Data:
The Poisson Regression Model
The analysis is completed with Poisson regressions with the 
objective of determining whether the citation ra tes were influenced
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by the paper cited, citation age and num bers of cross-over trials 
published in th a t year. For citation rate on each of these papers per 
year, Poisson regression models estim ated the num ber of citations 
and a  95% confidence interval as a  function of citation age and 
total num ber of cross-over trials. The GENMOD procedure in the 
SAS system was used to fit the regression models by maximum 
likelihood.
The variables fitted in this citation analysis included num ber of 
citations for each author (21 observations for both Grizzle and Hills 
& Armitage, 12 for Freeman), citation age (num ber of years since 
publication), au thor (as a  categorical variable) and tt (total num ber 
of cross-over trials found in Medline of the year, used  as a  proxy 
measure). An over-dispersion param eter w as fitted in order to 
correct for the effects of the larger variance on the p-values.
The SAS code is:
Proc genmod data=com;
Class author;
Model citation = author citage /offset=ltt dist=Poisson link=log 
obstats residuals dscale Typel Type3;
Estimate 'Grizzle-Freeman' author 1 0 -1;
Estimate 'H&A-Freeman' author 0 1 -1;
Estimate 1H&A-Grizzle' author - 1  1 0;
Results
The conclusion can be summ arised as follows. Hill and  Armitage 
(1979) [7] has the highest rate of citation, followed by Grizzle 
(1965)[4]. The total num ber of citations is in proportion to the total 
num ber of cross-over trials in th a t given year. The num ber of 
citations decreases as the citation ages. The overdispersion has
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been adjusted for by a parameter of 1.5.
Table 4.5-9: Criteria for assessing goodness of fit
Criterion DF Value Value/DF
Deviance 50 117.6588 2.3532
Scaled deviance 50 50.0000 1.0000
Pearson Chi-Square 50 111.2199 2.2244
Scaled Pearson X2 50 47.2638 0.9453
Log likelihood - 1462.2133
Table 4.5-10: Analysis of parameter estimates
Parameter DF Estimate Standard
E rror
Chi Square Pr>Chi
Intercept 1 -3.3751 0.2096 259.26 <.0001
Grizzle 1 1.8574 0.2623 50.15 <.0001
Hill&Armitage 1 2.4800 0.2147 133.10 <.0001
Freeman 0 0.0000 0.0000
Citation age 1 -0.0249 0.0073 11.68 0.0006
Scale 0 1.5340 0.0000
4.6. Results and Discussion
It has been shown in Section 4.4.1. th a t there were clear differences 
in term s of citation rates between any two of the three papers.
Despite the similarity in context, the difference in citation rates of 
Grizzle (1965)[4] and Hills and Armitage (1979)[7] h as been 
substantial. Such disparities were partly explained in Section 4.4.1. 
However, when looking a t citation types and journal types of citing 
papers, there were also some differences. In addition to the reasons 
exposed in Section 4.4.1. , other factors could explain the difference 
in citation rates.
It was shown in Table 4.5-4 th a t there were differences between 
types of journals th a t published citations on Grizzle (1965)[4] and 
Hills and Armitage (1979)[7]. Seventy-four per cent of citations 
given to Grizzle (1965) [4] were from medical journals while the
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percentage was as high as 89 per cent for Hills and  Armitage 
(1979)[7]. Grizzle (1965)[4] was published in a  statistical journal 
th a t is often not so reader friendly to those who conducted and 
analysed cross-over trials which were published in medical 
journals, while Hills and Armitage (1979)[7] was published in a  
medical journal. Both papers describing the two-stage procedure 
received m ost citations from cross-over trial reports which were 
published in medical journals. Therefore, it could be th a t the 
difference in citation rates between Grizzle (1965)[4] and Hills and 
Armitage (1979) was a  result of the type of jou rna l they were 
originally published in.
Another difference th a t could result in the disparity between 
citation rates of Grizzle (1965)[4] and Hills and Armitage (1979)[7] 
was their description of the two-stage procedure. The two-stage 
procedure described by Hills and Armitage was a  more complete 
version than  Grizzle (1965)[4]. Grizzle (1965)[4] did not propose a  
solution for analysing the trial when the carry-over effect was found 
to be significant. Hills and Armitage (1979) [7] suggested th a t the 
treatm ent difference should be evaluated using first period data  
only if the carry-over effect was found to be significant a t the 10% 
nominal level. It is possible tha t Grizzle (1965)[4] was less likely to 
be applied as there was a risk tha t the treatm ent effect could not be 
evaluated. However, it is also possible th a t m ost researchers who 
analysed and published the paper were not aware th a t there were 
two versions [Grizzle (1965)[4] and Hills and Armitage (1979)[7]] of
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the two-stage procedure. Hence, Hills and Armitage (1979)[7] was 
more cited simply because it was better known. The reason could 
be explained by a  snowball effect. Clinical researchers often seek 
other trial reports of similar design or treatm ent for references. It is 
a  potential path  of learning statistical analyses of cross-over trials 
and to generate a  higher citation rate for Hills and Armitage 
(1979)[7).
4.6.1. The difference in citation rates between papers 
describing the two-stage procedure and papers exposing its 
deficiencies
The reason for the disparity in citation rates between the two-stage 
procedure and Freeman (1989) [8] is more complicated and 
controversial.
The m ost common explanation of the low citation ra te  of a  
publication was th a t it was simply not as well-known as other 
highly cited papers. There were a  few reasons for its anonymity. The 
two-stage procedure had been established for 24 years before 
Freeman (1989) [8] found tha t it had a  high type I error rate. The 
two-stage procedure was a ‘classic’ and was so often encountered in 
cross-over trial reports tha t those who analysed cross-over trials 
may have considered it a  standard procedure. In addition, the two- 
stage procedure was also suggested by m any medical statistics 
books (see chapter 5) and clinical trial courses in medical school.
As Freeman (1989) [8] is a  paper which exposed the major deficiency 
of a  widely known and applied statistical procedure, anonymity
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might not be the only reason for its relatively low citation rates. 
There were a  few reasons th a t could resu lt in citation rates not 
meeting up  to awareness of such a  deficiency.
First, the citations on Grizzle (1965)[4] and  Hills and  Armitage 
(1979) [7] originated from a very homogenous research population 
(i.e., medical researchers), while Freem an (1989)[8] was better 
known by statisticians. As the population of medical researchers 
(doctors) was bigger than  the population of statisticians, the 
relatively low citation rates may be the resu lt of the difference in the 
size of the papers’ respective readerships. Freem an (1989)[8] was 
better known am ongst statisticians than  medical researchers who 
analysed and published the cross-over trial reports. Medical 
researchers may have been more likely to seek their references from 
analyses of similar study designs th a t have already been published 
in medical journals ra ther than  search for m ethods in statistical 
journals
Secondly, the impact of Freeman (1989) [8] may only be on a 
superficial level. It might have raised some aw areness of the 
deficiency bu t may not have been agreed with (examples of this can 
be found in the questionnaire survey of the pharm aceutical 
statisticians in Chapter 7 - ). In addition, testing for the carry-over 
effect was an  extremely attractive feature. Despite its deficiencies, 
many authors of cross-over trial reports feel th a t only by using it 
could they ensure tha t the treatm ent effect has not been biased due 
to the carry-over effect.
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In conclusion, the im pact of Grizzle (1965) [4] and Hills and 
Armitage (1979) [7] on the two-stage procedure were mainly on 
actual analysis of the two-stage published in periodicals. Hills and 
Armitage (1979) [7] who completed the m ethod described by Grizzle 
(1965)[4] had most influence on analysis of cross-over trials. The 
high type I error rate of the two-stage procedure discovered by 
Freeman (1989) [8] received far fewer citations in comparison to 
Grizzle (1965)[4] and Hills and Armitage (1979)[7). Freem an’s 
impact was mainly on theoretical discussion and  the aw areness of 
the deficiency of the two-stage procedure h as not been raised 
amongst researchers.
(For further discussion, please see the survey conducted among 
pharm aceutical statisticians regarding the issue of the two-stage 
procedure (in Chapter 7 - below), and a  comprehensive review of 
medical statistics books on w hat clinicians are told (in C hapter 6 - 
below).
4.7. Cited books
In addition to the three papers, there were three books dedicated to 
cross-over trials and all three discuss the statistical issues of such 
designs. As a  rule, about 20% of the references in science journals 
cite books and other non-journal items [26]. In order to provide 
other references used for analyses of cross-over trials published in 
medical journals, citations given to the three books of cross-over 
trials were also searched using the same database and options.
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Table 4.7-1: Citation rates of cross-over trial books
Jones and Kenward 
1989
Senn 1993 Ratkowsky 1993
Title The Design and Analysis 
of Cross-over Trials
Cross-over Trials in 
Clinical Research
Cross-over Experiments, 
Design, Analysis and 
Application
Number of 
Citations 411 174 36
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4.8. The updated search
A new search on the citation rates for the three key papers was 
conducted on the 5th of November 2004. The searching strategy for 
the new search is identical to the one used for the original search.
Table 4.8.1: The total numbers of citations on the three papers between Feb 2002 and Nov 
2004 ____________________________________________________________________
Grizzle (1965) Hills and Armitage 
(1979)
Freeman (1989)
Search conducted in 
Feb 2002 367 961 56
Search conducted 
on the 5th Nov 2004 468 1043 66
Total Number of 
Citation Years 39 25 15
The Web of Science has been updated since the original search was 
conducted in February 2002. Papers th a t were published between 
1945 and 1980 have been added to the Web of Science. The results 
of the updated citation rates were 468 citations for Grizzle (1965), 
1043 citations for Hills and Armitage (1979) and 66 citations for 
Freeman (1989).
The num ber of citation years for each of the three papers has also 
changed. The newly added citations on Freem an (1989) were 
papers th a t published between February 2002 and  Nov 2004 while 
the newly added citations on Grizzle (1965) contained papers tha t 
were published during this period of time as well as papers 
published between 1945 and 1980.
In term s of the citation types, the new citations given to Freeman 
(1989) contained only 1 cross-over trial report while new citations 
given to Grizzle (1965) and Hills and Armitage (1979) were mainly
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trial reports. The results of the new citation searches confirmed the 
previous prediction th a t it is unlikely th a t the citation rates on 
Freeman (1989) would catch up  with Grizzle (1965) or Hills and 
Armitage (1979).
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Chapter 5 - Cross-over trials in medical 
journals -  a systematic review________
5.1. Introduction
The overall objective of this thesis is to investigate the use of the 
two-stage procedure for the analyses of cross-over trials in four 
different realms of medical statistics. It was shown in C hapter 4 - 
th a t both papers [4] [7] th a t described the two-stage procedure of 
cross-over trials had been widely cited in medical jou rnals while the 
impact of the deficiencies was mainly on the discussion of analyses 
of cross-over trials. There were two questions which could not be 
answered by the citation analysis. First, w hether the two-stage 
procedure had been applied when a reference to th is procedure was 
not cited. Second, w hether citation of the two-stage procedure 
always indicated the usage of this procedure. These two questions 
will be investigated in this chapter.
5.2. Literature review of the use of the statistics in 
medical journals
The credibility of statistics in medical jou rnals has often been 
questioned. Several studies have shown th a t it is not uncom m on to 
find statistical errors in published articles. A review of 62 articles in 
British Medical Journal (BMJ) from Jan u a ry  to March 1976 by 
Gore et al [47] showed that *32 o f them had statistical errors o f one 
kind or another and 18 articles contained fairly serious faults. ”
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Felson et al [33] compared m isuses of statistical m ethods in the 
journal Arthritis and Rheum atism  in 1982 and between 1967 and 
1968. They found tha t methodological errors were contained in 66% 
of the articles published in 1982 and 60% in those published in 
1967-1968. They also found th a t there was a  growth in the use of 
statistics in medical journals from 1967/68 to 1982.
Another study, conducted by Cruses [35], reviewed 201 articles 
published in the American Journal of Tropical Medicine and 
Hygiene and found th a t 73.5% of the papers had  a t least 1 
detectable statistical error.
It was noted th a t two of the most commonly used  statistical 
methods: S tudent’s t-test and Chi-squared test also had  the highest 
rate of misuse. The m ost common mistake in using the S tudent t- 
test occurred when the data  were not (approximately) normally 
distributed, and the m isuse of the one and two sam ple t-tests.
In addition to the statistical errors, a  common problem in the 
reporting of trials was the publication bias (publication bias is a 
tendency on average to produce results th a t appear significant, 
because negative or near neutral resu lts are alm ost never 
published). Pocock et al [44] reviewed 45 reports of comparative 
trials published in British Medical Journal, the Lancet, or the New 
England Journal of Medicine and concluded that, overall, the 
reporting of clinical trials appeared to be biased toward an 
exaggeration of treatm ent differences.
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5.3. Statistics for the two-stage procedure and its 
deficiency in relation to general medical statistics 
books
The statistical concepts used to evidence the deficiencies of the two- 
stage procedure were beyond the average coverage of general 
medical statistics books. It would be unrealistic to expect clinical 
researchers who conducted cross-over trials to understand  the 
consequences in terms of statistics if the two-stage procedure was 
used. Nevertheless, it would be difficult to determ ine w hether not 
using the two-stage procedure was a  sign of no t knowing the 
existence of the method or a  full understanding of the deficiencies. 
On the other hand, considering the m isuse of basic statistical tests 
published in medical journals, the two-stage procedure of cross­
over trials which involves three t-tests including one and  two- 
sample type may contribute to more m isuse in medical journals if it 
was adopted. It is, however, not the intention of this study  to 
examine or criticise the level of statistical knowledge of au thors of 
cross-over trials reports. The objective is to evaluate and illustrate 
the impact of the two-stage procedure and its deficiencies.
In addition to medical statistics books and  statistics journals, 
analyses of a  cross-over trial may also be based on a  triad th a t is 
similar in the patient conditions, the trial design or the treatm ent. 
The author of the report may review other cross-over trials to 
ensure th a t the statistical method h e /sh e  used  was similar to w hat 
had been published. Therefore, a  snowball effect may be created in 
this context, especially when authors, research centres or medical
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journals with more credits may have some im pact on analyses of 
cross-over trials in medical journals. It is not the purpose of this 
thesis to analyse the snowball effect. It has therefore been left out 
of the systematic review.
5.4. Objective
The objective of the review is to investigate statistical m ethods used 
to analyse cross-over trials in medical journals, with em phasis on 
the two-stage procedure and w hether the carry-over effect has been 
tested for by statistics. O ther information provided in cross-over 
trial reports will be used to investigate design and  application 
aspects.
5.5. Methodology
Systematic review (as defined in Section 3.2.2. )
As a general rule, a  second reviewer is required for a  publication of 
a  systematic review. One was, however, not available for this thesis. 
As an alternative for the validity of results, original quotes of 
information used for drawing the results of this chap ter are given in 
an appendix for reference.
5.5.1. Sampling population
The sample population was all cross-over trial reports available on 
Medline. It was searched using the key words ‘cross-over trial’, 
‘cross-over trials’, ‘crossover trial’, ‘crossover trials’, ‘change-over 
trial’, ‘change-over trials’, ‘changeover trial’ and changeover trials’.
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The total num ber of cross-over trials published in medical journals 
between 1981 and 2001 was 3,162, an  average of 151 cross-over 
trials every year. See Appendices
Appendix A
5.5.2. Sampling method
A stratified, simple random  sampling method was used to choose 
reports to be reviewed. Four publication years were used  in order to 
study statistical methods used to analyse cross-over trials a t 
different years. The publication years (1988, 1992, 1996 and 2000) 
were chosen a t even intervals of 4 years, including the year before 
the major deficiencies of the two-stage procedure was published, in 
order to study the impact of the finding of the deficiency.
5.5.3. Sample size
The database was stored in Reference Manager® 9 and each report 
was given an identity num ber for sampling purposes.
It was estimated tha t a  sample size of 60 reports was a  feasible 
num ber as part of the PhD project and a  sufficient num ber 
comparing to systematic reviews published in medical journals. 
There were 4 publication years to be reviewed and it was decided to 
stratify by year with equal num bers per year, therefore the total 
num ber of papers being reviewed had to be a  multiple of four. 
According to the assessm ent of time from the pilot study, it would 
take approximately 3 m onths to complete the first round of the 
review. Once the first review was completed, the second review
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would be conducted in order to ensure th a t all relevant information 
regarding the design and analysis of trial would be extracted from 
the report. Time taken for second review was about half of the first 
review. In addition to the time taken for the review, time required 
for obtaining the triad reports was also taken into account. 
Therefore a  sample size of sixty-four reports was considered a 
feasible quantity to review in 6 months.
Similar sample sizes were commonly used for system atic reviews 
published in medical journals, which included 62 reports in the 
British Medical Journal (BMJ) by Gore et al (1977), 67 clinical trials 
by DerSimonian et al [48] and 45 triads by Pocock et al [44].
5.5.4. Sample selection
The list of cross-over triad reports to be reviewed was generated 
randomly on the SAS® programme. To choose reports from the 
sampling population, sixteen num bers with two decimad places 
between 0 and 1 were drawn amd the procedure was repeated four 
times for the four publication years. The figures were multiplied by 
the total num ber of triads of tha t year and round to the nearest 
integer. Reports of identity num bers which m et the num ber derived 
from the simulation were the cross-over trials to be reviewed.
Due to the use of simple random sampling for each of the selected 
four years, samples of cross-over trial reports chosen for analysis 
caime from publications across all types of journals. The selected 
reports were collected from university libraries and the British
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Library (if not available in university libraries). All of the selected 
reports drawn by simple random  sampling were obtained. Because 
the sample selection was chosen a t random, the sam ples cover 
various types of diseases, treatm ents, size of trial, type of cross-over 
designs and geographical locations. See Appendix B for the list of 
triad reports reviewed.
5.6. Pilot of the systematic review
A checklist of items to be reviewed was tested over a  pilot study in 
order to examine its completeness and practicality. A pilot study of 
20 cross-over triad reports was conducted using the exact method 
tha t was planned for the systematic review. By assessing the length 
of time taken to review each paper, the pilot study also served the 
purpose of estimating a practical num ber of cross-over triad reports 
to be reviewed. Time taken for each review depended on the 
complexity amd length of the paper. On average, each review took 
approximately one working day. It was also graduadly reduced as 
more papers were reviewed.
5.7. Checklist - references to guidelines
As there are no existing guidelines for reporting cross-over trials, 
the checklist of this systematic review took references from various 
guidelines (the CONSORT statem ent, ICH-E9 Statistical Principles 
for Clinical Triads, and BMJ checklist). The CONSORT statem ent 
[42] was the main framework for the checklist as it provided the 
standard report of parallel clinical trials in medical journals. It was
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introduced in 1996, and was intended to improve the reporting of 
the RCT (randomised controlled trials), enabling readers to 
understand  how a  trial had been conducted and to assess the 
validity of results. It has been endorsed by 175 medical journals 
[37] and 32 organisations, including pharm aceutical companies, 
medical associations, societies and  governm ent bodies [38]. 
Therefore a  checklist th a t covers equivalent item s for cross-over 
trials could be used as a  standard  criterion of w hat could be 
expected from cross-over trial reports. In addition to the items 
recommended by the CONSORT statem ent (Appendix E), the 
checklist for the systematic review on cross-over trial reports 
included a few items which only applied to cross-over design. The 
main objective of the checklist was to make sure th a t readers would 
be able to identify the design of trial from the report.
5.8. How to report a cross-over trial
How cross-over trials should be reported can be discussed in term s 
of two aspects: the design and the analysis.
5.8.1. Design
The main objective of the systematic review of cross-over trial 
reports published in medical journals was to investigate statistical 
methods used for such a  design. However, w ithout knowing the 
design of the trial, it is impossible to judge w hether the statistical 
analysis has been applied appropriately. Therefore the reporting of
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the design was also included in the system atic review in order to 
assess the statistical analysis.
The CONSORT statem ent was intended for reports of parallel-group 
randomised trials, therefore some information on design of cross­
over trials would be missing from the report even if the list was 
strictly followed. As a  consequence, readers would not be provided 
with sufficient information regarding the design of cross-over trials. 
For example, the CONSORT statem ent requires the num ber of 
interventions for the trial to be reported. However, unlike parallel 
trials, num bers of treatm ents are not always equivalent to num bers 
of treatm ent groups or treatm ent sequences for cross-over trials 
(For example, Balaam ’s design: AA/BB/AB/BA and
AABB/BBAA/ABBA/BAAB). While parallel trials involve only one 
treatm ent period, there are a t least two treatm ent periods in cross­
over trials. Numbers of periods are not always equivalent to num ber 
of treatm ents (For example, three period design with four 
sequences: ABB/BAA/BAB/ABA, four periods with four sequences: 
AABB/BBAA/ABBA/BAAB, and four period design with six 
sequences: AABB/BBAA/ABBA/BAAB/ ABBB/BAAA).
In addition to the items in the CONSORT statem ent, cross-over triad 
reports should specify the num ber of trea tm ent groups (sequences) 
and the num ber of treatm ents given for each patient. It is not 
sufficient to ju s t state the num ber of treatm ents or sequences. 
Items which should be included in cross-over trial reports are:
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Numbers o f randomised groups. This is usually equivalent to 
num bers of sequences.
Sequences o f treatm ents for each random ised group. This 
should include num bers of treatm ent periods and  which treatm ent 
is given a t each treatm ent period.
As incorporating a w ash-out period is the m ost reliable method to 
eliminate the possibility of the carry-over effect, w hether the w ash­
out period was incorporated between trea tm ent periods should 
always be reported. In addition, the length of the w ash-out period 
should also be included in the trial report. The half-life of the 
treatm ent can also be used to justify the length of the w ash-out 
period.
5.8.2. Randomisation
A difference between random isations of a  parallel trial and  a  cross­
over trial is the unit tha t patients are random ised to. Patients 
participate in cross-over trials are random ised to sequences of 
treatm ents while patients are random ised to treatm ents in a  
parallel trial. In a  randomised cross-over trial, the num ber of 
randomised groups is equivalent to the num ber of sequences, bu t is 
not necessarily the same as the num ber of treatm ents. The 
sequence tha t a  patient is random ised to would determ ine the order 
of treatm ents h e /sh e  is given. All random isation m ethods (e.g., 
simple randomisation, block random isation, stratified 
randomisation amd minimisation) should be based on sequences
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not treatm ents. For example, the block size would be a  multiple of 
the num ber of sequences ra ther than  the num ber of treatm ents. 
However, the reporting of random isation for a  cross-over trial is 
very similar to w hat is suggested in the CONSORT, except the 
sequence of each randomisation group should be specified.
5.8.3. Flowchart
A flowchart tha t indicates all stages of the cross-over trial is 
probably the most comprehensible tool for readers to identify the 
design. The recommendation for the flow diagram  of the progress 
through the phases of a  randomised parallel trial was made in the 
CONSORT statement. Below is an example of the diagram  for an  
AB/BA trial. Numbers of patient drop-outs a t different stages of the 
trial can also be specified using the flowchart.
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Figure 5.8.3: A suggested flow diagram of subjects progress through the phases 
of a AB/BA trial
Wash-out PeriodWash-out Period
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5.8.4. Analysis
A few factors such as the period effect, the carry-over effect and the 
patient effect, which are not generally relevant to parallel trials are 
often associated with the cross-over design.
The main outcomes of a  randomised controlled trial (RCT) are 
usually the treatm ent effects. However, there are a  few different 
m ethods for evaluating the treatm ent for cross-over trials (as shown 
in Chapter 2 - ). Therefore cross-over trial reports should be 
especially clear about how treatm ent effects are analysed. For 
example, whether direct treatm ent differences are assessed or 
period effects have been adjusted for and perhaps also w hether 
patient effects are treated as fixed or random.
In addition to the results of treatm ent effects, the carry-over effect 
and the period effect are often mentioned in trial reports. The carry­
over effect is considered to be the ‘chief difficulty’ of the cross-over 
design and an approach to testing for its presence was described by 
Grizzle (1965)[4] amd Hills and Armitage (1979)[7]. Although the 
carry-over effect should be designed out by allowing sufficient 
wash-out period (see previous section) and therefore not tested for, 
it is evident tha t the two-stage procedure was often cited in the 
cross-over trial reports.
If one chooses to report the results of the statistical test for the 
carry-over effect, one should be clear about the method used and 
its significance level. This should be followed by w hether the results
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of the test have affected how treatm ent effects are analysed. Similar 
rules should apply to the period effect.
5.9. Results
The results of the systematic review of cross-over triads will be 
discussed in two parts: designs and analyses. Designs of the cross­
over trials include the general background of the trial, such  as 
types of disease, size of the trial, type of cross-over trial and where 
the triad was conducted. The discussion of anadyses of cross-over 
triads includes statistical m ethods applied and  references used.
Although what has been reported in the cross-over trials published 
in medical journals may not cover every statistical procedure which 
had been carried out by the authors, the discussion of the resu lts is 
based on information given in the reports. It was sometimes 
feasible to contact the authors for further details of the report. This 
was, however, not considered. The reasons aire, first, th a t only w hat 
has been published would have influence on analyses of cross-over 
trials for other researchers. Second, omission of information is a 
common problem tha t is sometimes considered to be as serious as 
giving false information. Hence, the analysis presented in this 
chapter refers only to published information about trials.
5.9.1. Diseases
Cross-over designs are only appropriate when the disease of 
interest is not fatal or curable. Table 5.9-1 shows the distribution of 
the disease types among the 64 selected reports. More than  a
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quarter (27%) of the trials were conducted on healthy volunteers. 
Cross-over trials were m ost popular am ongst trials for behavioural 
disorders (14%). Other areas of diseases am ongst the cross-over 
trials were endocrine, nutritional and metabolic diseases (11%) and 
diseases of the circulatory system (10%).
Table 5.9-1: Disease type of cross-over trial 
classification of Diseases)
reports reviewed (using International
ICD-10 Number of Percentage of
Code cross-over trials cross-over trials
Neoplasms C00-D48 1 2%
Endocrine, nutritional and metabolic diseases E00-E90 7 11%
Mental and behavioural disorders F00-F99 9 14%
Diseases of the nervous system G00-G99 4 6%
Diseases of the ear and mastoid process H60-H95 1 2%
Diseases of the circulatory system 100-199 4 6%
Diseases of the respiratory system J00-J99 6 10%
Diseases of the digestive system K00-K93 2 3%
Diseases of the musculoskeletal system and 
connective tissue M06-M99 2 3%
Pregnancy, childbirth and the puerperium 000-099 3 5%
Symptoms, signs and abnormal clinical and 
laboratory findings, not elsewhere classified R00-R99 2 3%
Injury, poisoning and certain other consequences 
of external causes S00-T98 2 3%
Factors influencing health status and contact with 
health services Z00Z99 1 2%
Healthy (normal) 17 27%
Cigarette smoker 1 2%
Animal 1 2%
TOTAL 63 100%
5.9.2. Regions
Seventy-eight percent (n=49) of the cross-over trials reviewed were 
conducted in Europe or North America. Twenty-eight of the 64 
cross-over trials were conducted in Europe and half of the 28 cross­
over trials in the UK. Seventeen of the 21 trials conducted in North 
America were in the US. There were 6 cross-over trials in Asia and 
4 in Oceania. One of the trials was an international collaboration 
between Austria and UK in 1988.
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Table 5.9-2: Regions of cross-over trials reviewed
1988 1992 1996 2000 TOTAL
Africa 1 0 0 0 1
Asia 0 2 2 2 6
Europe 11 6 6 5 28
Middle East 0 1 1 1 3
North America 3 5 6 7 21
Oceania 1 2 1 0 4
TOTAL 16 16 16 15* 63
*  Location o f  one tr ia l (Appendix B, 2002-2) w as unknown.
5.9.3. Design of cross-over trials
Unlike parallel trials, there are many types of design for cross-over 
trials. Although the type of design is an essential feature of a  trial 
report, it was noticed tha t the num bers of periods and  treatm ents 
of the trial were often ambiguous and the design of the trial was 
rarely specified in the abstract and could only be determ ined when 
the methodology was carefully examined. None of the trial reports 
included the num ber of treatm ents and trial periods in the design.
For a  large percentage of the reports, designs could only be 
identified by reviewing num ber of treatm ents given to each patient. 
The most commonly used design am ongst cross-over triad reports 
reviewed was the AB/BA design which had been used  by 45 of the 
64 reports reviewed. Other designs applied were 3 period 3 
treatm ents and 4 periods 4 treatm ents.
There were also 12 trials for which the design could not be 
determined by reading the trial report. For example, the design of a  
trial tha t involves two treatm ents, both taken with or w ithout 
alcohol was described as 6-way (1992-9). No further information 
was given on whether all participants were enrolled for 6 periods 
and how many random isation groups were used.
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There were considerable percentages of cross-over trials which did 
not specify num ber of treatm ents or treatm ent period. It is possible 
th a t many considered AB/BA as a  standard  design of cross-over 
trials. Therefore, unless it was stated, it w as m ost likely to be two- 
period two-treatm ent design.
Table 5.9-3: Designs of cross-over trials reviewed
Design 1988 1992 1996 2000 TOTAL
2 treatments 2 periods 9 12 11 13 45
3 treatments 3 periods 2 1 r 1 4
4 treatments 4 periods 1 1 2
Not clear 4 a 2b 4d T 12
TOTAL 16 16 16 16 64
a (Letter to the editor 1988-5), (1988-6) (3 treatment groups, but number of treatments and period 
unknown 1988-9) (3 sequences 1988-12)
b (1996-4 4 treatments) (1996-9 6 way) 
c 3 treatment sequence by latin square
d (four types of computer assisted tutorial, periods unknown 1996-2)(1996-5X1996-9X1996-13)
'(2000-12) (2000-13)
5.9.4. Length of treatment period
The length of one treatm ent period varied from a  few hours to 12 
weeks. The shortest treatm ent period was 5 hours. The longest trial 
period was 28 weeks including 4 weeks of w ash-out period (1988- 
11) on 22 diabetes patients and the num ber of patients who 
dropped out was 4.
5.9.5. Wash-out period
Table 5.9-4 shows th a t the w ash-out period was incorporated 
between treatm ent periods by 24 (38%) of the 64 cross-over trial 
reports. Forty trial reports did not specify w hether there was a 
wash-out period. Eleven (46%) of the 24 reports which gave length 
of the w ash-out period were published in 2000. This may have 
indicated tha t there had been an improvement in design or report 
of cross-over trials or both.
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F orty  of the 64 trials did no t mention the  w ash-out period. It was 
n o t know n w hether it w as for clinical reasons th a t the carry-over 
effect w as unlikely to occur, or w hether it was no t feasible to 
inco rpo ra te  (e.g. patients needed to be treated  a t all times), or for 
p rac tica l reaso n s th a t adding a w ash-out period would lengthen the 
tria l period a n d  cause higher drop o u t rate, or simply th a t the 
a u th o rs  were unaw are  of the potential problem  of carry-over.
The longest w ash -o u t period was 6 weeks (2000-3) while the 
sh o rte s t one w as reported to be 4 days (1992-8). The decision on 
len g th  of the w ash -ou t period was rarely justified. One report, after 
th e  tria l was com pleted, concluded th a t their w ash-ou t period was 
too sh o rt and th a t  the carry-over effect could no t be completely 
elim inated. A nother report did not incorporate a  w ash-out period in 
th e  tria l and only found th a t it should have been incorporated when 
th e  resu lts  were analysed. They said “This has implications for the 
d esig n  o f the crossover intervention trial and suggests that a w ash­
out period should be incorporated betw een treatment periods to 
m inim ize carry-over e ffects”(1996-5).
Table 5.9-4; Use of wash-out period in cross-over trials reviewed
1988 1992 1996 2000 Total
Number of trials that 
incorporate a wash-out period
5 4 4 11 24
Wash-out period NOT 
mentioned in the report
11 12 12 5 40
Total Number of Reports 16 16 16 16 64
Proportion 5/16 4/16 4/16 11/16 24/64
Cl wash-out period (0.1416,
0.556)
(0.1018,
0.495)
(0.1018,
0.495)
(0.444,
0.8584
(0.2667,0.
4975)
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5.9.6. Drop-out rate
A cross-over trial is more likely to have a  higher drop-out rate than  
a  parallel trial. The problem with a  high drop out rate is th a t it may 
resu lt in inadequate power.
The num ber of patients who dropped out was specified in only 9 of 
the 64 trials. It is not known whether it was because there were no 
drop outs in the trial or w hether this information had been omitted. 
The num ber of patient drop outs was compared with the num ber of 
patients included in the final analysis, and one case (1992-12) 
showed th a t only 6 of the 14 patients completed the trial (such a 
high drop out rate was not mentioned in the text in the report). A 
clinical trial exhibiting such  a  low completion rate raises questions 
about the design of the trial. Since less than  half of the participants 
completed the trial, it is debatable whether a  statistical analysis 
was worth carrying ou t and whether results of the analysis (or the 
trial) were validated or published without discussing its drop out 
rate.
The second highest drop-out rate occurred in a multiple sclerosis 
trial which lasted  8 weeks for both periods with a  two week w ash­
out period in between. Five of the 26 patients random ised to trial 
dropped ou t before it was completed.
Although it seems plausible tha t a  longer period for the trial can 
cause a  higher drop out rate, it is not possible to establish such a 
relationship with such a small sample size. O ther possible causes
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of patien t drop out include treatm ents which are less tolerable or 
treatm ents which produce effects th a t were not noticeable to the 
patients. This might happen in the case of diseases which do not 
necessarily require treatm ent or treatm ents which are not effective. 
In addition, trials which require regular visits to the hospital are 
more likely to cause patients drop-out than  trials which require 
short period in-patient hospital stay.
5.9.7. Statistical analysis
The method used for the statistical analysis is a  required disclosure 
in m ost medical journals. Results of this section are based on the 
description of statistics in the cross-over trial reports published in 
medical journals.
The m ost commonly used  methods described in cross-over tried 
reports are listed in Table 5.9-5. It is regrettable th a t no further 
conclusion can be drawn from the review on statistical analyses of 
cross-over trials published in medical journals other them from the 
statistical methods m entioned in the reports. It was impossible to 
judge w hether the statistical methods applied were appropriate for 
the trial as statistical tests were often given w ithout mentioning to 
which variable they were applied to. For example:
“The statistics usedfor paired comparison were the McNemar test with Yates 
correction, and the paired Wilcoxon test. The Mann- Whitney U-test was usedfor 
comparison o f unpaired data. Exact 95% confidence intervals (Cl) are given in 
parentheses in the text. ” (1996-1)
“All analyses were performed using either SAS software programme (SAS 
Institute, Cary, NC) or Microsoft 4.1 (Ecosoft Inc., Indianapolis, IN). Analysis o f
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variance and paired t tests, or chi-squared and Fisher exact tests, were used to 
assess continuous or categorical variables respectively. All tests were two-tailed 
and alpha levels o f <0.05 were considered significant. Mean ± SE are 
presented. ” (1996-6)
Despite the requirem ent of journals, there was one report each in 
year 1992, 1996 amd 2000 where no other statistics were given 
beyond m ean and standard  error.
The m ost commonly used  methods were t-test and  ANOVA. Other 
m ethods which have been used  include two-sample t-test, Wilcoxon 
signed ranked test, Mann-Whitney, Fisher’s exact test, Chi- 
squared, MANOVA, regression analysis and general linear model.
Table 5.9-5; Most used methods of statistical analyses for cross-over trials reviewed
1988 1992 1996 2000 Total
A N O V A 4 4 5 4 13
Paired t-test 10 3 5 3 21
W ilcoxon signed rank test 6 2 3 3 14
H ills and A rm itage 1 1 1 1 4
Testing for the carry-over effect
Although testing for the carry-over effect is the key feature of the 
two-stage procedure, it is not confirmed th a t it necessarily implies 
the two-stage procedure had been used. It has been stated in m any 
reports th a t the carry-over effect was not significant or did not exist 
w ithout giving the test used. The followings are quotes from the 
trial reports which mentioned the carry-over effect w ithout giving 
the m ethod of the test.
"In each study pattern, similar values for the clinical and metabolic findings, 
vitamin E plasma levels, platelet aggregation tests, and TXB2 production were 
observed after each vitamin E and placebo period, thus excluding any carryover 
effect. ” (1988-8)
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“There was no evidence o f either a carryover effect or o f a period-treatment 
interaction ” (1992-10)
“No sequence effect was demonstrated with respect to the different dialytic 
therapies (RHSD and SD) in any o f the outcome measures ” (1996-6)
“No carryover effects were demonstrated, and baseline values did not differ 
significantly” (2000-8)
“Analysis is difficult, as adjustment has to be made fo r  both period effect and 
treatment period interaction" (2000-10)
“This has implications fo r  the design o f the crossover intervention trial and 
suggests that a wash-out period should be incorporated between treatment 
periods to minimize carry-over effects”(1996-5)
The two-stage procedure
The ‘two-stage procedure’ was only mentioned in two of the 64 
reports. One report stated  th a t the statistical m ethod used  for 
analysis of the cross-over trial followed the m ethod published by 
Hills and Armitage (1979) while the other report followed the book 
by Pocock (1984), which recommended the two-stage procedure, 
see C hapter 6 - .
Although testing for the carry-over effect was an  im portant feature 
of the two-stage procedure, it has been m entioned more frequently 
than  the method itself. It seems tha t testing for the carry-over effect 
had  a  high priority in analyses of cross-over trials. Below is an 
example in which, despite the w ash-out period between two 
treatm ent periods, testing for the carry-over effect was considered 
to be more im portant than  the deficiencies of such a  test.
The trial was conducted by Harvard Medical School with one of the 
authors from the departm ent of biostatistics. This report cited
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Freem an (1989) amd used  a  model suggested by Senn (1994), which 
excluded the carry-over effect from the analysis. Despite 
acknowledging th a t models including the carry-over effect “are 
biased and p o ssess  poor p o w e f  and incorporate a  w ash-out period 
between two treatm ent period, it was stated  th a t “in any event, a 
carryover effect seem ed unlikely with our design because evidence 
from  kinetic studies w ith testosterone cypionate suggest that 6-week 
w ashout period after 6-week treatment period allows neuroendocrine 
function to return to baseline. The observed carry-over effect raised 
some concerns despite the 6-week w ashout period which w as 
designed to ‘allow neuroendocrine function to return to baseline?. The 
statistical analysis was conducted on the first treatm ent period 
only. Their rationale for such  an analysis was “free o f concern about 
carryover e ffec t. This example illustrates the fear of the carry-over 
effect for clinicians and may explain why the two-stage procedure 
has been widely cited (Chapter 4 -).
In con trast to testing for the carry-over effect w ithout mentioning 
the m ethod used or w hether it was used as part of the two-stage 
procedure, the two-stage procedure has been cited w ithout giving 
the resu lt of the test for the carry-over effect. For example, 2000-16 
cited Hills and Armitage (1979) w ithout mentioning the result of the 
carry-over effect in discussion.
Although the carry-over effect was rarely m entioned in the 
description of analysis, it was often mentioned th a t the carry-over 
was not significant w ithout indicating methods of tests. Results of
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th is review indicated th a t the use of the two-stage procedure cannot 
be estim ated and it is possible th a t the two-stage procedure has not 
been fully understood or applied for analyses of cross-over trials.
5.9.8. Cited references
In addition to the statistics methods described in the report, 
citations and references were used as indicators of sources of 
statistics. Reference served the purpose of confirming the method 
used  for analysis and establishing the relationship between citation 
and  actual analysis.
Fifteen of the 64 papers provided references to statistics. There 
were 4 citations on Hills and  Armitage [7] while Grizzle [4] was not 
cited by any of these reports. Similar to the previous conclusion 
th a t the carry-over effect could still have been tested even it had 
not been stated in the statistics description, not citing any of the 
docum ents relating to the two-stage procedure does not necessarily 
imply th a t it had not been used. It was found th a t the carry-over 
effect was reported to be non-significant while no statistical method 
w as given and none of the two-stage procedure references was 
cited. It can be confirmed th a t the two-stage procedure was more 
commonly used  than  w hat was found in this systematic review 
(Table 5.9-5). Using citations as an  indicator of w hether the two- 
stage procedure had been used may have underestim ated the 
prevalence of its use.
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However, citation does not necessarily indicate usage. There were 
papers which cited Hills and Armitage [7] and did not report if the 
carry-over effect had been tested, or a t w hat level or w hether it was 
insignificant. None of the trials reported th a t treatm ent effects were 
evaluated using the first period data  only because the hypothesis of 
equal carry-over effects was not accepted
Table 5.9-6: Citations of cross-over trial reports reviewed
1988 1992 1996 2000 TOTAL
Number of cross-over trial reports that cited 
statistical references
5 1 4 5 15
Number of citations to Hills and Armitage 0 1 1 2 4
Citations give to Freeman 0 0 0 1 1
Citations give to Senn 0 0 1 1 2
Table 5.9-7: References for statistical analyses of cross-over trial reports reviewed
Reference 1988 1992 1996 2000
Cohen, Statistical power analysis for the behavioural 
science. New York: Academic Press, 1969
1
Miller RG. Simultaneous statistical interference. New 
York: McGraw Hill, 1966:62
1
Altman DG, Gore SM, Gardner MJ, Pocock SJ: 
Statistical guidelines for contributors to medical 
journals, Br Med J 286: 1489-93, 1983
1
Hollander, M., Wolf, D. A., Nonparametric Statistical 
Methods, J. Wiley Sons, New York (1973)
1
Pocock SJ. Clinical trials: a practical approach. New 
York: Wiley, 1983
1
Altman DG. Clinical trials; In: anonymouse. Practical 
statistics for medical research. London, Chapman & 
Hall, 1991:440-75
1
Hills and Armitage 1979 1 1 2
Wallenstein S, Fisher AC. The analysis o f the two- 
period repeated measurements crossover design with 
application to clinical trials. Biometrics 1977; 33: 
261-9
1
Senn S. In cross-over trials in Clinical Research. New 
York: John Wiley & Sons, 1993
1
Steinijans VW, Hauschka D: Update on the statistical 
analysis of bioequivalence studies. Int. J Clin 
Pharmacol Ther Toxicol 1990; 28: 105-110 
Hauschke D, Steinijans VW, Diletti E: A distribution- 
free procedure for the statistical analysis of 
bioequivalence studies. Int J Clin Pharmacol Ther 
Toxicol 1992; 30 (suppl. 1):S37-S43
1
Stolley PD, Strom BL. Sample size calculations for 
clinical pharmacology studies. Clin Pharmacol Ther 
1986;39:489-90
1
1. Senn S. The AB/BA crossover: past, present 1
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and future? Stat Methods Med Res. 1994; 
3:303-324
2. Freeman PR. The performace of the two- 
stage analysis of two-treatment, two-period 
crossover trials. Stat Med. 1989; 8:1421- 
1432
3. SAS Institute Inc. SAS/GIS Software 
[computer program]: release 6.12. Cary. NC: 
SAS Institute Inc; 1997
However, the fact th a t a  trial report cites the papers describing the 
two-stage procedure and the books which recommended tha t 
m ethod can be used to check the consistency of the statistical 
m ethods used  in the report. Citations can  only be used  as an 
additional confirmation th a t the method was used.
It can be concluded th a t the use of the two-stage procedure had in 
fact exceeded the num ber of its citations. W hether the two-stage 
procedure was more commonly used than the original simple cross­
over difference rem ains unknown. It is also impossible to conclude 
w hether not mentioning the two-stage procedure was a  result of 
Freem an’s [8] paper on its deficiencies. Such a possibility was, 
however, ra ther slim as the difference in citation rate between 
Freem an [8] and other references of the two-stage procedure is 
substantial.
The resu lts of this system atic review also show th a t Freem an’s [8] 
influence has not extended to the analysis of cross-over trials 
published in medical journals. Despite the high citation rates of the 
two-stage procedure in medical journals, the method was likely to 
be unknow n to m any clinical researchers. Therefore the change in 
the validity of the two-stage procedure would not have had any
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im pact on those who were not aware of this method in the first 
place.
5.9.9. Sample size calculation
Sample size calculation has always been a  common practice of 
experim ental design and a  basic requirem ent in medical journals. It 
has, however, become a  controversial issue in recent years [27].
Sample size calculation was originally planned to be included in the 
resu lts of the system atic review. However, in order to reflect the 
personal view on recent discussion of the sample size calculation, it 
h as been removed from the discussion of results.
5.9.10. Discussion on individual papers
Despite the inconclusive resu lts regarding the use of the two-stage 
procedure in analysis of cross-over trials, this system atic review 
has provided an opportunity to examine published cross-over trial 
reports. Although it is not the focus of this thesis, it was found tha t 
a  few papers have raised some concerns regarding different issues 
of clinical trials while reviewing the reports. Below are three papers 
which raised issues with ethics, random isation and design 
respectively.
5.9.11. Ethics
As clinical trials are experiments on hum an beings, the ethical 
issues should be carefully reviewed so th a t any potential harm  to 
the patien ts’ physical and m ental health may be avoided. It was
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found th a t there was a  cross-over trial in which patien ts’ health 
was a t risk. This report, which caused serious concern and should 
never have been allowed by the relevant ‘ethical committee’, was 
1992-6 on salt intake. It was a  trial with the objective of examining 
w hether the intake of salt would worsen the condition of asthm a 
patients, a lthough it has been acknowledged in the paper th a t a  
high sodium  intake had  been found to increase bronchial reactivity 
with asth m a patients. Participants in the trial were asked to add as 
m uch salt as possible to their regular diet and to take four tablets 
of sodium  chloride (500mg) daily. The trial consisted of three 
treatm ent periods of different levels of salt intake. The paper was 
accepted by Thorax, a  jou rna l with a  high im pact factor of 4.09.
This trial raised a  few concerns. First, it is a  trial w ithout a  justified 
objective. There was no benefit for hum an beings to increase 
sodium  chloride intake and  a  reduction in its intake has been 
widely encouraged. W hether a  high consum ption of sodium chloride 
would w orsen the condition of asthm a was irrelevant as it may 
cause o ther problems such  as high blood pressure and was 
certainly no t worth exploring by putting patients a t risk. The 
harm ful effect of sodium  has long been established and the upper 
limit of UK daily recommended nutrition intake (RNI) is 1,600 mg 
(2,400 mg for US sodium  RDA). The m ost common problem 
associated with high sodium  diet is raising blood pressure [41]. In 
addition to the trial design th a t required patients to “add as much
U s e  o f  t h e  t w o - s t a g e  p r o c e d u r e  f o r  a n a l y s i s  o f  c r o s s -o v e r  t r i a l s  in  f o u r  a s p e c t s  o f  m e d ic a l  s t a t i s t i c s
salt in their food as possib le”, participants were asked to take four 
tablets of 500mg of sodium  chloride everyday.
Another issue with this trial is th a t blinding/m asking had not been 
introduced. Instead, patients were deceived with the intention of 
blinding/m asking {“To minimise bias, patients were told that the 
response o f an individual to a change in dietary salt intake w as  
unpredictable.”). They were told th a t “a low and high dietary salt 
intake for two w eeks has no effect on p ea k  expiratory flow  in 
patients with mild asthm a”.
This trial was not only unethical b u t unnecessary. There were other 
possibilities to study w hether reduced sodium  chloride 
consum ption would help with the asthm a condition. A suggested 
design of this tried would include two treatm ent periods only. One 
treatm ent period would involve patients’ u su a l diet and  one 
treatm ent period with a  lower sodium diet. A diet in high sodium 
chloride should have never been encouraged anyway.
5.9.12. Randomisation
Random isation is generally agreed to be highly desirable for clinical 
trials [31] [32].
It was found th a t one cross-over trial (2000-2) did not incorporate 
random isation into the triad of which the objective was to determine 
the effect of the consum ption of a  fat substitu te  (olestra) in 
m easurem ents of fecal fat excretion. The two treatm ents to be 
compared were conventional potato chips and treatm ent chips
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containing olestra. The trial was carried out in two centres with 5 
participants each. All 10 patients were assigned conventional chips 
first, followed by chips containing olestra. This is a  serious design 
flaw as treatm ent was confounded with period, even though there 
does not seem  to be any practical difficulty in incorporating 
random isation into the trial.
5.9.13. Design
Cross-over trials are special designs requiring th a t the condition of 
patients stay stable throughout the trial periods. However, it was 
found th a t some trial reports did not meet this requirem ent and the 
cross-over design was not the optimum type of clinical trial on such 
an occasion.
The example was taken from (1996-11). The trial compared two 
types of oral analgesia in relieving the intensity of postoperative 
pain. The two treatm ent periods took place in the first and second 
day after the operation. Each treatm ent lasted for 5 hours. 
Postoperative pain intensity is unlikely to rem ain stable throughout 
both treatm ent periods. Such a design is very vulnerable to period 
effect.
5.10. Conclusion
The original objective of the systematic review was to investigate the 
use of the two-stage procedure in medical journals. However, 
resu lts of this system atic review showed th a t the reporting and the 
description of statistics m ethods used in the cross-over trial reports
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reviewed was insufficient to assess the prevalence of the two-stage 
procedure in medical journals. It can only be concluded th a t the 
m ethod was likely to be used more often than  the num ber of 
citations given to the papers describing the two-stage procedure 
would suggest.
The reason for this was th a t testing for the carry-over effect was 
often m entioned w ithout giving details of the m ethod and results. It 
can therefore not be confirmed th a t the two-stage procedure was 
carried out fully.
This system atic review h as shown th a t the design and analyses of 
cross-over trials has not been fully understood by all the clinical 
researchers who conducted the trials. The cross-over triad should 
only be used  when its strength can be fully utilised and weakness 
carefully avoided.
It adso worth mentioning th a t the quality of reporting often affects 
resu lts of designs and anadyses in the review. Therefore it is 
im portant th a t m ethods and  results of statistical tests should 
always be reported in medical journals.
The inconclusive resu lt of the systematic review implies th a t more 
concise reports, better understanding of cross-over triads and 
analyses aire needed to achieve good quadity science. One probable 
solution to this would be more collaboration between clinicians and 
statisticians. (Recommendations of information th a t should be 
included in cross-over trial reports is given in Chapter 8 - ).
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Chapter 6 - Analyses of cross-over 
trials in general medical statistics 
books -  a comprehensive review______
6.1. Introduction
General medical statistics books have been criticised for their 
errors in fundam ental concepts of statistics, for example the 
interpretation of p vadues, the confusion of the two sample t test 
and the presentation of ordered data  in chi-squared contingency 
tables to nam e ju s t  a  few [33]. The analysis of cross-over trials has 
a  more tu rbu len t history than  other statistics topics covered in 
general medical statistics books. It has been shown in the previous 
chapters th a t the two-stage procedure has been used by medical 
researchers while its deficiencies were rarely mentioned. Methods 
used  to analyse cross-over trials are often influenced by 
recom m endations given in medical statistics books. This chapter 
focuses on the statistical m ethods recommended to analyse cross­
over triads in general medical statistics books.
6.2. Objective
The objective of this chapter is to investigate statistical methods 
recom m ended for analyses of cross-over trials in general medical 
statistics books.
6.3. Methodology
The methodology used was a  comprehensive review of all general 
medical statistics books published in English. First, a  list of a
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complete selection of textbooks was gathered by searching the key 
words ‘statistics’ and ‘medical’ on several web-sites, such  as online 
bookshop www.amazon.com and university libraries. The list was 
sen t to statisticians on ALLSTAT (an UK-based worldwide e-mail 
broadcast system for the statistical community) with a  request to 
add any relevant titles omitted from the list. The final list consisted 
of 125 general medical statistics books. All of them  were reviewed 
for their statistical m ethods recommended for analysing cross-over 
triads.
Publication dates of the 125 medical statistics books reviewed 
ranged from 1963 to 2000, amd covered the whole duration of the 
development of the two-stage procedure (from the first paper tha t 
published such m ethod in 1965 to the finding of its major 
deficiency in 1989). Although two books published three decades 
apairt can hairdly be compared, the concepts and the basic 
statistical m ethods remauned the same during this period. 
Therefore, many of the early published medicad statistics books 
rem ained populair and cam usuadly be found in book shops and 
libraries. Analysis of cross-over trials is an  exception am ongst other 
commonly covered topics in generad medicad statistics books, the 
standard  operation having changed three tim es in the previous four 
decades (detailed in Section 1.2.2).
All 125 books were reviewed for their coverage of the cross-over 
design. They were categorised into three types: books with 
statistical analyses of cross-over trials, books with a description of
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the cross-over design b u t w ithout analyses and books not 
m entioning cross-over trials a t all. This comprehensive review 
included all books which covered statistical m ethods of cross-over 
trials (See Appendix C List of medical statistics books reviewed). 
The cross-over design was described in 47 books and 26 of them  
gave recom m endations of statistical m ethods to analyse cross-over 
trials. The resu lts given below are based on those 26 books.
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Figure 6.3: Flow diagram to show how the 26 books finally examined were obtained
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6.4. Results
It was found th a t some descrip tions/sta tem ents in general medical 
statistics books were ambiguous. As a  result, they may be perceived 
differently by different readers. In order to illustrate an  objective 
discussion of the books, results of the comprehensive review are 
presented in their original quotes.
6.4.1. The cross-over design -  General background
Many au thors of general medical statistics books held a  sceptical 
view on both the design and  the analysis of cross-over trials. The 
two m ain causes of concern were the carry-over effect and the 
potential of higher drop-out rates. For example, “Because of the 
problems described, crossover studies are probably overused.” 
(Altman 1994). The problem can in fact, be dealt with in m ost cases 
if the cross-over trial is an  appropriate design for the research to be 
undertaken . The solution to the former problem is to allow for a  
sufficient w ash-out period, and for the latter one it is to fit the 
patien t as a  random  effect. The solutions, especially the latter one 
is rarely offered to readers. In addition, analysis of cross-over trials 
was thought to be less straight-forward.
“The actual design and analysis are best carried out by a professional statistical 
advisor, but nevertheless some o f the main types o f design available will be 
described in general terms”(Goldstone 1983)
Lack of consensus in analysing cross-over trials could be the 
reason why general medical statistics books merely gave definitions 
of cross-over trials w ithout going into details of their analyses.
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There w as also a  tendency to prefer parallel over cross-over design. 
Bolton, (1997) reflected this:
“Properties o f  a particular design should be carefully considered before the 
final choice is made. For example, the presence o f carryover effects will negate 
the advantage o f a crossover design as presented ..However, caution should 
be used when considering this design in studies where carryover effects or other 
interactions are anticipated. Under this circumstance, a parallel design may be 
more appropriate. ”
The key advantage of cross-over designs, the w ithin-patient 
com parison, was rarely mentioned. The only exception was in 
reduction of sam ple size. “Therefore the only advantage o f such an 
intra-subject comparison is reduction o f sample size.” (Mainland and 
Sanders, 1963)
6.4.2. The carry-over effect
The term  ‘treatm ent-period interaction’ was also used to refer to the 
carry-over effect. The m ain question in analyses of cross-over trials 
was w hether or not to te st for the carry-over effect. The key feature 
of the two-stage procedure was to test for the cariy-over effect. It 
was not uncom m on to see books th a t insisted on the carry-over 
effect tested by statistics, and it often led to the use of the two-stage 
procedure. In addition to the preliminary t-test, it was shown how 
carry-over effects can be identified w ithout carrying out a  proper 
statistical test:
‘The assessment o f order effects must be based on a statistical model..Therefore, 
unless order effects are known to be negligible, the crossover design loses its 
advantages ’ (Bailer, Frederick, Mosteller, pp 90, 1992).
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In addition to testing for the carry-over effect as the first step of the 
two-stage procedure, a  common recommendation to identify the 
carry-over effect was to compare w hether the responses from both 
first and  second periods were the same. Here are some examples of 
suggestions of how th a t is done.
“The subjects showing the same response in both periods give no information 
about the difference between drugs but they do give information about whether 
the order or administration matters” (Colquhoun, 1971).
“I f  the patient is improved by both treatments or not improved by either he 
contributes no information about a possible difference between the two 
treatments, and consequently, in examining the results o f a crossover trial o f this 
kind, we must restrict ourselves to considering those pairs o f responses in which 
one treatment produces improvement and the other does not” (Smart, 1963).
“A carry-over effect is present when the true treatment effect is different fo r  
subjects in group A than fo r  subjects in group B " (Rosner, 1995)
These statem ents were vague and most importantly, only applied 
when endpoints were binary data. All three books quoted above 
failed to identify the type of the data  th a t applied to these 
recom m endations.
6.4.3. The two-stage procedure
In order to offer readers a  solution to the problem of the carry-over 
effect, the two-stage procedure was often recommended. Nine of the 
26 books reviewed recommended the two-stage procedure for 
analysing cross-over triads. Only one (Pocock, 1987) of these 9 
books was published before the high type I error rate was found by 
Freem an in 1989; the other 8 books were all published between 
1990 and  1998.
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Use of the two-stage procedure: N=9
Books which recommended the two-stage procedure usually 
considered it to be the correct and optimum method for analysing 
cross-over trials. The original quotes of the 9 books which 
recom m ended the two-stage procedure were extracted and 
presented below.
“It is incorrect to ignore the design o f the study andjust perform a simple 
comparison o f  treatments. The correct analysis consists o f three two sample t 
tests or Mann-Whitney tests. For categorical data we use Chi-squared tests. ” 
(Altman, Practical statistics fo r  medical research 1990)
“A test fo r  the existence o f  a TP interaction is obtained as follows. I f  there is no 
TP interaction, the sum o f  the two responses fo r  subject j  in group I, ejj=yjji+yjj2, 
should (apart from random error) be the same whether the subject is in group I  
or group II I f  there is a TP interaction, there will be little point in testing and 
estimating the treatment effect from the whole set o f  data". (Armitage and Berry, 
Statistical Methods in Medical Research, 1994)
“The general procedure fo r  comparing direct treatment effects is to first perform 
a preliminary test fo r  the equality o f the carryover effects. ” (Buncher, Tsay, 
Statistics in the Pharmace ideal Industry, 1994)
“Ifpresent (the carry-over effect), using only data from period 1 to estimate 
treatment effect. ..Suppose however, there had been evidence o f a non-zero 
carryover effect. Then the previously described estimators fo r  treatment and 
period effect would be biased and so could not be used. In such cases, Hills and 
Armitage (1979) advise that the treatment effect now be estimatedfrom the first 
period observations only. " (Everitt. Statistical Methods fo r  Medical 
Investigations, 1994)
“What can we do i f  we identify a significant carry-over effect using..? In this 
case, the second-period data are not useful to use since they provide a biased 
estimate o f treatment effects usually for subjects who were on active drug in the 
first period and on placebo in the second period, and we must base our
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comparison o f treatment efficacy on period-1 data only” (Rosner. Fundamentals 
o f Biostatistics, 1991)
“I f  a significant interaction is found, one’s best policy is to abandon the above 
within-patient analysis and resort to a between-patient comparison o f treatment 
using the first period only. ” (Pocock. Clinical Trials -  A Practical Approach 
1987)
“I f  there is reason to suspect a carry-over effect, the only way to salvage some 
o f the data is to analyse the results in parallel groups fo r the initial period o f the 
trial only, disregarding the subsequent ‘contaminated’periods" (Spriet, Dupin- 
Spriet, Simon. Methodology o f Clinical Drug Trials, 1998)
“Thus, it is o f  interest to perform some preliminary tests fo r  the presence o f the 
period effect and/or the carry-over effects before the comparison o f  
bioavailability between formulations is made. ..To increase the test power, 
however, Grizzle (1965) suggested testing the null hypothesis at the a=10% level 
instead o f  the traditional 5% level. ” (Chow, Liu. Design and Analysis o f  
Bioavailability and Bioequivalence Studies 1992)
“Grizzle has published an analysis to detect carryover (residual) effects. When 
differential carryover effects are present, the usual interpretation and statistical 
analysis o f crossover studies are invalid. Only the first period results can be 
used, resulting in a smaller, less sensitive experiment. An example o f Grizzle’s 
analysis is shown in this chapter in the discussion o f bioavailability studies (sec. 
11.4.2). Brown concludes that most o f the time, in these cases, the parallel 
design is probably more efficient. Therefore, i f  carryover effects are suspected 
prior to implementation o f the study, an alternative to the crossover design 
should be considered. ” (Bolton. Pharmaceutical Statistics -  Practical and 
Clinical Applications, 1997)
Versions o f the two-stage procedure
Despite the similarity in m ethods of analysis and description of the 
problem, the completeness of the two-stage procedure differed from 
book to book. Some books gave clear indications th a t the analysis 
should be based on the first period data  only. Others simply stated
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th a t the cross-over design w as no t appropriate  for the trial. In other 
words, no conclusion of the  trea tm en t effect could be drawn and 
the trial would have been conducted  in vain.
The difference in the  versions of the two-stage procedure could be 
traced  to the  two im p o rtan t papers  covering such  analysis. The 
original paper w hich proposed testing the carry-over effect was by 
Grizzle [4] w hich suggested th a t the design w as no t suitable if the 
carry-over effect w as to be found statistically  significant (“I f  residual 
effects are thought to be unequal, the change-over design should be 
avoided un less residual effects are o f  interest in their ow n right and  
are not regarded as a n u isa n ce ”). The best-know n (results from the 
citation analysis in  C h ap ter 4 - ) publication of the two-stage 
procedure w as pub lished  by Hills and  Armitage [7]. They completed 
the tw o-stage p rocedure by suggesting th a t the  trea tm ent effect be 
estim ated  using  the  first period data. Both Grizzle [4] and  Hills and  
Armitage [7] versions of the  two-stage procedure were reflected in 
general m edical s ta tis tic s  books. It is conceivable th a t with the 
possibility of no t gaining any inform ation abou t the treatm ent effect 
from the  cross-over trial, Grizzle’s version of the two-stage 
procedure w as m ore likely to discourage some clinical researchers 
from using  the  cross-over design. Although 11 of the books cited 
Grizzle [4] or Hills an d  Armitage [7], the nam e originally used  by 
Grizzle [4] w as n o t referred to by any of those books.
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Significance level o f the prelim inary te s t
Due to its low power, Grizzle [4] se t th e  significance level of the 
prelim inary test of the tw o-stage procedure a t 10%. It was one of 
the m ost im portant features of th e  procedure. However, am ongst 
the 9 books which recom m ended the  two-stage procedure, only 3 
books (Rosner 1991, Chow 8b Liu 1992, Buncher 8b Tsay (eds) 
1994) specified the 10% nom inal level for the carry-over effect.
It is m ost likely th a t the 5% significance level would otherwise have 
been used  if the 10% level h a d  no t been  indicated. There is one 
book (Everitt, 1994) which, d esp ite  citing Armitge [7], gave 5% as 
the significance level regardless of w h a t was recommended in the 
original papers. This shows th a t  general medical statistics books 
cannot always be relied on for a  correct or complete analysis of the 
two-stage procedure.
Not using the tw o-stage procedure N=7
Seven of the 25 books reviewed did n o t recommend the two-stage 
procedure for analysing cross-over trials. These included books 
which did not m ention testing for the carry-over effect a t all and 
those who explained why it sh o u ld  no longer be used. There were 5 
books (Jennison, Turbull. G roup  Sequential Methods with 
Applications to Clinical Triads, Sm art. Elements of Medical 
S tatistics 1993, Chow,editor. Encyclopedia of Biopharmaceutical 
Statistics, Zolman. B iostatistics -  Experim ental Design and 
Statistical Inference, Goldstone, 1983) w hich did not describe how 
carry-over effects could be te sted  statistically. Their methods for
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analysing cross-over trials were usually the simple cross-over 
difference for the treatm ent effect for continuous endpoints. For 
example:
“As with the cross-over trial, the analysis fo r matched pairs is fairly simple and 
lends itself to a technique known as sequential analysis. ” (Goldstone. 1983)
The two books which gave the m ost complete information regarding 
analysis of cross-over trials were Matthews (2000) and Chow 
(editor, 1992). They both all mentioned the two-stage procedure 
and explained why it should not be used.
“The approach is no longer recommended. There are several 
problems . ”. (Matthews. An Introduction to Randomized Controlled Clinical 
Trials)
Although no t falling in the category of the general medical 
statistics, it is w orth m entioning th a t there is a  book: Guiloff, 
Clinical trials in neurology (2001) went a  step further to warn 
readers w hat they m ight come across in other medical statistics 
books. This is considered highly informative. Because of the 
popularity of the two-stage procedure, the aw areness of its 
deficiency can only be raised by statem ents like this:
“As a result o f  a paper by Freeman, medical statisticians working on the 
methodology o f cross-over trials have now abandoned the so-called two-stage 
procedure. The reader should be warned, however, that general introductory 
text-books on medical statistics are still being written which recommend this 
biased procedure. In fact, most introductory textbooks cannot be trusted as 
regards the advice given on this issue”. (Guiloff. editor- Clinical Trials in 
Neurology 2001)
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Not clear N=2 (Books which did n o t specify  the second stage o f  
th e analysis)
Two books which could not be categorised into either of the groups 
m entioned above were by M ainland & Sanders and by Ingram and 
Bloch.
“In order to fin d  out whether the sequence per se had any influence on the 
outcome, we use from  each patient the sum o f his changes, period 1 + period2. ” 
(Mainland & Sanders. Elementary Medical Statistics. 1963)
“I f  such time period difference is found, then the interpretation o f the trial 
becomes rather difficult; interpretation depends more on the medical than the 
statistical pre-supposition. As a technical point, the statistical test to tell whether 
the results differ in the two time periods is not very powerful, so that merely 
deciding the difference between results is ‘not statistical significant ’ may be 
misleading. ” (Ingram, Bloch. Mathematical Methods in Medicine. 1983)
However, Ingram and  Bloch continued to recommend the references 
by Hills and  Armitage [7] and  Armitage and Hills [49]. Readers of 
th is book would be inclined to use  the  two-stage procedure.
6.4.4. Other: Two atypical books
There were books th a t were not typical general medical statistics 
books: One was the proceedings for a  symposium and the other 
w as a  system atic review of cross-over trials. However, their 
descriptions gave some indications of the type of analysis they 
would consider suitable for cross-over trials.
In the book edited by Bithell and Coppi (1981), cross-over designs 
were d iscussed in the chapter on repeated m easurem ents. And it 
was suggested th a t
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“One possible approach is the introduction o f so-called “carry-over” effects, 
e.g. the effect o f treatment A given in the first period interacting with the effects 
o f other treatments in the second period, third period etc. It should be noticed 
that these carry-over effects are confounded with other interactive effects 
between treatments and period and must be interpreted very carefully. ” (ppl69, 
Bithell, Coppi 1981)
The chap ter on cross-over trials in the book edited by Bailer et al 
was a  report of crossover studies th a t appeared in the New England 
Jo u rn a l of Medicine between 1978 and 1979. Both Grizzle [4] and 
Hills & Armitage [7]) were cited in the chapter and the authors 
com m ented th a t
“Unless order effects are known to be negligible, the crossover design loses its 
advantage. The assessment o f order effects must be based on a statistical 
model. ” (Bailer, Mosteller. 1992).
6.4.5. Deficiencies of the two-stage procedure in general 
medical statistics books
Ideally, the m ost u p  to date and fully informative book on the 
analysis of cross-over trials would describe the two-stage procedure 
and  explain why it should no longer be used  so th a t readers did not 
only learn the correct method for analysing cross-over trials bu t 
were aware of w hat m ight be seen in the literature. Nevertheless, 
such  suggestions could not be expected from books published 
before 1989. There were only three books which m et all these 
criteria: two of them  were published in the year 2000 and one in 
the year 2001.
It is essential for a  book to provide information on the deficiencies 
of the two-stage procedure if the procedure is to be discussed.
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However, with the exception of three books, all the authors of the 
books reviewed failed to do so and the two-stage procedure 
rem ained as recom m ended w ithout giving sufficient warning to 
readers. Although readers of the medical statistics books which did 
not m ention the two-stage procedure may also use the simple 
cross-over difference to evaluate the treatm ent effect, the book was 
also likely to be perceived as not giving enough information, and 
readers who were aware of the existence of the two-stage procedure 
may resort to o ther references. Therefore, the m ost informative 
books regarding the analysis of cross-over trials were those which 
give information abou t the two-stage procedure and  why it should 
not be applied any more.
6.4.6. The coverage of the low power of the two-stage 
procedure
The low statistical power of the two-stage procedure was mentioned 
in Hills and  Armitage [7], yet it had never been considered a serious 
enough issue for the two-stage procedure to be discouraged. Seven 
of the 25 books reviewed gave some information about the low 
power of the two-stage procedure and five were from books which 
recom m ended the two-stage procedure.
“A problem with the analysis o f crossover trials is that the important test fo r  a 
possible treatment-period interaction is notedfor its lack o f statistical power ”. 
(Altman, Practical statistics fo r  medical research. 1990)
“Unfortunately, this comparison is subject to between-subjects variation, and is 
therefore less precise than the fu ll crossover approach. .. A similar drawback 
applies to the test fo r  interaction. This is based on between-subjects variation,
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and i f  the latter is very large the t test will be relatively insensitive. ” (Armitage, 
Berry. Statistical methods in medical research. 1994)
“The preliminary test has comparatively low power. ” Buncher, Tsay. Statistics 
in pharmaceutical industry. 1994)
“This test usually has less power than the cross-over efficacy test, or 
alternatively requires a greater sample size to achieve a given level o f power. ” 
(Rosner. Fundamentals o f biostatistics. 1991)
“Unfortunately, this test fo r  interaction is not very sensitive since it is based on 
between-patient comparison, so that particularly in small crossover trials one 
may fa il to detect an interaction when it is present. ” (Pocock. Clinical trials -  a 
practical approach. 1987)
“Unfortunately, to detect the influence o f carry-over effects on the results, we 
must use a method based on the variability between individuals "(Spriet, Dupin- 
Spriet, Simon. Methodology o f  clinical drug trials. 1994)
“This approach is no longer recommended. ” (Matthews. An introduction to 
randomized controlled clinical trials 2000)
6A.7. The coverage of the type I error rate of the two- 
stage procedure in medical statistics books
The issue of type I error rate is rarely m entioned in medical 
statistics. Amongst all 16 books published after 1989, only 1 book 
(J.N.S. M atthews 2000, An Introduction to Randomized Controlled 
Clinical Trials) informed the readers about the problem with the 
type I error rate.
“This approach is no longer recommended. There are several problems. The 
most transparent one is that the £  (patient effect) have not been eliminatedfrom 
the test o f  y=0. Therefore, this test is affected by between-patient variation. This 
is likely to be large and as the size o f the trial would be determined by a sample 
size calculation based on the smaller variance a, it is likely that the test o f  y=0 
has poor power. Consequently, the decision to follow the procedure in section
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10.3 (crossover difference) may well be taken even in the presence o f substantial 
non-zero value of y . A more subtle problem with the approach is that Step 1 is 
not what it seems. The first period o f the trial appears to be a parallel group 
trial, so the difference in treatment means from the first period only should be an 
unbiased estimator o f t (treatment effect). However, i f  the analysis is only 
performed when the null hypothesis y=0 has been rejected, the analysis will be 
biased. This is because y=0 is based on Si=Xii+Xi2, which is highly correlated 
withXn. Consequently, i f  the difference in the treatments means based on Xu is 
computed only when there is a noticeable difference between the groups o f Sit 
the estimate cannot be expected to be unbiased. The recommended approach is 
not to use this particular crossover design when there is a possibility o f a 
carryover effect. You should try to use non-statistical arguments, perhaps based 
on the half-lives o f  drugs etc., to decide how long treatment effects are likely to 
persist. The AB/BA design can then be used i f  the treatment periods are 
separated by ‘washout periods ’ whose duration is sufficient to ensure that 
carryover cannot occur. ” (Matthews. An introduction to randomized controlled 
clinical trials 2000)
6.4.8. Sample Size
Although sam ple size calculation is a  common requirem ent for 
clinical trial reports, it is not discussed here. The reason is the 
sam e as in Section 5.9.9.
6.4.9. Patient withdrawal
Patien t w ithdraw al was considered to be very problematic for the 
cross-over design. A high drop-out rate may cause a  deficiency in 
the sam e size th a t is required to achieve the power it was originally 
designed for. However, the drop out rate should also be considered 
w hen calculating sam ple size. In the analysis of cross-over trials, it 
is possible to fit a  term  for patient as a  random  effect. By doing this 
information on patien ts who drop out is not wasted. This approach
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to the  analysis of cross-over trials was rarely m entioned in general 
m edical statistics books.
“Crossover trials are particularly vulnerable to the effects o f  patient 
withdrawal. I f  a patient withdraws after the first period they cannot be included 
in the analysis because they never received the other treatment. ” (Practical 
statistics fo r  medical research, Altman, 1990)
6.4.10. Misconceptions
There were also some m isconceptions of the cross-over design, for 
example “Finally, all these problems can be made much worse w hen  
testing three or more trea tm en ts  (Ingram, Bloch. M athematical 
m ethods in medicine, 1983)
The m ore com plicated design (more periods and treatm ents) of 
cross-over trials is the alternative to the AB/BA design, as the 
carry-over effect can  usually  be eliminated by design. The problem 
with th ree  or m ore periods is th a t the treatm ent period will be 
longer and  hence uneconom ical and cause a  higher drop out rate.
6.5. Conclusion
The resu lts  of the com prehensive review on general medical 
s ta tistics showed th a t in all general medical statistics books which 
included analyses of cross-over trials, the two-stage procedure was 
recom m ended by more th an  a  third of the books. Information given 
on its deficiency was, however, very limited. None of the 9 books 
th a t recom m ended the two-stage procedure mentioned its high type 
I error rate. This problem  was only explained in three of the books 
which did not recom m end the two-stage procedure.
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In addition to Grizzle’s (1965) original paper on the two-stage 
p rocedure and  Hills and  Armitage’s (1979), medicad statistics books 
are m ost likely to be the sources of references for au thors of cross­
over trial reports published in medical journals. With more than  a 
th ird  of general medicad statistics recommending the two-stage 
procedure, it explained the use  of the two-stage procedure in 
m edical jo u rn a ls  while Grizzle (1965) or Hills amd Armitage (1979) 
w as no t cited.
However, very little consensus existed among au thors of general 
m edical s ta tistics books even when core approaches were similar. 
For example, detadls (e.g. the nominal significance level of the 
prelim inary test) an d  the  2nd stage of the two-stage procedure 
differed from book to book. Applying the m ethods to the cross-over 
trials m ay resu lt in different m ethods of analysis when different 
books are  referenced. The diversity in m ethods of amalyses of cross­
over trials  th a t are published in medical journals is therefore not 
surprising.
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6.6. Books reviewed
Table 6.6-1: General medical statistics books which give recommendataions to analyses of 
cross-over trials
Altman, DG. Practical statistics for medical research 1994
Armitage, P, Berry, G Statistical methods in medical research 1994
Armitage, P. Colton, T. Encyclopedia of biostatistics 1998
Bailar III, JC. Mosteller, F. Medical uses of statistics 1992
Bolton, S. Pharmaceutical statistics - practical and clinical 
applications
1997
Buncher, JC, Tsay, JY. Statistics in the pharmaceutical industry 1994
Chow, SC. Liu, JP. Design and analysis of bioavailability and bioequivalence 
studies
1998
Colquhoun, D. Lectures on Biostatistics: An introduction to statistics 
with applications in biology and medicine
1971
Coppi, B Perspectives in medical statistics proceedings of the 
European Symposium of Medical Statistics, Rome, 1980
1981
Everitt, BS. Statistical methods for medical investigations 1994
Goldstone, LA. Understanding medical statistics 1983
Ingelfmger, Mosteller, Thibodeau, Biostatistics in clinical medicine 1983
Ware
Ingram, D, Bloch, RF Mathematical methods in medicine 1984
Jennison, C. Turbull, BW Group sequential methods with applications to clinical 
trials
2000
Mainland, D. Sanders, WB. Elementary medical statistics 1963
Matthews-JNS An introduction to randomized controlled clinical trials 2000
Petrie, A Lecture notes on medical statistics 1987
Piantadosi Clinical Trials - A methodologic perspective 1997
Pocock, S Clinical trials - a practical approach 1983
Rosner, B. Fundamentals of biostatistics 1995
Smart, JV Elements of medical statistics 1963
Spriet, Dupin-Spriet, Simon Methodology of clinical drug trials 1992
Zolman, JF. Biostatistics - experimental design and statistical 
inference
1993
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Chapter 7 - Analysis of cross-over trials 
in the pharmaceutical industry - A 
questionnaire survey________________
7.1. Introduction
Clinical trials carried ou t by the pharm aceutical industry  play an 
im portan t role in determ ining w hether a  new treatm ent will be 
brought to the general public. Despite their impact, the resu lts of 
cross-over trials carried ou t in the pharm aceutical industry are 
rarely published  and the d a ta  is only available internally. In order 
to fill th is gap and  investigate m ethods of analyses of cross-over 
trials in the pharm aceutical industry, a  survey with very specific 
questions concerning the  conduct and  analysis of cross-over trials 
w as conducted am ongst statisticians working in the 
pharm aceu tical industry .
7.2. Objective
The objective of the survey is to study cu rren t m ethods used to 
analyse cross-over trials and  general view of such  designs am ongst 
s ta tistic ians working in the pharm aceutical industry.
7.3. Sample population
The sam pling frame of the survey consists of every pharm aceutical 
com pany in the UK with a  listing am ongst PSI (Statisticians in the 
Pharm aceutical Industry) m embers. The survey was assisted  by the 
PSI, which is a  non-profit making, UK-based organisation and  aims 
to prom ote professional s tandards of statisticians in m atters
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p ertinen t to the pharm aceutical industry. There were 89 statistical 
u n its  listed on PSI. The num ber of statisticians working in these 
u n it varies from 1 to 58. Each u n it received one questionnaire 
w hich w as sen t to the person nom inated as the contact for th a t 
unit.
The PSI m em bers’ list is published every year in alphabetical order 
of the com p an ies/in s titu tes  and the m em berships are categorised 
into 7 types: ordinary, associate, academic, retired, teacher, affiliate 
and  studen t. The classification of the m em bership is by their 
affiliation w ith the  pharm aceutical industry  and  the type of 
organisation they work for. For example, m em bers who work in 
academ ic in s titu tes  would be qualified as academ ic m em bers while 
ordinary m em bers are those who work in the pharm aceutical 
industry . As the objective of the survey was to investigate how 
cross-over triads were analysed in the pharm aceutical industry, the 
tairget responden ts were therefore ordinary members.
Since one of the objectives of the questionnaire was to find ou t how 
m any triads have been analysed with the two-stage procedure and 
the to tal num ber of clinical trials and cross-over trials analysed by 
each u n it every year, the questionnaire was only sen t to the contact 
person  of the phairmaceutical unit. The questionnaire was also 
designed to be anonym ous, it would not have been possible to 
estim ate the percentage of un its  using the two-stage procedure if 
each u n it w as sen t more th an  one questionnaire.
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7.4. Method
The m ethod of the survey was a  questionnaire designed in three 
formats: an  electronic form at on the web-site, a  Microsoft Word® 
docum ent sen t as an  email attachm ent, and a  printed copy. The 
con ten t of all th ree  form ats was identical and  each u n it listed on 
the PSI con tac t list w as sen t a  questionnaire. The web address of 
the questionnaire  w as sen t to target statisticians by email, in 
addition to the  word docum ent as an a ttachm ent for respondents 
who were required to answ er on either the web-site or word 
docum ent. S tatistic ians who chose to answ er by word docum ent 
were invited to re tu rn  the  questionnaire by e-mail or by post. The 
questionnaire w as sen t by post to statisticians who did not provide 
their em ail addresses for PSI contact.
7.4.1. The permission of using the PSI member list
The first approach  to the  PSI was through the PhD supervisor who 
w as an  associate  m em ber, with the chairm an, Jo h n  C hapm an in 
Ja n u a ry  2001, to request the perm ission of using the PSI m embers 
list. The PSI chairm an suggested th a t it would be m ost appropriate 
and  efficient to send the questionnaire by email from the PSI 
executive office to the contact person a t each company or 
organisation.
F u rth er contact with the PSI regarding the details of the survey was 
th rough  the executive secretary, Joanie Lee-Irving. Details 
d iscussed  before the questionnaire was distributed included
U s e  o f  t h e  t w o - s t a g e  p r o c e d u r e  f o r  a n a l y s i s  o f  c r o s s - o v e r  t r i a l s  in  f o u r  a s p e c t s  o f  m e d i c a l  s t a t i s t i c s
w hether it would be possible to send the questionnaire to the 
ordinary  m em bers only, m ethods of distribution and the 
appropriate  form ats of the questionnaire. O ther m em bers of the PSI 
who have assisted  with the questionnaire distribution were Lesley 
Sm ith and  Robin Bickersteth.
7.4.2. The questionnaire distribution and the reminder
The final decision on how questionnaires should be distributed was 
em ailed to Lesley Sm ith of the PSI in May 2001 followed by the 
questionnaire  d istribution  on the 31st of Ju ly  2001. In order to 
increase the response rate, two m onths after the questionnaire was 
first d istribu ted  (October 2001), an  advertisem ent of rem inder was 
considered. To explore the possibility and  feasibility of such a  
rem inder, an  em ail w as sen t out to the PSI committee. The 
perm ission w as again requested from the chairwoman of the PSI a t 
th a t tim e, Sue McKeown.
It w as also discovered th a t some un its/com panies were not sen t 
any questionnaire  as they had  not nom inated a  contact person for 
the PSI. Therefore one statistician  was selected from each of the 9 
u n its  w here there was no PSI contact person and sent the 
questionnaire. The rem inder and the 9 sets of questionnaires were 
sen t ou t in Ja n u a ry  2002.
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7.5. Objective of the questionnaire
The questionnaire w as designed to investigate pharm aceutical 
s ta tistic ian s’ m ethods of analysing cross-over trials and their views 
on su ch  a  design and  its problems. In particular, the questionnaire 
asked  abou t how statistical models were fitted, the use  of the two- 
stage procedure, and  respondents’ aw areness of its deficiencies.
7.6. Contents of the questionnaire
Copy of the questionnaire cam be found in Appendix E
The questionnaire w as divided into three sections: the quantity of 
trials anadysed by the  un it, vairious aspects of analyses of cross­
over triads, and  open questions for personad opinions.
Q uestions asked  regarding the quantity of cross-over trials included 
the num ber of clinical trials, cross-over trials and AB/BA designs 
anadysed in the  yeair 2000. This provided the information required 
to estim ate the proportion of cross-over triads among adl clinical 
trials carried ou t in the pharmaceuticad industry, as well as the 
proportion of AB/BA design used  among cross-over trials.
The second section w as composed of questions on analyses and the 
designs of cross-over triads. The questions included respondents’ 
approaches to the carry-over effect and  the difficulty posed by 
various effects in analysing cross-over trials. For statistical models, 
respondents were asked about the effects they included to fit the 
statistical model and  their views on the two deficiencies of the two- 
stage procedure.
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The la s t section of the  questionnaire contained two open questions 
w here statistic ians were asked to give their opinions and references 
in relation to their analyses of cross-over trials.
The questionnaire w as designed in a  way th a t answ ers to different 
questions could be cross-checked to confirm the credibility of the 
resu lts. For example, statisticians who chose to approach the 
possibility of the carry-over effect by design only (in Q.4) would not 
be expected to incorporate the carry-over effect in the model or to 
u se  the Hills and  Armitage m ethod to analyse cross-over triads (Q.7 
and  Q.9). On the o ther hand, statisticiams who chose to u se  the 
sta tistics  to elim inate the possibility of the cairry-over effect (in Q.4) 
would be expected to include the cairry-over effect in the model (Q.7) 
and  to answ er yes to the  u se  of the two-stage procedure (in Q.9).
In addition, using  the two-stage procedure is equivalent to fitting 
the carry-over effect in the statistical model. Therefore those who 
answ ered yes to the u se  the two-stage procedure (in Q.9) would be 
expected to incorporate the cairry-over effect in the statistical model 
(in Q.7).
7.7. The pilot survey
A pilot survey of 6 statisticians was conducted in order to ensure 
th a t there  were no snags in the questionnaire and the questions 
served the purposes as they were intended to. The 6 statisticians 
(Fiona Campbell, Eddie Channon, Steve Julious, Stephen Jones, 
S usan  Talbot and  Angela Macleod) were asked to amswer the
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questions and  to give any suggestions they had regarding the 
design or wording of the questionnaire. Their answ ers to the 
questions were no t u sed  to modify the context of the questions b u t 
to check w hether the  objective of the survey was met. As a  resu lt of 
the pilot survey, a  few m inor changes, mainly to the form at of the 
questionnaire  were m ade while the m ain questions rem ained the 
sam e.
7.8. Results
7.8.1. Response from the original questionnaire 
distribution
The first reply from the  statisticians was received on the 31st of 
July . Forty-two se ts  of questionnaires were re turned  between 31st of 
Ju ly  and  24th of Septem ber. Fifteen of the 42 responses replied to 
explain why they did no t respond to the questionnaire. The m ost 
com m on reasons were th a t the cross-over design was not or rarely 
u sed  in the ir u n it o r /a n d  they were either working on pre-clinical 
phases or therapeu tic  areas where cross-over design was not 
applicable (e.g. oncology, fertility, stroke and long-term prevention 
triads). The re tu rned  questionnaires were then entered into a 
Microsoft® Excel file for the analysis.
7.8.2. Response from the reminder
Ten fu rther questionnaires were returned after the rem inder was 
sen t out. These included 3 statisticians who replied th a t the 
reasons they did no t respond to the earlier questionnaire was th a t
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they were no t working in this area  or had not been working on 
cross-over trials for a  long time. Answers from the other 7 
s ta tistic ians were entered to the Excel® file and analysed together 
w ith the questionnaires received during the first round.
7.8.3. Response rate
The response ra te  w as around  50%. This included statisticians who 
sen t back  the questionnaire and replied th a t cross-over design was 
no t u sed  in their un it. A poster of the prelim inary resu lts was 
p resen t in the  PSI 25th A nnual Conference and  the PSI chairwomen 
considered the response ra te  to be ‘huge’.
There were a  few reasons for the non-response. First, not all listed 
u n its  were working on the design and analysis of clinical trials. 
Twenty u n its  replied th a t they were working a t pre-clinical research 
discovery or non-clinical areas. For those who were working in 
clinical trials, the  cross-over design may not be appropriate for the 
therapeu tic  areas they worked in. One statistician  replied th a t he 
was working in fertility and  cross-over trial was not applicable in 
his un its . O ther areas th a t cross-over trial are rarely used include 
vaccine, cancer and  AIDS trials.
O ther reasons th a t could have caused the non-response was th a t 
the questionnaire w as sen t out in sum m er when statisticians might 
be on holiday and  m ight have too m uch (e)mail to deal with when 
they cam e back, therefore the questionnaire might have had  a  low 
priority.
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There were 52 re tu rned  questionnaires with 34 effective samples. 
Fourteen replied to notify th a t they did not analyse any cross-over 
trials in the year 2000, or th a t they did not work in the field of 
cross-over trials. The analysis of resu lts was based on the 34 
effective questionnaires returned.
7.8.4. Quantity and designs of cross-over trials
Am ongst the 34 effective questionnaires returned, thirty-one un its 
provided inform ation regarding the num ber of clinical trials or 
percentage of cross-over or AB/BA trials am ongst all clinical trials 
they anadysed in the year 2000. The 31 responses included 4 units 
th a t did no t ainalyse any trials. Numbers of clinical trials anadysed 
by the rem aining 27 u n its  varied from 2 to 50. They analysed 436 
clinical trials in to tal w ith a  m ean of 14.5 triads per unit.
Fourteen  of the 34 statistical un its  analysed cross-over triads in 
year 2000. These included twelve un its  which specified the num ber 
of clinical trials analysed and  two un its  which only indicated the 
percentage of cross-over trials am ongst all trials they analysed.
Among the  436 clinical trials analysed by all the 27 statistical units 
w hich gave the num ber of clinical trials anadysed in their units, 166 
were by cross-over trial design. The average percentage of cross­
over trials u sed  am ong all clinical trials was 38%. Since the figure 
w as derived from the u n its  where the cross-over design was used  (a 
few sta tistic ians replied th a t the cross-over design was not used in 
their u n its  and  therefore did not answ er the questions), it cannot be
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u sed  to approxim ate the percentage of cross-over trials of all 
clinical trials.
The m ost commonly u sed  design of cross-over trials was the two- 
period tw o-treatm ent design (which was also the targeted design of 
the two-stage procedure). This design accounted for 121 of 166 
cross-over trials analysed in the year 2000. The more complicated 
designs of cross-over trials used less frequently in the 
pharm aceu tica l industry: less than  a  th ird  (45/166) of cross-over 
trials analysed  by the pharm aceutical industry  involved more than  
two periods or two trea tm ents.
45 questionnaires returned
Questionnaires (n=89) 
distributed in June 2000
A reminder and 9 more 
questionnaires were sent out
Another 10 questionnaires 
were returned. Seven of 
them were included in the 
analysis
52 questionnaires 
received
18 replied to say that 
cross-over trials are 
not analysed in their 
unit
34 questionnaires 
analysed
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7.8.5. Approaches to the carry-over effect
The objective of the two-stage procedure was to te st the carry-over 
effect using  statistics. As a  consequence, the fact th a t the carry­
over effect is fundam entally  a  design problem ra ther th an  a 
sta tistica l problem  is often overlooked. There is very little th a t can 
be done ab o u t the  carry-over effect once the trial has been 
com pleted. The only solution for its elimination is by design, to 
allow an  adequate  w ash-ou t period between any two treatm ent 
periods.
In order to u n d e rs tan d  the rationale of their choice of m ethod for 
analysing cross-over trials, statisticians were first asked about their 
approaches to the carry-over effect in cross-over triads (Table 7.8-1). 
The table shows th a t the m ost popular approach to the carry-over 
effect w as by design alone. Forty-four per cent of statisticians 
considered th a t the possibility of carry-over effect should have been 
elim inated by design alone. There were nearly as m any statisticians 
who would u se  both statistics and  design to eliminate the carry­
over effect as  s ta tistic ians who considered it to be solely a  design 
problem . Combining these two categories, approximately 85% of the 
s ta tistic ians recognised th a t design was a  solution for the carry­
over effect if no t the only one. On the other hand, there were three 
sta tistic ians who considered th a t the carry-over effect should be 
dealt w ith by statistics. The problem of the carry-over effect was 
considered to be a  very serious problem by one of the statisticians, 
and  he w as therefore re luctan t to use  cross-over designs. An
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alternative m ethod suggested by a  statistician was th a t the carry­
over effect should  be elim inated by design and tested in secondary 
analysis.
The m ajority (85%) of the statisticians recognised th a t design is a  
solution for the carry-over effect, while 50% of them  also considered 
sta tistics  to be a  solution. With more th an  half of the respondents 
considering sta tistics to be one of the solutions for the carry-over 
effect, it is conceivable th a t the carry-over effect was included in 
sta tistica l analyses of cross-over trials.
Table 7.8-1; Approaches to the carry-over effect
Approaches to Carry— over Effect Frequency Percentage
Should have been eliminated by design 15 44.1%
Is dealt with by statistical tests 3 8.8%
Should be eliminated by trial design and tested by statistics 14 41.2%
Carry-over Effect cannot be dealt with 1 2.9%
Other 1 2.9%
TOTAL 34 100%
7.8.6. D ifficulty of each effect when analysing cross-over
data
In addition to the carry-over effect, there were other factors which 
were prone to occur in cross-over trials and which therefore made 
evaluating trea tm en t effects difficult. Such factors common to 
cross-over designs were the period effect and the patien t effect.
W hen sta tistic ians were asked to rate the difficulty caused by each 
effect in analysing cross-over trials, the carry-over effect was found 
to be m ore problem atic th an  the period or patient effect (Table
7.8-2). More th an  tw o-thirds of the statisticians found th a t the 
carry-over effect p resen ted  some difficulty or a  serious problem.
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There were more s ta tistic ians who found the carry-over effect posed 
som e difficulty or w as a  serious problem th an  the other two effects.
In com parison, period and  patient effects were of m uch less 
concern. Both effects were only considered to be a  serious problem 
by one statistician . The patien t effect was the least problematic 
am ongst the  three. Nearly a  third of statisticians (29%) found the 
period effect provided some difficulties while only 4 (12%) found the 
pa tien t effect in th is category.
Table 7.8-2: Rating o f difficulty for carry-over, period and patient effects
Carry-over Effect Period Effect Patient Effect
Is not a problem 10 29% 23 68% 29 85%
Provides some difficulty 15 44% 10 29% 4 12%
Is a serious problem 9 26% 1 3% 1 3%
TOTAL 34 100% 34 100% 34 100%
7.8.7. Approaches to the carry-over effect versus 
difficulty of the carry-over effect
It w as show n in the  previous section th a t the carry-over effect had 
posed som e degree of difficulty for 70 per cent of the statisticians. 
While the  m ain  objective of the two-stage procedure was to test for 
the significance level of the carry-over effect, this section uses the 
cross-tabu la tion  to exam ine w hether the approaches towards the 
possibility of the carry-over effects were related to the perceived 
difficulty th a t th is effect m ight cause (Table 7.8-3). Although results 
of the survey cannot establish  the cause and  effect relationship 
betw een the  approach  to and  the perceived difficulty of the carry­
over effect, s ta tis tic ian s’ rating of the difficulty of the carry-over 
effect gave an  indication as to w hether they were confident with 
their approaches.
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It w as noted th a t 7 of the 10 statisticians who did not consider 
‘carry-over’ to be a  problem  eliminated it by design alone. Of the 
tw enty-four statistic ians who found the carry-over effect to pose 
som e difficulty or to be a  serious problem, only 8 chose ‘design’ as 
the only solution for the carry-over effect.
The cany-over effect w as least likely to be a  problem when the 
s ta tistic ians elim inated it by design alone. It was m ost likely to be a  
serious problem  w hen statisticians used  both design and  statistics 
to elim inate the cany-over effect. It can also be argued tha t 
considering the carry-over effect a  serious problem was the cause of 
the sta tistic ians u sing  both design and  statistical m ethods to 
elim inate the problem, and  th a t eliminating the carry-over effect by 
design only w as the resu lt of cany-over effect not being a  problem.
Table 7.8-3: Approaches vs. perceived difficulty o f the carry-over effect
Perceived difficulty of the carry-over effect in the 
analysis of cross-over trials
Is not a 
problem
Provides some 
difficulty
Is a serious 
problem TOTAL
Approaches
to
Should have been 
eliminated by design
7 5 3 15
Carry-over
Effect
Is dealt with by statistical 
tests
1 2 0 3
Should be eliminated by 
trial design and tested by 
statistics
1 7 6 14
Cannot be dealt with, 
therefore I am reluctant to 
use cross-over design
1 0 0 1
Other 0 1 0 1
TOTAL 10 15 9 34
7.8.8. Guidelines and standard operations
Guidelines for analysing cross-over trials were used in nearly one 
fifth of the pharm aceutical companies. The two-stage procedure
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w as once treated  as a  s tan d ard  operation of cross-over trials in the 
pharm aceutical industry . If a  guideline is applied in th a t unit, 
answ ers given by the statistician  who responded to the 
questionnaire  represented  the m ethods used  to analyse cross-over 
trials in the entire unit. Otherwise, m ethods used  by other 
s ta tistic ians in the u n it were likely to be different.
Table 7.8-4; Number o f trials analysed VS. use of guideline
W ith G uidelines  
(N =6)
W ithout G uidelines 
(N =28)
Total Num ber o f  C linical Trials 
Mean
Total Num ber o f  Cross-over Trials 
Mean
Total number o f clinical trials and the mean were cal< 
Five o f the 6 units that had guidelines and 22 o f the 2
93
18.6
42
8.4
:ulated based on the units that specifi 
8 units that did not have guidelines v
343
15.6 
124
5.6
ed the number trials analysed, 
rere included in this calculation.
7.8.9. M odel fitting
The sta tistica l model suggested by Grizzle [4] included treatm ent 
effect, carry-over effect, period effect and patien t effect. S tatisticians 
were asked  which effects they had  included in model fitting (Table
7.8-5). A lthough it w as shown in 6.7.2 th a t 17 statisticians would 
u se  the  sta tistics  to te s t for the carry-over effect, only 9 statisticians 
w ould always fit the carry-over effect in the model.
Table 7.8-5: Statistical model fitting o f carry-over, patient and period effects for AB/BA 
design__________ _________ _ _______________________________________________________
Model Fitting for AB/BA Design
Carry-over Effect Patient Effect Period Effect
Always in the model 9 29 26
Never in the model 12 2 2
Included if significant 4 3 3
Included if it makes the 
treatment effect significant
0 0 1
Other 9 0 2
TOTAL 34 34 34
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Table 7.8-6: Statistical model fitting o f carry-over, patient and period effect for cross-over
trial designs with more than 2 periods
Figures of th is table are based on the results
Model Fitting
1st Order 
Carry-over 
Effect
2nd Order 
Carry-over 
Effect
Patient Effect Period Effect
Always in the model 9 2 28 25
Never in the model 9 20 1 2
Included if significant 7 4 3 4
Included if makes the 
treatment effect significant
0 0 0 0
Other 6 2 0 1
Missing 3 6 2 2
TOTAL 34 34 34 34
7.8.10. Use of the two-stage procedure
It w as show n th a t the two-stage procedure has been the m ost cited 
m ethod of cross-over trials (Chapter 4 - ) and has been 
recom m ended by m ore th a n  a  third of the general medical statistics 
books (C hapter 6 - ). W hen asked w hether the two-stage procedure 
(Table 7.8-7) w as u sed  in their units, 7 out of the 34 statisticians 
considered the m ethod as  being used  in their units. This figure was 
not co nsisten t w ith resu lts  of statistical model fitting in Table 7.8-5.
The tw o-stage procedure tended to be used  by bigger un its  (more 
clinical trials analysed in year 2000) with a  sm aller num ber of 
cross-over trials. A round 17% of all cross-over triads were anadysed 
by the  two-stage procedure in the pharm aceutical industry  in the 
year 2000.
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Table 7.8-7; Number o f trials analysed VS. use of the two-stage procedure
The two-stage procedure USED 
(N=7)
The two-stage procedure 
NOT USED (N=27)
Clinical trials
Total number o f clinical trials 107 329
analysed in year 2000 among
all companies
Mean number o f clinical trials 17.8 15.7
analysed
Cross-over trials
Total number o f cross-over 24 142
trials analysed by all companies 
Mean number o f cross-over 4 6.8
trials
Total number o f clinical trials and the mean were calculated based on the units that specified the number trials analysed. Six 
o f the 7 units that used the two-stage procedure and 21 o f the 27 units that did not have guidelines were included in this 
calculation
7.8.11. The two-stage procedure used as a standard 
operation
The u se  of the two-stage procedure was com pared with the use of 
guidelines in pharm aceutical companies in order to study w hether 
the tw o-stage procedure w as adopted as a  standard  operation. In 
pharm aceu tical com panies where there were guidelines for 
analysing cross-over trials, only one of them  used  the two-stage 
procedure.
For the  27 u n its  not using  the two-stage procedure, 22 of them  did 
no t have guidelines for analysing cross-over trials. This indicated 
th a t the  two-stage procedure might still be used by different 
s ta tistic ian s  in their units.
Table 7.8-8: Use o f guidelines VS. the two-stage procedure
The two-stage procedure 
USED
The two-stage procedure 
NOT USED
TOTAL
Guidelines 1 5 6
No Guidelines 6 22 28
TOTAL 7 27 34
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7.8.12. Approaches to the carry-over effect versus use of 
the two-stage procedure
Theoretically speaking, decisions to use  the two-stage procedure 
can  be predicted from answ ers which described respondents’ 
approaches to the carry-over effect, Table 7.8-9 examines w hether 
th a t is the  case and  cross the approaches by the use  of the two- 
stage procedure. There were some inconsistencies in the answ ers to 
the two questions. Two statisticians who chose to approach the 
carry-over effect by design alone worked in pharm aceutical 
com panies where the  two-stage procedure was used. There were 
also two u n its  where statistic ians would eliminate the carry-over 
effect by statistics b u t answ ered th a t the two-stage procedure was 
no t u sed  in the ir un it.
Therefore, d iscussion  involving the use of the two-stage procedure 
refers to w hether the two-stage procedure was ‘considered’ for use 
ra th e r th an  w hether it w as actually applied.
Table 7.8-9: Approaches to the carry-over effect VS. use of the two-stage procedure -  survey 
results _______________  ___ ______________________
Use o f the Two-stage Procedure 
Yes NO TOTAL
Eliminated by design 2 13 15
By statistics 1 2 3
By both design and 
statistics
4 10 14
Cannot be dealt with 0 1 1
Other 0 1 1
TOTAL 7 27 34
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7.8.13. Use of the two-stage procedure versus difficulty
of the carry-over effect
The cross-tabu lation  of the two-stage procedure and the difficulty of 
the carry-over effect (Table 7.8-10) exam ined w hether testing for the 
significance of the carry-over effect using  the two-stage procedure 
eased the  problem . It does not give information to establish w hether 
the  conceived difficulty of the carry-over effect explained why the 
tw o-stage procedure w as used  or, w hether knowing the problems of 
the  two-stage procedure m akes the carry-over effect difficult to deal 
w ith. The table shows however, th a t analysing cross-over trials with 
the  two-stage procedure does not make the carry-over effect less 
problem atic for the statisticians. Five of the 7 statisticians from the 
u n its  w here the two-stage procedure was used  considered the 
carry-over effect a  very serious problem. In contrast, only 4 of the 
27 sta tistic ians whose u n its  did not use  the two-stage procedure 
found the  carry-over effect a  serious problem.
Not u sing  the  two-stage procedure also m eant th a t the statisticians 
were m ore likely to find the carry-over effect did not to pose a  
problem . Among the 10 statisticians who considered the carry-over 
effect no t a  problem, 8 worked in un its  where the two-stage 
procedure w as no t considered for use. In comparison, 9 of the 
s ta tistic ians who considered the carry-over effect a  very serious 
problem , 5 worked in statistical un its  where the two-stage 
procedure w as considered for use. Therefore, it can be concluded
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that the two-stage procedure did not help to ease the difficulty of
the carry-over effect.
Table 7.8-10: Use o f the two-stage procedure VS. difficulty o f the carry-over effect
Perceived difficulty o f the carry-over effect
Is not a Provides some Is a serious TOTAL
problem difficulties problem
Use o f the two- YES 2 0 5 7
stage procedure NO 8 15 4 27
TOTAL 10 15 9 34
R esults of the  perceived difficulty of the carry-over effect and the 
m ethod of statistical analyses were som ewhat different when 
different variables were compared. Due to the inconsistency 
betw een u se  of the  two-stage procedure and  statistical model 
fitting, a  cross-tabu lation  between the difficulty of the carry-over 
effect and  statistica l m odels for the carry-over effect is shown 
below.
In the category in w hich th a t the carry-over effect was always in the 
model, there  w as only one statistician  who found such an effect a  
serious problem. This contradicts the previous resu lt th a t 5 of the 7 
u n its  w hich considered the two-stage procedure for use thought the 
carry-over effect to be a  serious problem. In the category of never 
fitting the  cairry-over effect in the model, half of them  considered 
the  carry-over effect no t to be a  problem.
These resu lts  implied th a t never fitting the cairry-over effect in the 
model contributed  the h ighest to the category of the carry-over 
effect no t being a  problem, w hereas in the previous table not using 
the tw o-stage procedure was the main contributor to the category 
th a t the cairry-over effect provided some difficulty.
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Table 7.8-11: Fitting o f the carry-over effect in the model VS. difficulty of the carry-over
effect
Perceived difficulty o f the carry-over effect 
Is not a Provides some Is a serious 
problem difficulty problem
TOTAL
Fitting Always in the model 4 4 1 9
the Never in the model 6 3 3 12
model Included if  significant 0 2 2 4
Other 0 6 3 9
TOTAL 10 15 9 34
7.8.14. Use of the two-stage procedure versus approaches 
to the carry-over effect
The inconsistency of the above results can  be explained by the 
difference in the perception of model fitting (Table 7.8-12). Seven of 
the  27 s ta tistic ians whose un its did not u se  the two-stage 
procedure s ta ted  th a t the carry-over effect was always fitted in the 
model. Another inconsistency is th a t 2 of the 7 statisticians from 
the u n its  w here the two-stage procedure was used considered the 
carry-over effect never fitted in the model.
It w as shown th a t w hether the carry-over effect had been fitted in 
the sta tistica l model was inconsistent with the statistic ians’ 
approach  to the carry-over effect. Due to the inconsistency between 
u se  of the  two-stage procedure and model fitting of the carry-over 
effect, s ta tis tic ian s’ approaches to the carry-over effect were 
checked against the u se  of the two-stage procedure and further 
inconsistencies were found. The two-stage procedure was used in 
two u n its  w here the s ta tistic ians’ approach to the possibility of a  
carry-over effect w as th a t it should have been eliminated by design.
Such inconsistency may indicate th a t there were other statistical 
m ethods being used , and  th a t they simply did not consider fitting
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the  carry-over effect in the model to be part of the two-stage 
procedure.
Table 7.8-12: Fitting o f the carry-over effect VS. use o f the two-stage procedure
The two-stas e procedure
Used Not Used TOTAL
Fitting the model Always in the 
model
2 7 9
Never in the 
model
2 10 12
Included if 
significant
1 3 4
Other 2 7 9
TOTAL 7 27 34
7.8.15. Lack of power
The low power of the two-stage procedure was first m entioned in 
Hills an d  Armitage [7]. Its disadvantage has  also been flagged in 
several general m edical statistics books where the two-stage 
procedure is recom m ended (Chapter 6 - ). However, lack of power 
h as  no t been u sed  as a  reason to avoid the practice of the two-stage 
procedure.
The sta tistic ians were asked w hether they agreed, disagreed or did 
no t know th a t the two-stage procedure lacks power. The deficiency 
w as acknowledged by 70 per cent (24/34) of the statisticians. 
A lthough su ch  a  deficiency was mentioned in the m ost cited paper 
(Hills an d  Armitage [7]) for the analysis of cross-over trials (Chapter 
4 - ), 2 s ta tistic ians disagreed and 8 did not know one way or the 
other.
Table 7.8-13: Recognition o f low power o f the two-stage procedure
Count Percentage
Agree 24 70.6%
Disagree 2 5.9%
Don’t know 8 23.5%
Total 34 100%
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7.8.16. High type I error rate
The high type I error ra te  of the two-stage procedure was a  more 
recen t finding com pared to the problem of low power. The original 
reference for th is  deficiency is by Freem an in Statistics in Medicine 
[8]. F u rth e r references following this issue include Senn (1993, 
1994, 1995).
Sim ilar to the low power of the two-stage procedure, statisticians 
were asked  ab o u t the ir views on the high type I error rate of the 
tw o-stage procedure (Table 7.8-14). Among statisticians who 
com pleted th is survey, more of them  were unaw are of this problem 
th a n  those who were. There were also three statisticians who 
disagreed w ith the  statem ent.
Table 7.8-14; Recognition o f low type I error rate o f the two-stage procedure
Count Percentage
Agree 15 44.1%
Disagree 3 8.8%
Don’t know 16 47.1%
Total 34 100%
7.8.17. Deficiencies of the two-stage procedure
W hen recognitions of the two deficiencies were compared, lack of 
power w as the  better-know n deficiency of the two-stage procedure. 
The frequency of recognition of both deficiencies is examined in 
Table 7.8-15. More th an  a  third of statisticians recognised both 
deficiencies of the two-stage procedure, followed by nine 
s ta tistic ian s  who agreed with the power problem b u t were not 
aw are of the  high type I error rate. There were also 7 statisticians 
who were no t aw are of either of the problems and one who 
disagreed w ith both  problems.
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Table 7.8-15; Recognition o f both deficiencies
Agree
Low Power 
Disagree Don’t know TOTAL
Type I error Agree 13 1 1 15
Rate Disagree 2 1 0 3
Don’t Know 9 0 7 16
TOTAL 24 2 8 34
7.8.18. Deficiencies VS. number of cross-over trials 
analysed
Table 7.8-16: Number o f trials analysed VS. recognition o f the deficiencies
Type I Error Rate Power
Agree
(n=15)
Disagree
(n=3)
Don’t Know 
(n=16)
Agree
(n=24)
Disagree
(n=2)
Don’t Know 
(n=8)
Clinical Trials
Total number of 
clinical trials 
analysed
125 41 270 319 33 84
Mean number of  
clinical trial 
analysed
11.4 13.7 20.8 16 16.5 16.8
Cross-over Trials
Total number of 
cross-over trials 
analysed
16 7 81 66 2 33
Mean number of 
cross-over trials 
analysed
1.5 2.3 6.2 3.3 1.0 6.6
Total number o f clinical trials and the mean were calculated based on the units that specified the number 
trials analysed.
Numbers of units included in the calculations were 11,3 and 13 for the categories of agree, disagree and 
don’t know about the type I error rate respectively.
Numbers of units included in the calculations were 20, 2 and 5 for the categories of agree, disagree and 
don’t know about the power o f the two-stage procedure.
7.8.19. Deficiencies versus use of the two-stage 
procedure
In order to investigate w hether such aw areness of deficiencies 
discouraged the statistic ians from applying the method, 
s ta tis tic ian s’ recognitions of the two deficiencies of the two-stage 
procedure were tabu lated  against the use  of the two-stage 
procedure (Table 7.8-17). There were four broad categories in term s 
of recognition of the deficiency and use of the two-stage procedure:
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1. A c k n o w le d g in g  the deficiency/deficiencies and n o t u s in g  the tw o-stage  
p roced u re
The m ajority of the statistic ians who recognised both deficiencies of 
the tw o-stage procedure did not use the method to analyse cross­
over trials. However, the two-stage procedure was used  in 3 of the 
13 u n its  w here the statistic ians agreed with both deficiencies. In 
o ther words, the percentage acknowledging both deficiencies was 
h igher am ong statistical u n its  where the two-stage procedure was 
u sed  th a n  where it w as not. Three statisticians of the 7 un its  which 
u sed  the two-stage procedure were aware of both deficiencies 
com pared to 10 of the 27 un its  which did not u se  the two-stage 
procedure. Such a  re su lt could indicate th a t not using the two- 
stage procedure w as no t necessarily the resu lt of understanding  its 
deficiency, and  knowing the deficiencies did not always lead to 
avoiding su ch  a  procedure (unless the two-stage procedure is the 
s tan d a rd  operation of the  unit. There was 1 un it which fell in this 
category).
2. A c k n o w le d g in g  th e deficiency/deficiencies and still u sin g  the tw o-stage  
p roced u re
Among the  24 statistic ians who agreed th a t the power of the two- 
stage procedure w as low, 5 of them  worked in un its where the two- 
stage procedure w as considered for use. A sim ilar resu lt applied to 
the high type I error rate: despite 15 statisticians agreeing with the 
high type I error rate, the two-stage procedure rem ained in use in 
three of these un its .
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There w as no significant difference between the two deficiencies in 
influencing the decision to use  the two-stage procedure. Agreeing 
w ith e ither of the deficiencies was alm ost equally likely (low power 
1 2 /15 , type I error ra te  19/24) to lead to not using the two-stage 
procedure.
3. N o t a ckn o w led g in g  the deficiencies and n o t u s in g  the tw o-stage procedure
Six s ta tistic ians of the 27 un its  th a t did not use the two-stage 
procedure were no t aw are of the deficiencies. Thirteen of them  did 
no t know abou t its high type I error problem, 7 did not know about 
the  low power and  6 did no t know either.
4. N o t  a ck n ow led g in g  th e  d eficiencies and u s in g  the tw o-stage procedure
Not being aw are of the  deficiencies was considered to be the chief 
reason  th a t the two-stage procedure continued to be used. 
However, less th a n  half of the u n its  where the two-stage procedure 
w as u sed  fell into th is category.
Am ongst the  7 s ta tistic ians who worked in units where the two- 
stage procedure w as used , 3 of them  did not know the problem of 
high type I e rror ra te  and  1 did not know about the low power.
In addition, am ongst the three statisticians who disagreed with the 
high type I error ra te  of the two-stage procedure, 2 of them  worked 
in the  u n its  w here the m ethod was not considered for applications.
One of the  two sta tistic ians who disagreed that the two-stage lacks 
power worked in the u n its  where the two-stage procedure was used
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while the o ther worked in the un its  where the m ethod was not 
used .
Rationale:
The sta tistic ian  who disagreed with both deficiencies worked in a  
u n it w here the two-stage procedure was considered for application.
The im plication w as th a t w hether the two-stage procedure was 
u sed  w as no t directly influenced by the aw areness of the 
deficiencies of the two-stage procedure. Agreeing with both 
deficiencies was no t followed by giving up  the method. On the other 
h and , not knowing any of the deficiencies of the two-stage 
procedure did no t necessarily  indicate keeping the method.
Table 7.8-17: Use o f the two-stage procedure VS. recognition of the two deficiencies
High Type I Error Rate
Agree Disagree Don’t
Know
TOTAL
The two-stage Low Agree 3 0 2 5
procedure Power Disagree 0 1 0 1
USED Don’t know 0 0 1 1
TOTAL 3 1 3 7
The two-stage Low Agree 10 2 7 19
procedure Power Disagree 1 0 0 1
NOT used Don’t Know 1 0 6 7
TOTAL 12 2 13 27
7.8.20. Recognition of the deficiencies and difficulties of 
the carry-over effect
The purpose  of th is section is to investigate w hether the aw areness 
of the  deficiencies of the two-stage procedure contributed to the 
perceived difficulty of the carry-over effect. All statisticians who 
agreed on the high type I error rate of the two-stage procedure, 
there w as an  equal num ber of statisticians who found the carry-
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over effect to be a  serious problem and those who thought carry­
over effect was no t a  problem a t all. The distribution was sim ilar 
am ongst the  statistic ians who agreed on the low power of the two- 
stage procedure. S tatisticians who ‘did not know’ about the high 
type I error ra tes were also equally likely to find the carry-over 
effect no t a  problem  or a  serious problem.
S ta tistic ians who agreed on either of the deficiencies were more 
likely to th in k  th a t the carry-over effect provided some difficulties 
th a n  o ther s ta tistic ians who held other views on the deficiencies of 
the tw o-stage procedure. The carry-over effect providing some 
difficulties was also the  category th a t was more likely to occur than  
the o ther two categories where statisticians agreed on either of the 
deficiencies.
Half of the  8 statistic ians who did know about the low power of the 
tw o-stage procedure considered the carry-over effect not a  problem. 
Almost a  th ird  of the  statistic ians who did not know about the type 
I erro r ra te  problem  considered the carry-over effect not a  problem.
Difficulty of the carry-over effect was evenly distributed among 
s ta tistic ian s  who ‘did no t know’ about the high type I error rate of 
the tw o-stage procedure.
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Table 7.8-18: Recognition o f the two deficiencies VS. difficulty o f the carry-over effect
Perceived difficulty of the carry-over effect
Is not a 
problem
Provides some 
difficulties
Is a serious 
problem
TOTAL
Low Power Agree 5 13 6 24
Disagree 1 0 1 2
I don’t know 4 2 2 8
TOTAL 10 15 9 34
High Type I 
Error Rate
Agree 4 7 4 15
Disagree 1 2 3
Don’t know 5 6 5 16
TOTAL 10 15 9 34
7.9. Conclusion
The tw o-stage procedure w as considered for use  by nearly a  fifth of 
the  sta tistica l u n its  an d  the carry-over effect in the cross-over 
design rem ained problem atic. For individual questions in the 
survey, there  w as no consensus on approaches to the carry-over 
effect or how it should  be analysed among the pharm aceutical 
sta tistic ians. In addition, there were some inconsistencies between 
answ ers given to questions regarding analyses and approaches to 
the  carry-over effect.
The reason  why the two-stage procedure was used  has not been 
estab lished . The recom m endation by Freem an (1989) who found 
the m ajor deficiency of the two-stage procedure has not been 
generally adopted. Agreeing with the deficiency of the two-stage 
procedure did no t always discourage researchers from using the 
m ethod an d  no t knowing either the lower power or high type I error 
ra te  of the  two-stage procedure did not indicate th a t the two-stage 
procedure would still be used.
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The design of the questionnaire was based on the concept th a t the 
tw o-stage procedure w as a  common problem and its deficiency of 
high type I error rate, which was only published 25 years after the 
m ethod w as in troduced, m ight have had some im pact on its use. 
However, the resu lts  of the survey showed th a t the choice of 
analysis of cross-over trials involved more than  w hether its 
deficiencies were recognised and there was a  question in consensus 
of fundam ental perception of the two-stage procedure and model 
fitting of the  cany-over effect.
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Chapter 8 - Summary of Results______
This ch ap te r p resen ts a  com prehensive description of the use of the 
tw o-stage procedure in different aspects of medical statistics by 
com paring the  resu lts  draw n from the four independent studies 
(C hapter 4 - C hapter 5 - C hapter 6 - and C hapter 7 -).
The sum m ary  of resu lts  includes direct com parisons between any 
two aspects  of m edical statistics as well as overviews by combining 
resu lts  from two or more aspects of general medical statistics books 
to give a  com plete p icture of analyses of cross-over trials and to 
com pare the m ethods u sed  to analyse cross-over trials am ongst 
different professions.
8.1.1. Medical journals -  citation analysis and systematic 
review
The citation analysis and  the system atic review were the two 
research  m ethods u sed  to investigate the two-stage procedure in 
periodicals. The citation analysis included all scientific periodicals 
while system atic review focused on cross-over trial reports 
pub lished  in m edical journals.
The m ain objective of the citation analysis was to investigate how 
often the two-stage procedure was used. Citation analysis is based 
on the  assum ption  th a t a  citation given to a  paper describing the 
tw o-stage procedure indicated the usage of the method. It has not 
been estab lished  th a t no t citing the m ethod implied th a t the two- 
stage procedure w as no t used. The system atic review of medical
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jo u rn a ls  w as used  to give a  more detailed exam ination on analyses 
of cross-over trials and  assisted  in verifying the relationship 
betw een a  citation and  the actual application.
The key finding of the citation analysis w as th a t the two papers 
describing the  two-stage procedure have been more cited than  the 
paper ab o u t its deficiencies. Such a  difference is m ost substantia l 
in the field of m edical research. Results of the system atic review on 
cross-over trial reports showed th a t the carry-over effect was often 
tested  w ithout citing the two-stage procedure or specifying the 
m ethod used. However, as the method of testing was often not 
specified in the report, it could not be established w hether the two- 
stage procedure w as applied. As a  result, the relationship between 
citation /non -c ita tion  and  application/non-application was not 
established. Therefore, resu lts  drawn from the citation analysis 
can n o t be used  as an  indicator of the use of the two-stage 
procedure for analyses of cross-over trials published in medical 
jo u rna ls . However, it can be confirmed th a t incidences of testing for 
the carry-over effect were more common than  citations given to the 
two-stage procedure.
The relationship  betw een c itation  and use o f the m ethod
As a  re su lt of the insufficient information given in cross-over trial 
reports, a  citation on the two-stage procedure indicates the 
application of the m ethod was assum ed b u t was not verified. On 
the o ther hand , neither did the reverse apply. The use of the two- 
stage procedure did not always imply th a t a  citation was given to a
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reference of the m ethod. Such examples were found in system atic 
review in C hapter 5 - . Similarly, not citing the two-stage procedure 
did no t imply th a t the m ethod was not used. The only association 
th a t can  be assum ed  w as th a t not using the method usually 
ind icates th a t  the m ethod w as not cited.
8.1.2. The pharmaceutical industry and medical journals 
- a comparison
Both pharm aceu tical industry  and  medical journals involve actual 
anailyses of cross-over trials. Results drawn from the survey eind 
system atic  review showed how cross-over triads had  been analysed 
an d  the  difference in m ethods of analyses by different research 
populations.
It w as show n in C hapter 5 - and C hapter 7 - th a t the use of the 
tw o-stage procedure could not be estim ated in either medical 
jo u rn a ls  or the  pharm aceutical industry. For cross-over triad 
reports published  in m edical journals, information given in cross­
over trial reports w as no t sufficient to determ ine w hether the two- 
stage p rocedure w as applied. For analyses of cross-over triads in the 
pharm aceu tica l industry , the inconsistency in fitting the statistical 
m odels an d  the u se  of the two-stage procedure was found in the 
resu lts  of the  survey for phairmaceuticad statisticiams. Seven of the 
34 pharm aceu tica l com panies who responded to the questionnaire 
amswered yes to w hether the two-stage procedure had been used in 
the ir u n its . However, resu lts  drawn from questions regarding their 
approaches to the carry-over effect and  the variables they fitted in
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the  s ta tistica l model showed th a t using statistics to test for the 
carry-over effect w as estim ated to be higher than  the rate of the use 
of the  two-stage procedure. It highlighted the issue th a t the two- 
stage procedure had  no t been well-recognised and it m ight have 
been  practised  w ithout knowing the method. It therefore m akes 
ra ising  the  aw areness of the deficiencies even more difficult.
A nother sim ilarity in the finding of the two studies was the 
percentages of AB/BA design used  am ongst cross-over triads in 
m edical jo u rn a ls  and  the pharm aceutical industry. The AB/BA 
design w as u sed  by 45 (70%) of the 64 cross-over trial reports 
reviewed and  121 (73%) of the 166 cross-over trials anadysed in the 
pharm aceu tica l industry .
8.1.3. Medical statistics books and pharmaceutical 
industry -  A comparison
M edical s ta tistics  books aind the phairmaceutical industry involve 
different aspects  aind stages of anadyses of cross-over triads. 
However, research  m ethods for both studies served the purpose of 
investigating the  aw areness of the deficiencies of the two-stage 
procedure, views on the carry-over effect aind m ethods 
u sed /recom m ended  for analyses of cross-over trials.
The role of m edical statistics books in term s of the deficiencies of 
the  tw o-stage procedure is to give readers the information regarding 
su ch  problem s while phairmaceutical statisticians were directly 
asked  ab o u t the ir aw areness of the two deficiencies of the two-stage 
procedure.
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The resu lts  of the com prehensive review and the survey showed 
th a t the  two-stage procedure was more commonly recommended 
and  the  deficiencies were less acknowledged by general medical 
sta tistics  books th an  the phairmaceutical industry. However, it 
can n o t be concluded th a t the pharm aceutical industry was more 
u p  to date  th an  general medical statistics books in term s of the 
analyses of cross-over trials as the comprehensive review of generad 
m edical s ta tistics covered publication yeairs from 1963 to 2000 
while the  survey w as conducted in the yeair 2001. W hat can be 
concluded w as th a t the two-stage procedure continued to be 
recom m ended and  applied by these two research populations while 
its deficiencies were no t fully acknowledged and understood in both 
realm s of m edical statistics.
Table 7.9-1: Comparison of main results from general medical statistics books and the
pharmaceutical industry
General Medical 
Statistics Books
Pharmaceutical
Industry
Use of the two-stage procedure 9/26 7/34
Awareness of low power 7/26 24/34
Awareness o f type I error rate 3/26 15/34
8.1.4. Citation analysis and medical statistics books
The citation analysis on the papers about the two-stage procedure 
and  the  com prehensive analysis on medical statistics books were 
both  u sed  to investigate references for analysing cross-over trials. 
High citation ra tes on Grizzle [4] and Hills and Armitage [7], 
together w ith more th an  a  th ird  of general medical statistics books 
recom m ending the two-stage procedure, showed th a t the method 
has  been a round  and  will rem ain so for some time in the future.
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8.1.5. Citation analysis and the pharmaceutical industry
The citation analysis w as used  as an  indicator of the u se  of the two- 
stage procedure in published cross-over trial reports. W hether the 
tw o-stage procedure w as used  in their u n it was one of the survey 
questions for the pharm aceutical statisticians. The results 
com pared the u se  of the two-stage procedure in different realms of 
m edical statistics. As in the results in Section 8.1.4. the two-stage 
procedure is likely to be applied by some cross-over trial reports 
published  in m edical journals and some pharm aceutical 
s ta tistic ians for some time.
8.1.6. Medical statistics books and medical journals
The purpose of com paring resu lts drawn from the comprehensive 
review of m edical sta tistics  books aind the system atic review on 
m edical jo u rn a ls  is to investigate w hether medical statistics books 
had  any  influence on analyses of cross-over trials in medical 
jou rna ls .
The re su lts  in C hapter 4 - showed th a t m ost citations given by 
cross-over trial reports were papers from periodicals ra ther than  
m edical sta tistics  books. However, there was a  considerable 
percentage of cross-over trial reports th a t did not give citations to 
any sta tistica l references. These included reports which m entioned 
th a t the  carry-over effect had  been tested. It indicated th a t there 
were likely to be o ther sources of references for the analysis. 
Medical s ta tistics books are considered to be the m ost commonly
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u sed  sources th a t provide m ethods of analyses. Furtherm ore, it was 
found th a t  m any books have recommended testing for the carry­
over effect w ithout referring it as the two-stage procedure. 
Therefore, cross-over trial reports th a t indicated testing for the 
carry-over effect w ithout giving information on m ethods used  could 
well indicate the influences cf general medical statistics books on 
analyses of cross-over trials published in medical journals.
8.2. Summary of Results
The original objective of the thesis was to investigate the use of the 
tw o-stage procedure for analysing cross-over trials in four different 
aspec ts  of m edical statistics. However, the resu lts from the four 
s tud ies showed th a t it is difficult to estim ate the prevalence of the 
u se  of the two-stage procedure in cross-over triads. The overall 
conclusion of th is thesis  is th a t the two-stage procedure is not the 
only a rea  in the  anadysis of cross-over trials th a t has deficiencies. 
None of the  four m ethods w as able to give an estim ation of the 
percentage of cross-over trials being analysed with the two-stage 
procedure because of the deficiencies in each realm  of medical 
statistics.
The reasons for not m eeting the objective of the studies were tha t 
those objectives were based on assum ptions which were only found 
to be unreliab le w hen resu lts of the studies were analysed. 
Violations of the assum ptions were the major finding of the thesis. 
Below is the  d iscussion regarding the assum ptions and the results.
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1. As an  assum ption  of bibliometric study, it was assum ed tha t 
citation indicated use. Although the evidence found in the 
system atic review of cross-over trial reports was not strong enough 
to reject such  an  assum ption, neither was it supported. It was also 
assu m ed  th a t the analysis section of cross-over trial reports would 
indicate w hether the two stage procedure was used or not. 
However, resu lts  of the system atic review on cross-over trials 
published  in m edical jou rnals  showed th a t the two-stage procedure 
w as cited while it w as no t mentioned anywhere in the trial report. 
On the  o ther hand , the  carry-over effect was described as ‘non­
ex isten t’ while the m ethod of testing was not indicated. Therefore 
citations canno t be trea ted  as a  reliable indicator of the use of the 
two-stage procedure. The m ajor finding of the system atic review 
w as th a t the design, m ethods and  discussion th a t had been 
published  w as generally not sufficient to judge w hether the design 
and  analyses of cross-over trials were appropriate.
2. Inform ation provided by cross-over trial reports published in 
m edical jo u rn a ls  w as inadequate and did not meet the requirem ent 
of the  ‘CONSORT sta tem en t’ or journal checklists. As a 
consequence, the relationship between citations and usages was 
no t established. Insufficient information from cross-over trial 
reports also applies to the section of statistical analyses.
3. There were unforeseen inconsistencies between answ ers to 
the questions of the  survey for the pharm aceutical statisticians. 
Use of the two-stage procedure was not consistent with the
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sta tistica l model fitting. In addition, neither did their views on how 
carry-over effects should be dealt with reflect on the statistical 
m ethods they used.
The conclusion th a t can  be drawn from the results of the four 
s tud ies w as th a t w ithout being recognised by those who analysed 
trials, the two-stage procedure had been more commonly used than  
the evidence suggested. It is impossible to ascertain  the aspect of 
m edical s ta tistics in which the two-stage procedure was m ost or 
leas t used . It can  only be concluded th a t the two-stage procedure 
continued  to be highly u sed  in all aspects of medical statistics 
studied . The reason  why it was still used  was associated with the 
fact th a t its deficiencies have not been as well-recognised as the 
m ethod itself. Furtherm ore, the fact th a t testing for the carry-over 
effect w ithout realising it w as the so-called ‘two-stage procedure’ or 
‘the Hills-Armitage m ethod’ made it more difficult to raise 
aw areness of its deficiencies.
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Table 8.2-1: Comparison o f main results from the four studies
Aspect of 
medical statistics
Periodicals Medical
journals
General medical 
statistics books
Pharmaceutical
industry
Research
Method
Citation
analysis
Systematic
review
Comprehensive
review
Questionnaire
survey
The two-stage 
procedure
1,328 citations 
on Grizzle 
(1965)and 
Hills and 
Armitage 
(1979)
Cannot be 
estimated
9 of 26 books 
recommended the 
two-stage 
procedure
7 of 34
pharmaceutical 
companies used 
the two-stage 
procedure
Acknowledging 
Low power
3 trial papers 
cited Freeman 
(1989)
2 7/26 24/34
Acknowledging 
High type I erro r 
rate
3 trial papers 
cited Freeman 
(1989)
2 3/26 15/34
Regarding the con ten t of the two-stage procedure, it was found th a t
there  have been different versions of the two-stage procedure in 
general m edical sta tistics  books and a  lack of understanding in the 
pharm aceutical industry .
As for the m ajor deficiency (high type I error rate) of the two-stage 
procedure, th is h as  been acknowledged by newly published general 
m edical sta tistics  books. Yet, although infrequent, the aw areness 
could be found in cross-over trial reports published in medical 
jou rnals. In general, analyses of cross-over triads were often 
associated w ith the two-stage procedure. Although it is hoped tha t 
there will be a  change in analyses of cross-over trials, the two-stage 
procedure is unlikely to be eliminated from analyses of cross-over 
trials soon.
8.3. Suggestions for improvements
The resu lts  draw n from the four studies suggest tha t improvements 
in analyses of cross-over trials aire needed in each realm  of medical 
statistics. Suggestions are given below.
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8.3.1. Authors of cross-over trials reports to be published 
in medical journals
The two fundam ental issues of cross-over trial reports published in 
m edical jo u rna ls  are reporting and  analyses. Both areas are equally 
im portan t as it is often impossible to differentiate w hether it is a  
problem  of reporting or analyses.
For reporting o f  trials: Details of design should always be 
included in the report. Designs of cross-over trials should always be 
specified. The essential information regarding designs of cross-over 
trials  are num bers of treatm ents, treatm ent periods and treatm ent 
groups. As the carry-over effect is one of the m ost problematic 
a reas  for concern in u sing  cross-over designs, w hether a  w ash-out 
period h as been incorporated and  the choice of its length should 
always be justified.
For an alyses o f  cross-over trials: Report of cross-over trials is 
sim ilar to an  ordinary parallel trial except when carry-over effects 
are tested. There should  always be clear indications of which 
m ethods have been used  and  on which variables they have been 
tested  on. The two-stage procedure is not recommended for 
analyses of cross-over trials due to its high type I error rate and low 
power. However, if the two-stage procedure has to be used, how 
carry-over effects have been tested and a t w hat nominal level 
should  be s ta ted  clearly. Results of the test for carry-over effects 
and  how trea tm en t effects are evaluated should always be provided.
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Statistic ians should be consulted whenever possible, and  the focus 
should  be on the validity of the m ethod for their data.
In term s of citations of references, references should be given if 
s ta tistica l analyses involve more than  testing for simple cross-over 
differences. References should always be cited if they have been 
m entioned in the report. Giving correct citations is not only for the 
a u th o r’s credibility of their work b u t will benefit readers if further 
details /re ad in g  are needed.
8.3.2. For the editorial board/peer review
Editorial b o a rd /p eer review plays an  im portant role in the quality of 
cross-over trials pub lished  in medical journals. In order to improve 
the reporting and  analyses of cross-over trials published in medical 
jo u rn a ls , there should  be guidelines on how cross-over trials should 
be analysed and  a  checklist of items included in cross-over trial 
reports. Such  a  guideline/checklist would not only improve the 
quality of cross-over trials published in medical journals b u t also 
direct au th o rs  to be tter reports. Such guidelines should include all 
item s m entioned in Section 8.3.1.
8.3.3. General medical statistics books
Despite the  m ajor deficiencies of the two-stage procedure, it is not 
the  purpose of th is thesis to condemn all general medical statistics 
books w hich recom m ended the two-stage procedure. A good general 
m edical sta tistics  book as a  reference for analyses of cross-over 
trials would give inform ation on deficiencies of the two-stage
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procedure even if the m ethod is recommended. However, it was 
found th a t m any general medical statistics books did not provide 
the correct version of the two-stage procedure, such as the 
recom m ended nom inal level of testing for the carry-over effect and 
how trea tm en t effects should be analysed when carry-over effects 
are found to be significant or non-significant. If they know the 
deficiencies of the two-stage procedure and still consider the two- 
stage procedure the optim al method for analyses of cross-over, 
au th o rs  should  give a  correct and complete version of the two-stage 
procedure.
Suggestions for au th o rs  are to em phasise the deficiencies of the 
two-stage procedure an d  m ake it clear th a t despite its attractive 
feature of testing for the  carry-over effect, it actually has a  high 
price to pay in  term s of the false positive (type I error) rate. If the 
au th o rs  were no t su re  abou t their views or the latest development 
of the m ethod, they would skip the topic about analyses of cross­
over trials  a n d /o r  refer to o ther books which specialise in cross­
over trials or experim ent designs.
As it w as found th a t there were no two books which gave identical 
suggestions on analyses of cross-over trials, it m ust have caused 
researchers  who analyse cross-over trials da ta  trouble choosing 
which book to follow. The suggestion for them  is th a t newly 
published  m edical statistics books are more reliable than  the old 
ones regarding analyses of cross-over trials. If more specific
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analysis is needed, readers should consult specialty books such as 
S en n ’s.
8.4. Pharmaceutical industry
No conclusion can be draw n from the survey am ongst the 
pharm aceu tica l s ta tistic ians in regard to the use of the two-stage 
procedure as the  resu lts  showed some inconsistency in m ethods of 
the  tw o-stage procedure.
The deficiencies of the two-stage procedure have not always been 
acknowledged. The high type I error rate is a  more serious problem 
th a n  lower power. Therefore it is im portant for statisticians to be 
inform ed ab o u t the  problem  before they decide to analyse cross­
over trials w ith the  tw o-stage procedure.
8.5. Future work
In order to improve the statistics in medical journals, it will be 
usefu l to investigate how clinicians acquire their knowledge of 
statistics. In addition, more effort should be made in dem onstrating 
and  recom m ending the correct method for analyses of cross-over 
triads. A nother a rea  th a t requires attention is potential 
reseaLrchers/cliniciams’ understanding  of the design of cross-over 
trials.
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Appendices
Appendix A - Number of cross-over trials listed on the MEDLINE
Year Total N um ber of C ross-over Trials
1981 95
1982 126
1983 121
1984 129
1985 134
1986 168
1987 160
1988 156
1989 165
1990 148
1991 182
1992 181
1993 177
1994 166
1995 166
1996 167
1997 161
1998 126
1999 122
2000 124
2001 188
Total 3162
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Appendix B - 1988 List of cross-over trial reports sampled for
review
1988-1 Schaer DH, Buff LA, Katz RJ. Sustained antianginal efficacy 
of transderm al nitroglycerin patches using an  overnight 10-hour 
n itrate-free interval. Am.J Cardiol. 1988;61(l):46-50.
Ref ID: 3
1988-2 McMenemin IM, Parbrook GD. Comparison of the effects of 
su b an aesth e tic  concentrations of isoflurane or nitrous oxide in 
volunteers. B r.J Anaesth. 1988;60(l):56-63.
Ref ID: 5
1988-3 Cam pbell N, Paddock V, Sundaram  R. Alteration of 
m ethyldopa absorption, metabolism, and blood pressure control 
caused  by ferrous sulfate and  ferrous gluconate. Clin 
Pharm acol.Ther. 1988;43(4):381-6.
Ref ID: 24
1988-4 Sasso E, Perucca E, Calzetti S. Double-blind comparison of 
prim idone and  phenobarbital in essential tremor. Neurology 
1988;38(5):808-10.
Ref ID: 30
1988-5 Strom berg C, S eppalaT , Mattila MJ. Acute effects of 
m aprotiline, doxepin and  zimeldine with alcohol in healthy 
volunteers. Arch.Int.Pharm acodyn.Ther. 1988;291:217-28.
Ref ID: 32
1988-6 Niemi MK, Keinanen-Kiukaanniem i SM, Salmela PI. Long­
term  effects of guar gum  and  microcrystalline cellulose on 
glycaemic control and  serum  lipids in type 2 diabetes. E ur.J  Clin 
Pharmacol. 1988;34(4):427-9.
Ref ID: 57
1988-7 Gleeson JG , Price JF . Controlled trial of budesonide given 
by the neb u h ale r in preschool children with asthm a. BMJ 
1988;297(6642): 163-6.
Ref ID: 63
1988-8 W heatley D. New hypnotic agents: clinical studies in general 
practice. Pharmacol.Biochem.Behav. 1988;29(4):811-3.
Ref ID: 69
1988 -9 Gsinger C, Jerem y J , Speiser P, Mikhailidis D, D andona P, 
S ch em th an er G. Effect of vitamin E supplem entation on platelet 
throm boxane A2 production in type I diabetic patients. Double­
blind crossover trial. D iabetes 1988;37(9): 1260-4.
Ref ID: 75
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1988-10 Theron AJ, A nderson R. Investigation of the effects of oral 
adm inistration  of ascorbate on the functional activity of serum  
a lp h a -1 -protease inhibitor and  oxidant release by blood phagocytes 
from cigarette sm okers in a  placebo-controlled, doubleblind, 
crossover trial. In t.J  Vitam.Nutr.Res. 1988;58(2):218-24.
Ref ID: 84
1988-11 Catterall JR , Rhind GB, Whyte KF, Shapiro CM, Douglas 
NJ. Is noctu rnal a sth m a  caused  by changes in airway cholinergic 
activity? Thorax 1988;43(9):720-4.
Ref ID: 99
1988-12 Ney P, Neal T, M anku MS. Double blind cross-over trial 
w ith fenfluram ine. C an .J  Psychiatry 1988;33(6):574.
Ref ID: 102
1988-13 E ngelhart M. K etanserin in the treatm ent of Raynaud’s 
phenom enon associated w ith generalized scleroderma. Br. J  
Dermatol. 1988; 119(6):751-4.
Ref ID: 108
1988-14 Weisweiler P. Effects of bezafibrate and gemfibrozil on 
serum  lipoproteins in prim ary hypercholesterolemia. 
Arzneim ittelforschung. 1988;38(7):925-7.
Ref ID: 111
1988-15 Stoller JK, W iedem ann HP, Loke J , Snyder P, Virgulto J , 
M atthay RA. Terbutaline and  diaphragm  function in chronic 
obstructive pulm onary disease: a  double-blind randomized clinical 
trial. B r.J D is.Chest 1988;82(3):242-50.
Ref ID: 137
1988-16 A rm brecht U, Lundell L, Stockbrugger RW. The benefit of 
pancreatic enzyme substitu tion  after total gastrectomy.
Aliment. Pharm acol.Ther. 1988;2(6):493-500.
Ref ID: 140
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Appendix B - 1992 List of cross-over trial reports sampled for
review
1992-1 Atala A, Amin M, Harty JI. Diethylstilbestrol in treatm ent of 
postorchiectom y vasom otor symptoms and  its relationship with 
serum  follicle-stimulating hormone, luteinizing hormone, and 
testosterone. Urology 1992;39(2): 108-10.
Ref ID: 8
1992-2 Brodows RG. Benefits and risks with glyburide and  glipizide 
in elderly NIDDM patients. Diabetes Care 1992;15(l):75-80.
Ref ID: 11
1992-3 Hood MA, Sm ith WM. Adenosine versus verapamil in the 
trea tm en t of supraven tricu lar tachycardia: a  randomized double­
crossover trial. Am .Heart J  1992;123(6):1543-9.
Ref ID: 48
1992-4 Clifton PM, W ight MB, Nestel PJ. Is fat restriction needed 
with HMGCoA reductase  inhibitor treatm ent? Atherosclerosis 
1992;93(l-2):59-70.
Ref ID: 49
1992-5 Uden S, Schofield D, Miller PF, Day JP, Bottiglier T, 
B raganza JM . A ntioxidant therapy for recurrent pancreatitis: 
biochem ical profiles in a  placebo-controlled trial.
Aliment. Pharm acol.Ther. 1992;6(2):229-40.
Ref ID: 53
1992-6 Lieberm an D, Heimer D. Effect of dietary sodium on the 
severity of bronchial asthm a. Thorax 1992;47(5):360-2.
Ref ID: 62
1992-7 Hay JG , Stone P, C arter J , C hurch S, Eyre-Brook A, 
Pearson MG et al. Bronchodilator reversibility, exercise 
perform ance and  breath lessness in stable chronic obstructive 
pulm onary disease. Eur.R espir.J 1992;5(6):659-64.
Ref ID: 74
1992-8 Laffi G, M arra F, Carloni V, Azzena G, De Feo ML, Pinzani 
M et al. Throm boxane-receptor blockade increases w ater diuresis in 
cirrhotic pa tien ts with ascites. Gastroenterology 1992; 103(3): 1017- 
2 1 .
Ref ID: 88
1992-9 Ram aekers JG , Uiterwijk MM, O’Hanlon JF. Effects of 
loratadine and  cetirizine on actual driving and psychometric test
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perform ance, and  EEG during driving. E u r.J  Clin Pharmacol. 
1992;42(4):363-9.
Ref ID: 95
1992-10 H auser SL, Doolittle TH, Lopez-Bresnahan M, Shahani B, 
Schoenfeld D, Shih VE et al. An antispasticity  effect of threonine in 
m ultiple sclerosis. Arch.Neurol. 1992;49(9):923-6.
Ref ID: 100
1992-11 Goel A, Suri JC , Aggarwal K. Role of corticosteroids in the 
m anagem ent of chronic obstructive lung disease: factors predicting 
response. Indian J  C hest Dis.Allied Sci. 1992 ;34(l):ll-7 .
Ref ID: 101
1992-12 Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, 
O rt SI e t al. Double-blind, crossover trial of fluoxetine and placebo 
in children and  adolescents with obsessive-compulsive disorder. J  
Am.Acad.Child Adolesc Psychiatry 1992;31(6): 1062-9. 
Ref ID: 116
1992-13 B uchsbaum  MS, Potkin SG, Siegel B-VJ, Lohr J , Katz M, 
G ottschalk LA et al. S tria tal metabolic rate and  clinical response to 
neuroleptics in schizophrenia. Arch.Gen.Psychiatry 
1992;49(12):966-74.
Ref ID: 120
1992-14 Kishida H, H ata  N, Kunimi T, Miyagawa H, Nishiyama H, 
Katoh K. A ntianginal effects of amlodipine a t a  single dose on 
exertional angina patien ts using  treadmill exercise testing—a 
random ized crossover study in comparison with placebo. 
Cardiovasc.D rugs Ther. 1992;6(5):481-7.
Ref ID: 122
1992-15 Palm er AJ, Fletcher AE, Rudge PJ, Andrews CD,
C allaghan TS, Bulpitt CJ. Quality of life in hypertensives treated 
with atenolol or captopril: a  double-blind crossover trial. J  
H ypertens 1992; 10(11): 1409-16.
Ref ID: 139
1992-16 Sanderson A, C arpenter R. Eye movement desensitization 
versus image confrontation: a  single-session crossover study of 58 
phobic subjects. J  Behav.Ther.Exp.Psychiatry 1992;23(4):269-75.
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Appendix B - 1996 List of cross-over trial reports sampled for
review
1996-1 H ansen O, Pfeiffer P, Madsen B, Andersen I, H ansen B, 
M athiesen B. Sustained-release metoclopramide plus 
m ethylprednisolone versus placebo plus m ethylprednisolone as 
antiem etic prophylaxis during non-cisplatin chemotherapy. A 
random ized double-blind cross-over trial. Acta Oncol. 
1996;35(1):57-61.
Ref ID: 17
1996-2 Hong D, Regehr G, Reznick RK. The efficacy of a  computer- 
assisted  preoperative tu torial for clinical clerks. C an.J Surg. 
1996;39(3):221-4.
Ref ID: 19
1996-3 Sekine I, Nishiwaki Y, Kakinum a R, Kubota K, Hojo F, 
M atsum oto T et al. A random ized cross-over trial of granisetron and 
dexam ethasone versus granisetron alone: the role of 
dexam ethasone on day 1 in the control of cisplatin-induced delayed 
emesis. J p n .J  Clin Oncol. 1996;26(3): 164-8.
Ref ID: 28
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Appendix C List of medical statistics books reviewed
MEDICAL STATISTICS BOOKS WITH RECOMMENDATIONS TO ANALYSIS 
OF CROSS-OVER TRIALS (N= 26 )
Altman-DG Practical Statistics for Medical Research
Armitage-P and Colton-T Encyclopedia of Biostatistics
Armitage-P, Berry-G 
Bailar lll-JC, Mosteller-F
Bithell-JF, Coppi-R 
Bolton-S
Buncher-CR, Tsay-JY 
Chow-SC 
Chow-SC, Liu-JP
Colquhoun-D
Everitt-BS
Friedman-LM, Furberg-CD,
DeMets-DL
Goldstone-LA
Ingelfinger-JA, Mosteller-F,
Ware-JH, Thibodeau-LA
Jennison, Turnbull
Mainland-D, Sanders-WB
Matthews-JNS
Petrie-A
Piantadosi-S
Pocock
Rosner-B
Smart-JV
Spriet-A, Dupin-Spriet-T, 
Simon-P 
Whitehead-J 
Zolman-JF
Statistical Methods in Medical Research 
Medical Uses of Statistics
Perspectives in Medical Statistics-Proceedings of the European Symposium on Medical 
Statistics, Rome, 1980
Pharmaceutical Statistics: Practical & Clinical Applications
Statistics in the Pharmaceutical Industry
Encyclopedia of biopharmaceutical statistics
Design and Analysis of Bioavailability and Bioequivalence Studies
Lectures on Biostatistics: An Introduction to Statistics with Applications in Biology and
Medicine
Statistical Methods for Medical Investigations
Fundamentals of Clinical Trials 
Understanding Medical Statistics
Biostatistics in Clinical Medicine
Group Sequential Methods with Applications to Clinical Trials
Elementary Medical Statistics
An Introduction to Randomised Controlled Clinical Trials
Lecture Notes on Medical Statistics
Clinical Trials - A Methodologic Perspective
Clinical Trials: A Practical Approach
Fundamentals of Biostatistics
Elements of Medical Statistics
Methodology of Clinical Drug Trials 
The Design and Analysis of Sequential Clinical Trials 
Biostatistics: Experimental Design and Statistical Inference
MEDICAL STATISTICS BOOK WITH STATISTICAL APPLICATONS OF 
CROSS-OVER TRIALS (N=21)
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Clinical Trials in Neurologic Practice 2001 
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Medical Statistics A Commonsense Approach 
Statistics in Medicine
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Bertelsmann-A
Biller-J, Bogousslavsky-J
Bland-M
Bowers-D
Campbell-MJ, Machin-D 
Colton-T
Daly-LE, Bourke-GJ 
Dawson-Saunders-B, 
Trapp-RG 
De Muth-JE
Elston-RC, Johnson-WD
Faragher-B, Marguerie-C
Fisher-LD, Van Belle-G
Hill-AB
Holland-BK
Kirkwood-BR
Lindsey-J
Motulsky-H
Pereira-Maxawell-F
Riffenburgh-RH
Rimm-AA
Wooding-WM
Basic & Clinical Biostatistics
Basic Biostatistics and Pharmaceutical Statistical Applications
Essentials of Biostatistics
Essential Statistics for Medical Examinations
Biostatistics: A Methodology for the Health Sciences
Principles of Medical Statistics
Probability Without Equations: Concepts for Clinicians
Essentials of Medical Statistics
Revealing Statistical Principles
Intuitive Biostatistics
A-Z of Medical Statistics: A Companion for Critical Appraisal 
Statistics in Medicine
Basic Biostatistics in Medicine and Epidemiology
Planning Pharmaceutical Clinical Trials - Basic Statistical Principles
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MEDICAL STATISTICS BOOK WITHOUT MENTIONING CROSS-OVER 
TRIALS (N=83)
Andersen-B 
Armitage-P 
Bahn-AK 
Bailey-NTJ 
Bailey-NTJ 
Bellman-R 
Bowers-D 
Brown, Swanson 
Brown-BW, Hollander-M 
Castle-WM, Morth-PM 
Clark-GM 
Cleophas-TJ, et al 
Coggon-D 
Daniel-WW 
Duncan-RC 
Dunn-G
Dunn-G, Everitt-B 
D unn-0J, Clark-V 
Dwyer-JH, et al 
Eldridge-S, Ashby-D 
Elwood-M 
Emery-AEH 
Feinstein-AR 
Forthoher-RN, Lee-ES 
Gardner-MJ, Altman-DG 
Gehan-EA, Lemak-NA 
Glantz-SA (editor)
Glaser-AN 
Greenbery-NT 
Harris-EK, Boyd-JC 
Hawkins-B
Hirsch-RD, Riegelman-RK 
Holm-S
Hoppensteadt-E, Peskin- 
CS
Hulley-SB
Jekel-JF, Elmore-FG,
Katz-DL 
Jordan-K 
Kachigan-SK 
Katz-MH 
Kuzma-JW 
Lange, et al 
Leave rton-PE 
Le-CT, Boen-JR 
Lewis-AE
Matthews-DE, Farewell-VT 
McCall-J 
McFadden-F 
Michelson-S, Schofield-T
Miller-RG, Efron-B, Brown- 
BW, Moses-LE 
Morton-RF, Hebel-JR,
McCarter-RJ 
Mould-RF 
Munro-AJ 
Munro-BH 
Murphy-EA 
Nimmo-W, Tucker-G 
Norman-GK, Streiner-DL 
Norman-GR, Streiner-D 
Petrie-A, Sabin-C
Methodological Errors in Medical Research 
Sequential Medical Trials 
Basic Medical Statistics
Mathematics, Statistics and Systems for Health 
The Mathematical Approach to Biology and Medicine 
Mathematical Methods in Medicine
Statistics Further from Scratch: For Health Care Professionals 
Medical Statistics on Personal Computers 
Statistics: A Biomedical Introduction 
Statistics in Small Doses
Statistics and Experimental Design-An Introduction for Biologists and Biochemists 
Statistics Applied to Clinical Trials 2000 
Statistics in Clinical Practice
Biostatistics - A Foundation for Analysis In the Health Sciences 
Introductory Biostatistics for the Health Sciences 
Statistics in Psychiatry
Clinical Biostatistics - An Introduction to Evidence Based Medicine 
Basic Statistics: A Primer for the Biomedical Sciences 
Statistical Methods for Longitudinal Studies of Health 
Statistical Concepts (Master C lasses in Primary Care Research No.3)
Critical Appraisal of Epidemiological Studies and Clinical Trials 
Methodology in Medical Genetics: An Introduction to Statistical Methods 
Clinimetrics
Introduction to Biostatistics: A Guide to Design, Analysis and Discovery 
Statistics with Confidence: Confidence Intervals and Statistical Guidelines 
Statistics in Medical Research: Developments in Clinical Trials 
Primer of Biostatistics 
High-Yield Biostatistics 
Medical Statistical Epidemiology
Statistical B ases of Reference Values in Laboratory Medicine 
Elements of Medical Statistics (yr1829)
Statistical Operations: Analysis of Health Research Data
Ethical Problems in Clinical Practice: The Ethical Reasoning of Health Care Professionals
Mathematics in Medicine and the Life Sciences 
Designing Clinical Research: An Epidemiology Approach
Epidemiology, Biostatistics and Preventive Medicine
Mastering Statistics: A Guide for Health Service Professionals & Researchers
Multivariate Statistical Analysis -  A Conceptual Introduction
Multivariable Analysis: A Practical Guide for Clinicians
Basic Statistics for the Health Sciences
Case Studies in Biometry
A Review of Biostatistics
Health and Numbers: Basic Biostatistical Methods 
Biostatistics (Reinhold Books in the Biological Sciences)
Using and Understanding Medical Statistics 
Statistics: A Guide for Therapists 
Management of Data in Clinical Trials 1998
The Biostatistics Cookbook: The Most User-Friendly Guide for the Biomedical Scientists 
Biostatistics Casebook
A Study Guide to Epidemiology and Biostatistics
Introductory Medical Statistics
Clinical Trial Procedure: Notes for Doctors
Statistical Methods for Health Care Research
Biostatistics in Medicine
Clinical Measurement in Drug Evaluation
PDQ Statistics
Biostatistics: the Bare Essentials 
Medical Statistics at a Glance
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Pipkin-FB Medical Statistics Made Easy
Po-LW Statistics for Pharmacists
Puri-BK Statistics in Practice: An Illustrated guide to SPSS
Rao-CR, Chakraborty-R
(editors) Statistical Methods in the Biological and Health Sciences
Rees-DG Essential Statistics for Medical Practice : A Case-Study Approach
Reid-NG, Boore-JRP Research Methods and Statistics in Health Care
Roberts-EA Sequential Data in Biological Experiment
Salsburg-D The Use of Restricted Significance Tests in Clinical Trials
Sanders-DH Statistics: A First Course
Selvin-S Practical Biostatistical Methods
Senn-S Statistical Issues in Drug Development
Shott-S Statistics for Health Professionals
Shoukri-NW, Pause-CA Statistical Methods for Health Sciences
Simon-W Mathematical Techniques for Biology and Medicine
Sogliero-Gilbert-G Drug Safety Assessm ent in Clinical Trials
Strike-PW Medical Laboratory Statistics
Swinscow-TDV, Revised
by Campbell-MJ Statistics at Square One
Witten-M (editor) Mathematical Models in Medicine: D iseases and Epidemics
Woolson-RF Statistical Methods for the Analysis of Biomedical Data
Zar-JH Biostatistical Analysis
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Appendix E: The CONSORT Checklist
PAPER SECTION 
And topic
Item Description Reported
on
Page #
TITLE & ABSTRACT 1 How participants were allocated to interventions 
(e.g., “random allocation”, “randomised”, or 
“randomly assigned”).
INTRODUCTION
Background
2 Scientific background and explanation of 
rationale
METHODS
Participants
3 Eligibility criteria for participants and the settings 
and locations where the data were collected.
Interventions 4 Precise details of the interventions intended for 
each group and how and when they were 
actually administered.
Objectives 5 Specific objectives and hypotheses.
Outcomes 6 Clearly defined primary and secondary outcome 
measures and, when applicable, any methods to 
enhance the quality of measurements (e.g., 
multiple observations, training of assessors).
Sample size 7 How sample size was determined and, when 
applicable explanation of any interim analyses 
and stopping rules.
Randomization -- 
Sequence generation
8 Method used to generate the random allocation 
sequence, including details of any restrictions 
(e.g., blocking, stratification)
Randomization -- 
Allocation 
concealment
9 Method used to implement the random sequence 
(e.g., numbered containers or central telephone), 
clarifying whether the sequence was concealed 
until interventions were assigned.
Randomization -- 
Implementation
10 Who generated the allocation sequence, who 
enrolled participants, and who assigned 
participants to their groups.
Blinding (masking) 11 Whether or not participants, those administering 
the interventions, and those assessing the 
outcomes were blinded to group assignment. 
When relevant, how the success of blinding was 
evaluated.
Statistical methods 12 Statistical methods used to compare groups for 
primary outcomes(s); Methods for additional 
analyses, such as subgroup analyses and 
adjusted analyses.
RESULTS 
Participant flow
13 Flow of participants through each stage (a 
diagram is strongly recommended). Specifically, 
for each group report the numbers of participants 
randomly assigned, receiving intended treatment, 
completing the study protocol, and analysed for 
the primary outcome. Describe protocol 
deviations form study as planned, together with 
reasons.
Recruitment 14 Dates defining the periods of recruitment and 
follow-up.
Baseline data 15 Baseline demographic and clinical characteristics 
of each group.
Numbers analyzed 16 Number of participants (denominator) in each 
group included in each analysis and whether the 
analysis was by “intention-to-treat”. State the
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results in absolute numbers when feasible (e.g., 
10/20, not 50%).
Outcomes and 
estimation
17 For each primary and secondary, a summary of 
results for each group, and the estimated effect 
size and its prevision (e.g., 95% confidence 
interval).
Ancillary analyses 18 Address multiplicity by reporting any other 
analyses performed, including subgroup 
analyses and adjusted analyses, indication those 
pre-specified and those exploratory.
Adverse events 19 All important adverse events or side effects in 
each intervention group.
DISCUSSION
Interpretation
20 Interpretation of the results, taking into account 
study hypotheses, sources of potential bias or 
imprecision and the dangers associated with 
multiplicity of analyses and outcomes.
Generalizability 21 Generalizability (external validity) of the trial 
findings.
Overall evidence 22 General interpretation of the results in the 
context current evidence.
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Appendix E Survey Questionnaire
QUESTIONNAIRE for ANALYSIS of CROSS-OVER TRIALS
This questionnaire is being sent to one person per statistical unit or grouping as given in the PSI 
members list of November 2000. If you have received this questionnaire, it is because you are 
listed as a contact person, or (where no contact person is given) because you have been otherwise 
chosen.
Questions regarding ‘your unit’ refer to the group or unit is given in the PSI members list in which 
your name appears.__________________________________________________________________
Q l. How many clinical trial reports for which your unit was responsible for 
analysis have been signed off in the period 1st Jan -  31st Dec 2000? -----------
Q2. Among all clinical trials mentioned in Q.l above, how many were of
cross-over design? (please give the answer in approximated percentage if the number of cases 
cannot be recalled) -------------
Q3. Among all cross-over trials mentioned in Q.2, how many were two-period 
two-treatment (AB/BA) designs? (please give the answer in approximated percentage if 
the number of cases cannot be recalled)
Q4. What is your approach to the possibility of carry-over effect in cross-over 
trial?
□ Carry-over effect should have been eliminated by design
□ Carry-over effect is dealt with by statistical tests
□  Carry-over effect should be eliminated by trial design and tested by statistics
□  Carry-over effect cannot be dealt with and I am therefore reluctant to use 
cross-over designs
□  Other (please state)
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Q5. What do you consider the most serious/difficult problem with statistical 
analysis of cross-over trials? (Please tick the category that applies.)
Is Not a 
Problem
Provides some 
Difficulty
Is a Serious 
Problem
Carry-over Effect
Patient Effect
Period Effect
Other 
Please specify:
Q6. Does your unit have a guideline or standard operating procedure that 
covers the analysis of cross-over trials?
□ Yes
□ No
Q7. Looking at AB/BA designs, and considering the primary analysis only, (in 
which either a confidence interval or p-value for the treatment effect is 
presented), please indicate below your approach to dealing with the factors 
listed by ticking the appropriate column. [For example, if  you always use the 
matched-paired approach (either t-test or W ilcoxon signed rank test) you should 
tick “always in the model” for patient effect and “ never in the model” for the 
other effects.]
Always in 
the Model
Never in 
the Model
Include if 
Significant
Include if 
makes 
Treatment 
Significant
Other*
Patient
Effect
Period
Effect
Carry-over
Effect
* Please explain what other strategy is used if  any in the space below.
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Q8. Looking at designs with three or more periods and considering the 
primary analysis only, (in which either a confidence interval or p-value for 
the treatment effect is presented), please indicate below your approach to 
dealing with the factors given by ticking the appropriate column.
Always in 
the Model
Never in 
the Model
Include if 
Significant
Include if 
makes 
Treatment 
Significant
Other*
Patient
Effect
Period
Effect
First Order 
Carry-over 
Effect
Second
Order
Carry-over
Effect
* Please explain what other strategy is used if  any in the space below.
Q9. Is the two-stage procedure for analysing AB/BA designs, as proposed by 
Grizzle and endorsed by Hills and Armitage, used in your unit?
□ Yes
□ No
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Q10. The two-stage procedure for analysing AB/BA designs has raised some 
concerns about its statistical validity. The following statements are two main 
concerns regarding this procedure. What is your opinion on the following 
statements?
Q10.1 The Two-Stage Procedure is problematic because the test for carry­
over lacks power
□ I Agree
□ I Disagree
□ I D on’t Know
Q10.2 Analysing cross-over trials by the Two-Stage Procedure generates a 
higher overall type I error rate than the nominal rate claimed
□ I Agree
□ I Disagree
□ I D on’t Know
Q ll. Could you recommend some references on analysis of cross-over trials?
Q12. We would like to hear your opinions on analysis of cross-over trials
CONFIDENTIAL Supplementary Questions 
Name* (optional):
Organisation* (optional):
♦Providing us with these details will help us check your answers should we have 
any queries. However w e will not reveal results o f  individual answers.
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